# National Institute for Health and Care Excellence

Consultation

## **Perioperative care in adults**

## [H] Evidence review for pre-operative fasting

NICE guideline Intervention evidence review November 2019

Draft for Consultation

This evidence review was developed by the National Guideline Centre



#### Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their careful or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <u>Welsh Government</u>, <u>Scottish Government</u>, and <u>Northern Ireland Executive</u>. All NICE guidance is subject to regular review and may be updated or withdrawn.

#### Copyright

© NICE 2019. All rights reserved. Subject to Notice of rights.

## Contents

1	Preo	perativ	e fasting strategy	6
	1.1		w question: What is the most clinically and cost effective preoperative strategy for adults?	6
	1.2		uction	
	1.3		table	
	1.4		al evidence	
		1.4.1	Included studies	7
		1.4.2	Excluded studies	7
		1.4.3	Summary of clinical studies included in the evidence review	8
		1.4.4	Quality assessment of clinical studies included in the evidence review	. 19
	1.5	Econo	mic evidence	. 34
		1.5.1	Included studies	. 34
		1.5.2	Excluded studies	. 34
		1.5.3	Unit costs	. 34
	1.6	Evider	nce statements	. 34
		1.6.1	Clinical evidence statements	. 34
		1.6.2	Health economic evidence statements	. 37
	1.7	The co	ommittee's discussion of the evidence	. 37
		1.7.1	Interpreting the evidence	. 38
		1.7.2	Cost effectiveness and resource use	. 39
		1.7.3	Other factors the committee took into account	. 39
Ap	pendi	ces		50
- 1-	-		Review protocols	
	• •	endix B:	-	
			linical search literature search strategy	
			ealth Economics literature search strategy	
	Appe	endix C:		
		endix D:		. 68
	Appe	endix E:	Forest plots	118
		E.2 Ca	arbohydrate drinks versus placebo drinks	122
		E.3 W	/ater versus Fasting	123
	Арре	endix F:	GRADE tables	125
	Арре	endix G	: Health economic evidence selection	132
	Арре	endix H:	Health economic evidence tables	133
	Арре	endix I:	Excluded studies	134
		I.1 Ex	xcluded clinical studies	134
		I.2 Ex	xcluded health economic studies	136
	Appe	endix J:	Research recommendation	137

## 1 **Preoperative fasting strategy**

## 1.1 Review question: What is the most clinically and cost a effective preoperative fasting strategy for adults?

## 4 1.2 Introduction

5 Patients are expect to be 'nil by mouth', or have a period of starvation, prior to undergoing a 6 surgical procedure that requires a general anaesthetic. While some may not fully understand 7 the mechanism of risk (aspiration of stomach contents), all are aware that eating and drinking 8 prior to your operation can be very bad for you.

9 While we have consensus guidance from the royal colleges of Anaesthetists and Nursing 10 promoting the liberal, or relaxed, fasting guidance we still see variance in our local practice. 11 Unsurprisingly this causes confusion, not only for the patient, but also the clinical staff, who 12 often opt for a 'better safe than sorry' strategy. This in turn leads to prolonged periods of 13 starvation and the negative consequences being without fluid and sustenance.

14 Over the past 10 years we have seen perioperative care evolve. One such advancement is 15 the use of high energy, carbohydrate rich, drinks to aid recovery. These are given before and 16 after surgery with the assumption that they provide the patient with a metabolic boost to 17 overcome the negative effects, and reduce the complications, of surgery. Again, as with 18 fasting, the timing and impact of these drinks appears varied, with no clear guide on 19 appropriate timing or dosing of these drinks.

This review will include an analysis of evidence to hopefully clarify these issues and provide clinicians the detail needed to develop standardised and safe fasting protocols.

## 22 1.3 PICO table

23 For full details see the review protocol in appendix A.

## 24

## Table 1: PICO characteristics of review question

Population	Adults 18 years and over having surgery.
Interventions/ Comparisons	<ul> <li>no food for &lt;4 hours</li> <li>no food for 4-6 hours</li> <li>no food for &gt;6 hours</li> <li>no fluids for &lt;2 hours</li> <li>no fluids for 2-4 hours</li> <li>no fluids for 4-6 hours</li> <li>no fluids for &gt;6 hours</li> <li>maintaining clear fluids (non-milk, non-particulate drinks) before surgery</li> <li>combinations of food and fluid restriction strategies</li> </ul>
Outcomes	Critical outcomes: • health-related quality of life • mortality • patient, family and carer experience of care • adverse events and complications (Clavien-Dindo, postoperative morbidity score (POMS), aspiration – pulmonary complications, acute kidney injury) Important outcomes: • length of hospital stay • unplanned ICU admission

© NICE 2019. All rights reserved. Subject to Notice of rights.

	<ul><li> thirst</li><li> headache</li><li> cancellation of surgery</li></ul>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs. Observational studies if no relevant RCTs are identified.

## 1 1.4 Clinical evidence

## 2 1.4.1 Included studies

- One Cochrane review including twenty seven RCTs and a further nineteen randomised
   controlled trials were included in the review;<sup>3, 7, 17, 19, 20, 30 31, 37, 41, 43, 44, 58, 73, 84, 96-98, 102, 110, 115</sup>
   these are summarised in Table 2 below. Evidence from these studies is summarised in the
   clinical evidence summary below (Table 3).
- See also the study selection flow chart in appendix C, study evidence tables in appendix D,
  forest plots in appendix E and GRADE tables in appendix F.

## 9 1.4.2 Excluded studies

- 10 See the excluded studies list in appendix I.
- 11
- 12

## .3 Summary of clinical studies included in the evidence review

## Table 2: Summary of studies included in the evidence review

Study	Intervention and comparison	Population	Outcomes	Comments
Smith 2014 <sup>102</sup>	Cochrane Reviews of twenty one compared carbohydrate drinks to fasting. The population of patients elective surgery. The intervention are summarized below: Clear fluids (carbohydrate): The intervention group included a at least 45 g of carbohydrate by of intravenous route. To be included to administer the carbohydrates w start time, or induction of anaesth other oral substances in the four permitted so long as the dose of of Control: The intervention group was comp consisting of participants who red carbohydrate in the four hours be participants may have received a than 45 g of carbohydrate, clear I during this time. The control grou intravenous fluid therapy during the start time, so long as the total cor- given by oral and intravenous rou	a placebo drink or traditional s were adults undergoing protocols for the two groups all participants who were given oral beverage or by the d, studies must have planned within four hours of surgery nesia. Co-intervention with hours before surgery was carbohydrate was at least 45g.	<ul> <li>Length of hospital stay</li> <li>Postoperative complication rate</li> <li>Aspiration</li> <li>Fatigue</li> <li>Nausea and vomiting</li> <li>General wellbeing</li> </ul>	Six studies from this Cochrane review were not included for analysis as they included populations or interventions not suitable for this review (cardiac surgery or a comparison with only water).
Ajuzieogu 2016 <sup>3</sup>	Clear fluids (carbohydrate drink): 800 mL of oral carbohydrate solution containing 12.5% glucose, 50 kcal/100 mL	Patients ASA physical status I and II scheduled for abdominal myomectomy Age range:	<ul><li>Patient satisfaction</li><li>Nausea and vomiting</li></ul>	

Study	Intervention and comparison	Population	Outcomes	Comments
	<ul> <li>(Nutricia preop®; Nutricia, Zoetermeer, The Netherlands) the night before surgery and an additional 400 mL 2 h before induction of anaesthesia (n=30)</li> <li>Control (fasting): Fasting from midnight until the surgery (n=30)</li> </ul>	18-42 years Nigeria		
Asakura 2015 <sup>7</sup>	Clear fluids (carbohydrate drink): Received 250ml of preoperative CHO (Arginaid Water™, 18% carbohydrates, Nestle Health Science, Tokyo, Japan) between 6.00–6:30 a.m. on the morning of surgery. This is because 250ml of Arginaid Water are approved as a meal (n=46) Control (fasting): Control group, did not receive any preoperative CHO and were fasted starting at midnight on the day of surgical procedure (N=45)	Patients ASA physical status 1 and 2 adults, age 20 to 79 years, who were scheduled to undergo a surgical procedure of body surface Mean age (SD): CHO: $63.4 \pm 13.6$ ; Fasting: $64.5 \pm 10.4$ ;	<ul> <li>Patient reported quality of recovery</li> <li>Length of stay</li> </ul>	The QoR-40 is a global measure of quality of recovery. It incorporates five dimensions of health: patient support, comfort, emotions, physical independence, and pain; each item is graded on a five-point Likert scale. QoR-40 scores range from 40 (extremely poor quality of recovery) to 200 (excellent quality of recovery) is given as a median
Cakar 2017 <sup>17</sup>	Clear fluids (carbohydrate drink): These patients were given an oral carbohydrate solution (PreOp-Nutricia-12.5% carbohydrate, 50 kcal 100 mL21, 290 mOsm kg21,pH:	Adult patients undergoing an elective thyroid operation and ASA physical status I or II. Mean age (SD):	<ul> <li>Thirst</li> <li>Tiredness</li> <li>Headache</li> <li>Nausea</li> <li>Vomiting</li> </ul>	Results reported as an Incidence Rate Ratio

Study	Intervention and comparison	Population	Outcomes	Comments
	<ul> <li>5.0); 800 mL at 12:00 a.m. and 400 mL 2 hours before surgery (n=30)</li> <li>Control (fasting): The routine fasting procedure was implemented, in which patients were instructed not to take any fluid or food by mouth after midnight (12:00 a.m.) preoperatively and were not given an intravenous (IV) injection (n=33)</li> </ul>	CHO: 48.17 (9.81) Glucose infusion: 55.53 (19.20) Fasting: 50.07 (9.95) Turkey		
Canbay 2014 <sup>19</sup>	Clear fluids (carbohydrate drink): received 800 ml oral glucose solution containing 12.5 % glucose (Nutricia preop) at 24:00 h before surgery and 400 ml at 04:00 h, 2 h prior to the surgery (n=25) Control (fasting): oral intake was restricted starting from 24:00 h (n=25)	Adult patients who were in ASA I–II group and would undergo open radical retropubic prostatectomy surgery under elective conditions Mean age (SD): CHO: 60.00 ± 10.37 Fasting: 58.36 ± 11.19 Turkey	• Thirst	
Celiksular 2016 <sup>20</sup>	Clear fluids (carbohydrate drink): The patients were given 800 mL and 400 mL (12.5%) of oral carbohydrate solution (PreopQ, Nutricia, Holland) 8 h and 2 h before their elective surgery, respectively (n=40)	Patients ASA I-II patients undergoing total hip replacement surgery due to coxarthrosis Mean age (SD): 52.9 (16.47)	<ul> <li>Nausea and vomiting (postoperative)</li> </ul>	Patients in either group underwent surgery with general anaesthesia OR epidural

Study	Intervention and comparison	Population	Outcomes	Comments
	Control (Fasting): This group of patients underwent surgery under general anaesthesia or epidural after an 8-h preoperative fasting period (n=40)	Turkey		
Doo 2018 <sup>30</sup>	Clear fluids (carbohydrate): Subjects in the carbohydrate group also fasted, but received 400 ml of carbohydrate-rich drink (12.8% carbohydrates, 50 kcal/100 ml; Nucare NONPO(®, Daesang Wellife, Korea) 2 hours before induction of anaesthesia. (n=25) Control (fasting): Subjects in the control group were requested to obey traditional preoperative fasting after midnight prior to the day of surgery. (n=25)	Patients aged 20–65 years with ASA I or II, who were scheduled to undergo open thyroidectomy under general anaesthesia Mean age (SD): CHO: $49.8 \pm 7.1$ Fasting: $51.0 \pm 7.5$ Korea	<ul> <li>Thirst</li> <li>Fatigue</li> <li>Nausea and vomiting</li> <li>Anxiety</li> <li>Patient satisfaction</li> </ul>	All outcomes reported as a median from a 0-10 scale for thirst, fatigue, nausea, vomiting and anxiety, and a five point scale for patient satisfaction
Faria 2009 <sup>31</sup>	Clear fluids (carbohydrate drink): Received 200 ml of a carbohydrate beverage containing 12.5% (25 g, 50 kcal per 100 ml and approximately 285 mOsm) of maltodextrine (Nidex, Nestle, Brazil) 2 h before operation (n = 12)	Adult women scheduled to undergo elective laparoscopic cholecystectomy Median age (range): CHO: 47 (19–65); Fasting: 48 (29–65) Brazil	Vomiting	

Study	Intervention and comparison	Population	Outcomes	Comments
	Control (fasting): conventional preoperative fasting of 8 h (n = 13)			
Gilbert 1995 <sup>37</sup>	Clear fluids (water): Patients in group A (water) were asked to drink 500 ml- 1L of water over 2 h, before a 3 h pre-operative fast (n=46) Control (fasting): Group B (fasting) followed the standard regimen of fasting from midnight for the morning list or 'tea and toast' before 08.00 h for the afternoon session (n=49)	Patients scheduled for minor operations who were ASA I or II Water: 45.6 (15.6); Fasting: 48.3 (16.6) UK	<ul> <li>Thirst</li> <li>Nausea</li> <li>Vomiting</li> <li>Drowsiness</li> <li>Headache</li> </ul>	
Hausel 2001 <sup>41</sup>	<ul> <li>Clear fluids (carbohydrate):</li> <li>During the evening before surgery, the CHO group consumed 800 mL of an iso- osmolar carbohydrate-rich drink (12.5% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg, pH 5.0, Nutricia Preop®; Numico, Zoetermeer, the Netherlands).</li> <li>After midnight, nothing by mouth was allowed, except a single morning dose of 400 mL of the CHO drink (n=80)</li> <li>Control: patients were fasted from midnight (n=86)</li> </ul>	Patients scheduled for elective laparoscopic cholecystectomy or elective major colorectal surgery Median age (IQR): Laparoscopic cholecystectomy – Fasted: 48 (37–59); Placebo: 52 (34–58); CHO: 49 (36–58); Colorectal surgery: Fasted 52 (34–66); Placebo 56 (46–69);	<ul> <li>Malaise</li> <li>Nausea</li> </ul>	

Study	Intervention and comparison	Population	Outcomes	Comments
		CHO 56 (50–67)		
		Sweden		
Helminen 2009 <sup>44</sup>	Clear fluids (carbohydrate): Patients in the CHO group were given nothing after midnight and a 12.5% CHO (Nutricia Preop; Numici, The Netherlands), that is 400ml (=200 kcal), between 6 and 7 a.m. (n=80) Control: Patients in the fasting group were given nothing by mouth after midnight. (n=80)	Adult patients undergoing elective abdominal, anal, thyroid or parathyroid operations and ASA physical status I–III. Mean age (SD): Glucose: 61±16; CHO: 60±15; Fasting: 58±4 Finland	<ul> <li>Thirst</li> <li>Anxiety</li> <li>Tiredness</li> <li>(results preoperative)</li> </ul>	
Helminen 2019 <sup>43</sup>	Clear fluids (carbohydrate): 200ml of carbohydrate rick drink (Providextra; Fresineus Kabi Ab; Bad Homburg Vor der Hohe, Germany) containing 300kcal, 67g carbohydrate and 8g protein at home before leaving for the hospital or by 6am for surgery scheduled at 9am or 8pm at the latest for later surgery (n=57) Control (fasting): Patients were instructed to take nothing by mouth after midnight on the night before surgery (n=56)	Adults aged between 18 - 70 with ASA I to II scheduled for day case cholecystectomy. Mean age (SD): CHO: 47 (13); Fasting: 46 (11) Finland	<ul> <li>Thirst</li> <li>Tiredness</li> <li>Nausea</li> </ul>	

Study	Intervention and comparison	Population	Outcomes	Comments
.ee 2018 <sup>58</sup>	Clear fluids (carbohydrate drink): Received 800ml of a clear carbohydrate beverage (12.8% carbohydrates, 50kcal/100ml, 290 mOsm/kg, Daesang WelLife Co, Korea). Patients were instructed to ingest 400ml of this beverage on the evening before surgery (400ml) 2h before any anaesthetic medication was administered (n=51) Control (fasting): Patients within this group were not allowed to drink any solution or fluid after midnight before surgery (n=51)	Patients ASA I – II adults who had a Karnofsky performance status scale greater than 70 undergoing laparoscopic cholecystectomy Mean age (SD): CHO: 50 (13) Fasting: 49 (12) Korea	Postoperative global QoR-40 score	The QoR-40 is a global measure of quality of recovery. It incorporates five dimensions of health: patient support, comfort, emotions, physical independence and pain; each item is graded or a five-point Likert scale. QoR-40 scores range from 40 (extremely poor quality of recovery) to 200 (excellent quality of recovery)
Melis 2006 <sup>73</sup>	Clear fluids (carbohydrate drink A): Drink was poured out into a class 4 hours before surgery and had to be consumed 3 hours before surgery. Drink A was Nutricia preOp (Nutricia, Zoetermeer, the Netherlands), which contained 50.4g of the carbohydrates; consisting of 0.8g glucose, 5.2g polysaccharides and a small amount of organic acids and 200mg sodium, 488mg Potassium, 24mg chloride, 24mg calcium, 4mg of	Adult patients undergoing elective orthopaedic surgery Mean age (SD): Drink A: 59 (9) Drink B: 47 (17) Fasting: 56 (13) Netherlands	<ul> <li>Thirst</li> <li>Nausea</li> <li>Anxiety</li> <li>Tiredness</li> </ul>	Outcomes given are a difference n baseline and preoperative scores of well-being, expressed as a median increase or decrea and inter-quartile range in mm of a 100mm visual analogue scale

Study	Intervention and comparison	Population	Outcomes	Comments
Study	<ul> <li>Intervention and comparison phosphor, and 4mg of Magnesium in a solution of 400ml with an osmolality of 260mOsm/kg (n=9)</li> <li>Clear fluids (carbohydrate drink B): Drink was poured out into a class 4 hours before surgery and had to be consumed 3 hours before surgery. Drink B was Roosvicee vruchtenmix (Heinz, Zeist, the Netherlands), a syrup of rosehip and other fruits, which was diluted in water (70ml syrup : 330ml water) and contained 48mg of carbohydrates, consisting of 6.2g fructose, 6.2g of glucose and furthermore carbohydrate with unidentified chemical structure of 0.2g fibre, 0.2g protein, 6.4mg sodium, 73mg potassium, 6.9mg calcium, 7.mg phosphor, 0.1mg iron and 41mg Vitamin C in a solution of 400ml with an osmolality of 574 mOsm/kg (n=10)</li> <li>Control (fasting): Fasted after midnight on the</li> </ul>			Comments
84	day of surgery (n=10)			
Onalan 2018 <sup>84</sup>	Clear fluids (carbohydrate drink): the patients were given an oral	Patients aged >18 years but <65 years undergoing laparoscopic	<ul><li>Thirst</li><li>Anxiety</li></ul>	High values from the general comfort scale are indicative of increased comfort.

Study	Intervention and comparison	Population	Outcomes	Comments
Study	glucose solution (Nutricia preop) containing 12.5% glucose, first 800 mL at 12 a.m., and then 400 mL at 6 a.m., 2 hours before the surgery. The solution was ingested in 10 minutes.	cholecystectomy Median age (IQR): CHO: 53 (16) Fasting: 54 (14)	Outcomes	Comments
	Nutricia preop, one of the OCSs containing maltodextrin and electrolytes, contains 12.5% glucose. It passes through the stomach in 90 minutes. Its osmolality is 285 mosm/kg/H2O and it has 50 kcal/100 mL. In addition, it contains 0.46 mg/mL sodium and 1.93 mg/mL potassium. (n=25) Control (fasting): Food and water were cut off in the control group as of 12 a.m. the night before surgery. (n=25)	Turkey		
Raksakietisak 2014 <sup>96</sup>	Clear fluids (carbohydrate drink): Assigned to drink 400ml of 10% carbohydrate rich orange juice (Greenmate) between 18:00 and 24:00 and another 400ml at about 2 hour before anaesthesia (6:00 to 7:00am) (n=48) Control group (fasting): The control group had to starve	Patients aged 50 – 80 years with unilateral total knee replacement Mean age (SD): CHO: 69.8 (7.3) Fasting: 70.8 (8.5) Thailand	<ul> <li>Thirst</li> <li>Anxiety</li> <li>Nausea &amp; vomiting</li> </ul>	Preoperative thirst and anxiety measured on a 0-10 scale

Study	Intervention and comparison	Population	Outcomes	Comments
-	from midnight (n=50)			
Read 1991 <sup>97</sup>	Clear fluids (water): Permitted to drink water up until 2 hours before the operation (n=25)	Patients ASA I or II, between the ages of 18-60 and scheduled to have elective surgery normally requiring tracheal intubation	<ul><li>Nausea</li><li>Vomiting</li><li>Headache</li></ul>	
	Control (fasting): Abstain from eating and drinking from midnight (morning operation) or after a light breakfast at 6:30am (afternoon operation) (n=29)	Median age (range): Water: 30 (17-56) Fasting: 32 (18-50) Wales		
Sada 2014 <sup>98</sup>	Clear fluids (carbohydrate):	Patients were older than 18	Thirst	CHO vs Fasting
	The study group received 800	years, undergoing an	Anxiety	
	mL (per os) of carbohydrate beverage in the evening before surgery (22:00) and an additional 400 mL 2 h before anaesthesia induction. (n=44)	operation of the colon and rectum for benign and malignant diseases, or open abdominal cholecystectomy for chronic cholecystitis	Nausea	All outcomes given as a median (range) at two different time points (0-24h & 36-48h)
	Control:			
	The control group did not receive any of these drinks and were subject to the traditional preoperative fasting.(n=52)	Mean age (SD): CHO: 56.85 (12.8); Placebo: 55 (14.1); Fasting: 56.45 (14.28)		
		Kosovo		
Wang 2010 {Wang, 2010 #4285}	Clear fluids (carbohydrate): Patients in the CHO group consumed 400ml Nutricia PreOp (12.5% carbohydrate, 0.5kcal/ml, 240mOsm/kg, pH 4 - 9, Nutricia Zoetermeer,	Patients undergoing elective open colorectal cancer resection surgery Age – Median (range): CHO 66 (48 - 74);	<ul><li>Anxiety</li><li>Tiredness</li><li>Nausea</li><li>Thirst</li></ul>	Some outcomes from this study have been included with Smith 2014 {Smith, 2014 #3480}. Outcomes not included in this systematic review have been extracted separately.

Study	Intervention and comparison	Population	Outcomes	Comments
	induction of anesthesia completing CHO ingestion within 1h. Patients were nil by mouth after 2100 hours apart from single morning dose of 400ml carbohydrate drink. (n=18) Control (fasting): Patients were fasted from midnight before surgery (n=17)	Fasting 63 (37 - 74); China		
Yagmurdur 2011 <sup>110</sup>	Clear fluids (carbohydrate): During the evening before surgery, patients in the CHO group ingested 800 mL of an iso-osmolar carbohydrate-rich drink [12.5% carbohydrates (glucose: 0.2 g, maltose: 0.7 g, polysaccharides: 10 g), 50 kcal/100 ml, 290 mOsm/kg, pH 5.0; Nutricia Preop ; Numico, Zoetermeer, The Netherlands]. Nothing per os was allowed from midnight except another 400 mL of CHO in the morning at least 90 minutes before spinal anesthesia in the CHO group. (n=22) Control: The patients in the control group underwent spinal anesthesia after the routine fast from midnight. (n=22)	Patients ASA classes I-II adult patients scheduled for elective inguinal hernia repair surgery under spinal anaesthesia Mean age (SD): CHO: 45 (7); Fasting: 43 (8) Turkey	<ul> <li>Thirst</li> <li>Nausea</li> <li>Anxiety</li> </ul>	All results in median (interquartile range) form
Zhang 2019 <sup>115</sup>	Clear fluids (carbohydrate	Patients aged 18 – 55, ASA I	Thirst	Thirst and tiredness outcomes are

Study	Intervention and comparison	Population	Outcomes	Comments
	drink): Patients in the CHO group consumed CHO (12.5g of carbohydrate per 100ml, 285 mOsm/kg; Nutricia Preop, Nutricia, Zoetermeer, The Netherlands) in doses of 800ml on the evening before surgery (between 8pm and 10pm) and 400ml 2h before their scheduled operation (n=29) Control (fasting): Patients in the fasting group were forbidden from eating anything after midnight before the induction of anaesthesia (n=29)	<ul> <li>Il scheduled to undergo elective open gynaecological surgery</li> <li>Mean age (SD): CHO: 42.64 (5.26) Fasting: 43.57 (5.60)</li> <li>China</li> </ul>	<ul> <li>Tiredness</li> <li>Nausea</li> <li>Headache</li> </ul>	given as a median value (range) from a 100 point VAS scale

See appendix D for full evidence tables.

## Quality assessment of clinical studies included in the evidence review

 Table 3: Clinical evidence summary: Carbohydrate drinks versus fasting

	No of		Anticipated absolute effects		
Outcomes	Participant s (studies) Follow up	Quality of the evidence (GRADE)	Relativ e effect (95% CI)	Risk with Fasting	Risk difference with CHO (95% CI)
Patient Satisfaction (0-10)	58 (1 study) 24 hours	⊕⊕⊕⊝ MODERATE1 due to risk of bias		The mean patient satisfaction (0- 10) in the control groups was 6	The mean patient satisfaction (0-10) in the intervention groups was 2 higher (1.67 to 2.33 higher)
Postoperative global	95	$\oplus \oplus \ominus \ominus$		The mean postoperative global qor-	The mean postoperative global qor-

	No of			Anticipated absolute effects		
Outcomes	Participant s (studies) Follow up	Quality of the evidence (GRADE)	Relativ e effect (95% CI)	Risk with Fasting	Risk difference with CHO (95% CI)	
QoR-40 score	(1 study) 24 hours	LOW1,2 due to risk of bias, imprecision		40 score in the control groups was 194.5	40 score in the intervention groups was 7.8 lower (13.09 to 2.51 lower)	
Length of hospital stay	673 (11 studies)	⊕⊕⊖⊖ LOW1,3 due to risk of bias, inconsistency		The mean length of hospital stay in the control groups was 5.962 days	The mean length of hospital stay in the intervention groups was 0.37 lower (0.68 lower to 0.06 higher)	
Length of hospital stay - Major abdominal surgery	334 (6 studies)	⊕⊖⊖⊖ VERY LOW1,2,3 due to risk of bias, inconsistency, imprecision		The mean length of hospital stay - major abdominal surgery in the control groups was 10 days	The mean length of hospital stay - major abdominal surgery in the intervention groups was 1.43 lower (2.68 to 0.18 lower)	
Length of hospital stay - Intermediate Abdominal Surgery	97 (1 study)	$\oplus \oplus \bigcirc \bigcirc$ LOW1,2 due to risk of bias, imprecision		The mean length of hospital stay - intermediate abdominal surgery in the control groups was 2.38 days	The mean length of hospital stay - intermediate abdominal surgery in the intervention groups was 0.21 higher (0.52 lower to 0.94 higher)	
Length of hospital stay - Minor abdominal surgery	203 (3 studies)	⊕⊕⊕⊖ MODERATE1 due to risk of bias		The mean length of hospital stay - minor abdominal surgery in the control groups was 1.182 days	The mean length of hospital stay - minor abdominal surgery in the intervention groups was 0.07 lower (0.18 lower to 0.03 higher)	
Length of hospital stay - Orthopaedic surgery	39 (1 study)	$\oplus \oplus \bigcirc \bigcirc$ LOW1,2 due to risk of bias, imprecision		The mean length of hospital stay - orthopaedic surgery in the control groups was 6 days	The mean length of hospital stay - orthopaedic surgery in the intervention groups was 1.00 lower (1.73 to 0.27 lower)	
Thirst (0-10) (preoperative)	98 (1 study)	$\oplus \oplus \bigcirc \bigcirc$ LOW1,2 due to risk of bias,		The mean thirst (0-10) (preoperative) in the control groups was	The mean thirst (0-10) (preoperative) in the intervention groups was 0.2 higher	

	No of			Anticipated absolute effects		
Outcomes	Participant s (studies) Follow up	Quality of the evidence (GRADE)	Relativ e effect (95% CI)	Risk with Fasting	Risk difference with CHO (95% CI)	
		imprecision		2.2	(0.71 lower to 1.11 higher)	
Thirst (0-10) (postoperative)	50 (1 study)	⊕⊕⊕⊖ MODERATE1 due to risk of bias		The mean thirst (0-10) (postoperative) in the control groups was 7.8	The mean thirst (0-10) (postoperative) in the intervention groups was 7.16 lower (8.2 to 6.12 lower)	
Thirst (mild)	50	$\oplus \oplus \ominus \ominus$	RR 0.46	Moderate		
	(1 study)	LOW1,2 due to risk of bias, imprecision	(0.21 to 1.02)	520 per 1000	281 fewer per 1000 (from 411 fewer to 10 more)	
Thirst (moderate)	50	$\oplus \oplus \ominus \ominus$	RR 0.09	Moderate		
	(1 study)	LOW1,2 due to risk of bias, imprecision	(0.01 to 1.56)	200 per 1000	182 fewer per 1000 (from 198 fewer to 112 more)	
Headache (postoperative)	58	$\oplus \oplus \ominus \ominus$	RR 0.33	Moderate		
	(1 study)	LOW1,2 due to risk of bias, imprecision	(0.1 to 1.11)	310 per 1000	208 fewer per 1000 (from 279 fewer to 34 more)	
Complication rate	348	$\oplus \Theta \Theta \Theta$	RR 1.05	Moderate		
	(5 studies)	VERY LOW1,2 due to risk of bias, imprecision	(0.59 to 1.87)	148 per 1000	7 more per 1000 (from 61 fewer to 129 more)	
Well-being (postoperative)	87 (2 studies)	⊕⊕⊕⊖ MODERATE1 due to risk of bias		The mean well-being (postoperative) in the control groups was 15.4	The mean well-being (postoperative) in the intervention groups was 0.04 standard deviations higher (0.4 lower to 0.47 higher)	
Nausea & Vomiting 0-10 (postoperative)	58 (1 study)	$\oplus \oplus \ominus \ominus$ LOW1,2 due to risk of bias, imprecision		The mean nausea & vomiting 0-10 (postoperative) in the control groups was 6	The mean nausea & vomiting 0-10 (postoperative) in the intervention groups was 2.0 lower (2.58 to 1.42 lower)	

	No of			Anticipated absolute effects				
Outcomes	ParticipantsQuality of the(studies)evidenceFollow up(GRADE)		Relativ e effect (95% CI)	Risk with Fasting	Risk difference with CHO (95% CI)			
	100	<b>*</b>	DD 0 77					
Nausea & Vomiting - Nausea & Vomiting	138 (2 studies)	⊕⊖⊝⊖ VERY LOW1,2	RR 0.77 (0.38 to	Moderate	EQ fourier per 1000			
	(_ 0120100)	due to risk of bias, imprecision	1.54)	219 per 1000	50 fewer per 1000 (from 136 fewer to 118 more)			
Nausea & Vomiting -	98	$\oplus \Theta \Theta \Theta$	RR 0.94	Moderate				
Nausea	sea (1 study) VERY LOW1,2 due to risk of bias, imprecision	(0.42 to 2.1)	200 per 1000	12 fewer per 1000 (from 116 fewer to 220 more)				
Nausea & Vomiting -	232	$\oplus \oplus \ominus \ominus$			RR 0.61	Moderate		
Vomiting	(3 studies)	LOW1,2 due to risk of bias, imprecision		240 per 1000	94 fewer per 1000 (from 158 fewer to 24 more)			
Anxiety (0-10) (preoperative)	98 (1 study)	⊕⊕⊕⊝ MODERATE1 due to risk of bias		The mean anxiety (0-10) (preoperative) in the control groups was 3.3	The mean anxiety (0-10) (preoperative) in the intervention groups was 0.3 higher (1.05 lower to 1.65 higher)			
Anxiety (0-10) (postoperative)	50 (1 study)	⊕⊕⊕⊝ MODERATE1 due to risk of bias		The mean anxiety (0-10) (postoperative) in the control groups was 5.12	The mean anxiety (0-10) (postoperative) in the intervention groups was 5 lower (6.1 to 3.9 lower)			
Fatigue	108 (2 studies)	⊕⊕⊕⊖ MODERATE1 due to risk of bias		The mean fatigue in the control groups was 10.77	The mean fatigue in the intervention groups was 0.08 standard deviations lower (0.47 lower to 0.31 higher)			

Perioperative care: DRAFT FOR CONSULTATION Preoperative fasting strategy

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was

	No of			Anticipated absolute effects	
	Participant		Relativ		
	S	Quality of the	e effect		
	(studies)	evidence	(95%		
Outcomes	Follow up	(GRADE)	ĊI)	Risk with Fasting	Risk difference with CHO (95% CI)

#### at very high risk of bias

2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs 3 Downgraded by 1 or 2 increments because: The point estimate varies widely across studies, unexplained by subgroup analysis. The confidence intervals across studies show minimal or no overlap, unexplained by subgroup analysis Heterogeneity, I2=50%, p=0.04, unexplained by subgroup analysis.

Evidence includes data from Smith M, McCall J, Plank L, Herbison G, Soop M, Nygren J. Preoperative carbohydrate treatment for enhancing recovery after elective surgery. Cochrane Database of Systematic Reviews 2014, Issue 8. Copyright Cochrane Collaboration, reproduced with permission.

	No of			Anticipated absolute effects	
Outcomes	Participant s (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Risk with placebo	Risk difference with CHO (95% CI)
Length of hospital stay	674 (10 studies)	⊕⊕⊝⊝ LOW1,2 due to risk of bias, inconsistency		The mean length of hospital stay in the control groups was 6.9 days	The mean length of hospital stay in the intervention groups was 0.04 lower (0.21 lower to 0.14 higher)
Length of hospital stay - Major abdominal surgery	441 (6 studies)	⊕⊖⊖⊖ VERY LOW1,2 due to risk of bias, inconsistency		The mean length of hospital stay - major abdominal surgery in the control groups was 9.4 days	The mean length of hospital stay - major abdominal surgery in the intervention groups was 0.59 lower (1.82 lower to 0.64 higher)
Length of hospital stay - Minor abdominal surgery	144 (2 studies)	⊕⊕⊕⊝ MODERATE1 due to risk of bias		The mean length of hospital stay - minor abdominal surgery in the control groups was 1.2 days	The mean length of hospital stay - minor abdominal surgery in the intervention groups was 0.06 lower

#### Table 4: Clinical evidence summary: Carbohydrate drinks versus placebo drinks

	No of			Anticipated absolute effects		
Outcomes	Participant s (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Risk with placebo	Risk difference with CHO (95% CI)	
					(0.12 lower to 0.01 higher)	
Length of hospital stay - Orthopaedic surgery	89 (3 studies)	⊕⊕⊕⊖ MODERATE1 due to risk of bias		The mean length of hospital stay - orthopaedic surgery in the control groups was 3.9 days	The mean length of hospital stay - orthopaedic surgery in the intervention groups was 0.1 higher (0.32 lower to 0.53 higher)	
Complication rate	554	$\oplus \oplus \ominus \ominus$	RR 0.92	Moderate		
	(8 studies) LOW1,3 (0.73 due to risk of bias, 1.17) imprecision	(0.73 to 1.17)	192 per 1000	15 fewer per 1000 (from 52 fewer to 33 more)		
Fatigue (postoperative)	268 (3 studies)	⊕⊖⊖⊖ VERY LOW1,2 due to risk of bias, inconsistency		The mean fatigue (postoperative) in the control groups was 25.44	The mean fatigue (postoperative) in the intervention groups was 0.28 standard deviations higher (0.22 lower to 0.78 higher)	
Well-being (postoperative)	205 (2 studies)	⊕⊕⊕⊝ MODERATE1 due to risk of bias		The mean well-being (postoperative) in the control groups was 61.2	The mean well-being (postoperative) in the intervention groups was 0 standard deviations higher (0.27 lower to 0.28 higher)	
Nausea (24 h)	234 (2 studies)	⊕⊕⊕⊝ MODERATE1 due to risk of bias		The mean nausea (24 h) in the control groups was 13.1	The mean nausea (24 h) in the intervention groups was 1.71 lower (4.06 lower to 0.64 higher)	
Vomiting (postoperative)	248	$\oplus \Theta \Theta \Theta$	RR 1.18	Moderate		
	(3 studies) VERY LOW1,3	(0.65 to 2.12)	85 per 1000	15 more per 1000 (from 30 fewer to 95 more)		

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Downgraded by 1 or 2 increments because: The point estimate varies widely across studies, unexplained by subgroup analysis. The confidence intervals across studies show minimal or no overlap, unexplained by subgroup analysis Heterogeneity, I2=50%, p=0.04, unexplained by subgroup analysis.

	No of			Anticipated absolute effects	
	Participant		Relative		
	S	Quality of the	effect		
	(studies)	evidence	(95%		
Outcomes	Follow up	(GRADE)	ĊI)	Risk with placebo	Risk difference with CHO (95% CI)
2 Downgraded by 1 increment if the confidence interval crossed and MID or by 2 increments if the confidence interval crossed both MIDs					

Preoperative fasting strategy

erioperative care: DRAFT

FOR CONSULTATION

3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

Evidence includes data from Smith M, McCall J, Plank L, Herbison G, Soop M, Nygren J. Preoperative carbohydrate treatment for enhancing recovery after elective surgery. Cochrane Database of Systematic Reviews 2014, Issue 8. Copyright Cochrane Collaboration, reproduced with permission.

#### Table 5: Clinical evidence summary: Clear fluids (water) versus fasting

	No of     Participants       (studies)     Quality of the evidence       Outcomes     Follow up     (GRADE)				bsolute effects
Outcomes			Relative effect (95% CI)	Risk with Fasting	Risk difference with Clear fluids (Water) (95% Cl)
Nausea (POD1)	Nausea (POD1) 54 (1 study) LOW1,2 due to risk of bias, imprecision		RR 0.39	Moderate	
		due to risk of bias,	(0.16 to 0.91)	517 per 1000	315 fewer per 1000 (from 47 fewer to 434 fewer)
Vomiting (POD1)	54	$\oplus \oplus \ominus \ominus$	RR 0.35	Moderate	
	(1 study) LOW1,2 due to risk of bias, imprecision	(0.11 to 1.13)	345 per 1000	224 fewer per 1000 (from 307 fewer to 45 more)	
Headache (POD1)	54	$\oplus \Theta \Theta \Theta$	RR 0.58	Moderate	
	(1 study) VERY LOW1,2 due to risk of bias, imprecision		(0.26 to 1.32)	414 per 1000	174 fewer per 1000 (from 306 fewer to 132 more)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

Outcome	Study	Risk of bias	Comparison results	Intervention results	P value
	(no. of participants)				
Global QoR-40 score (Scale 40 – 200)	n=91 Asakura 2015 <sup>7</sup>	High	Median (IQR) Fasting: 197 (189.5–200)	Median (IQR) CHO: 196 (191–198)	-
Length of stay (days)	n=91 Asakura 2015 <sup>7</sup>	High	Median (IQR) Fasting: 3 (2–6)	Median (IQR) CHO: 3 (2–3)	-
	n=65 Yuill 2005 <sup>113</sup>	High	Median (IQR) Fasting: 8 (4)	Median (IQR) CHO: 10 (6)	
Patient Satisfaction (preoperative) Scale (1-5)	n=50 Doo 2018 <sup>30</sup>	Very High	Median (IQR) Fasting: 4 (3-4)	Median (IQR) CHO: 4 (3-4)	1
Patient Satisfaction (postoperative) Scale (1-5)	n=50 Doo 2018 <sup>30</sup>	Very High	Median (IQR) Fasting: 4 (3-4)	Median (IQR) CHO: 4 (3-4)	0.715
Thirst VAS (0-100)	n=60 Cakar 2014 <sup>17</sup>	High	Incidence Rate Ratio (range): Fasting: 11.23 (9.41 to 3.40)	Incidence Rate Ratio: CHO: 1.0 (reference)	0
Thirst (preoperative) NRS (0-10)	n=50 Doo 2018 <sup>30</sup>	High	Median (IQR) Fasting: 2 (1-2)	Median (IQR) CHO: 1 (0-2)	0.099
Thirst (postoperative) NRS (0-10)	n=50 Doo 2018 <sup>30</sup>	High	Median (IQR) Fasting: 3 (1.5-4)	Median (IQR) CHO: 2 (1-3)	0.456
Thirst (difference in baseline and preoperative scores)	n=29 Melis 2006 <sup>73</sup>	High	Median difference (IQR) Fasting: +34 (34) (increase)	Median difference (IQR) CHOA: -7 (39) (decrease); CHOB: 0 (18) (no difference)	-

Outcome	Study (no. of participants)	Risk of bias	Comparison results	Intervention results	<i>P</i> value
VAS (0-100)					
Thirst (6 hours postoperative) VAS (0-100)	n=56 Zhang 2019 <sup>115</sup>	High	Median (range) Fasting: 40 (20-55)	Median (range) CHO: 20 (10-30)	<0.001
Thirst (24 hours postoperative) VAS (0-100)	n=56 Zhang 2019 <sup>115</sup>	High	Median (range) Fasting: 40 (20-50)	Median (range) CHO: 30 (25-40)	-
Thirst VAS (0-10) Preoperative	n=160 Helminen 2009 <sup>44</sup>	High	Median (IQR) Fasting: 3 (0-5)	Median (IQR) CHO: 1 (0-4.5)	-
Thirst (0-10) 0-24 hours Postoperatively	n=96 Sada 2014 <sup>98</sup>	High	Median (range) Colorectal patients: Fasting: 4 (1-7) Cholecystectomy patients: Fasting: 4 (1-7)	Median (range) Colorectal patients: CHO: 3 (1-5) Cholecystectomy patients: CHO: 3 (1-5)	P value > 0.05
Thirst (0-10) 36-48 hours Postoperatively	n=96 Sada 2014 <sup>98</sup>	High	Median (range) Colorectal patients: Fasting: 2 (1-5) Cholecystectomy patients: Fasting: 2 (1-5)	Median (range) Colorectal patients: CHO: 2 (1-3) Cholecystectomy patients: CHO: 2 (1-3)	Colorectal <0.05 Cholecystectomy >0.05
Thirst (0-100) 90 minutes post CHO	n=44 Yagmurdur 2011 <sup>110</sup>	High	Median (IQR) Fasting: 60 (56-64)	Median (IQR) CHO: 20 (16-24)	-
Thirst (0-100) 60 minutes post anesthesia	n=44 Yagmurdur 2011 <sup>110</sup>	High	Median (IQR) Fasting: 64 (59-69)	Median (IQR) CHO: 18 (13-23)	-
Thirst (before induction)	n=113 Helminen 2019 <sup>43</sup>	High	Median (IQR): Fasting: 40 (8 - 63)	Median (IQR): CHO: 22 (6 - 50)	-

Outcome	Study (no. of participants)	Risk of bias	Comparison results	Intervention results	<i>P</i> value
Thirst (2 hours post op)	n=113 Helminen 2019 <sup>43</sup>	High	Median (IQR): Fasting: 46 (24-70)	Median (IQR): CHO: 41 (20 - 61)	-
Thirst (4 hours post op)	n=113 Helminen 2019 <sup>43</sup>	High	Median (IQR): Fasting: 20(0-50)	Median (IQR): CHO: 28 (9-61)	
Thirst (1hr preoperative)	n=35 Wang 2010 <sup>107</sup>	High	Median (range) Fasting: 24 (19-60)	Median (range) CHO: 20 (8-59)	
Nausea & Vomiting (preoperative) NRS (0-10)	n=50 Doo 2018 <sup>30</sup>	High	Median (IQR) Fasting: 0 (0-0)	Median (IQR) CHO: 0 (0-1)	0.192
Nausea & Vomiting (postoperative) NRS (0-10)	n=50 Doo 2018 <sup>30</sup>	High	Median (IQR) Fasting: 1 (1-2)	Median (IQR) CHO: 1 (0.5-2)	0.926
Nausea (difference in baseline and preoperative scores) VAS (0-100)	n=29 Melis 2006 <sup>73</sup>	High	Median difference (IQR) Fasting: 0 (7) (no change)	Median difference (IQR) CHOA: 0 (6) (no differece); CHOB: +1 (6) (increase)	-
Nausea (0-10) 40 minutes post CHO drink	n=166 Hausel 2001 <sup>41</sup>	High	Median (IQR) Fasting: 3 (2–10)	Median (IQR) CHO: 4 (2–6)	-
Nausea (0-10) 90 minutes post CHO drink	n=166 Hausel 2001 <sup>41</sup>	High	Median (IQR) Fasting: 4 (2–12)	Median (IQR) CHO: 3 (2–7)	-
Nausea (before induction)	n=113 Helminen 2019 <sup>43</sup>	High	Median (IQR): Fasting: 0 (0-2)	Median (IQR): CHO: 0 (0-0)	-

Perioperative care: DRAFT FOR CONSULTATION Preoperative fasting strategy

Outcome	Study	Risk of bias	Comparison results	Intervention results	P value
	(no. of participants)				
Nausea (2 hours post op)	n=113 Helminen 2019 <sup>43</sup>	High	Median (IQR): Fasting: 0 (0-6)	Median (IQR): CHO: 0 (0-14)	-
Nausea (4 hours post op)	n=113 Helminen 2019 <sup>43</sup>	High	Median (IQR): Fasting: 0 (0-10)	Median (IQR): CHO: 0 (0-4)	-
Nausea (2 hours postoperative) VAS 0-100	n=95 Gilbert 1995 <sup>37</sup>	High	Median Water: 1.0	Median Fasting: 0	0.32
Nausea (0-10) 0-24 hours Postoperatively	n=96 Sada 2014 <sup>98</sup>	High	Median (range) Colorectal patients: Fasting: 3 (1-6) Cholecystectomy patients: Fasting: 3 (1-6)	Median (range) Colorectal patients: CHO: 1 (1-5) Cholecystectomy patients: CHO: 1 (1-5)	>0.05
Nausea (0-10) 36-48 hours Postoperatively	n=96 Sada 2014 <sup>98</sup>	High	Median (range) Colorectal patients: 2 (1-5) Cholecystectomy patients: Fasting: 2 (1-5)	Median (range) Colorectal patients: CHO: 1 (1-3) Cholecystectomy patients: CHO: 1 (1-3)	>0.05
Nausea (1hr preoperative)	n=35 Wang 2010 <sup>107</sup>	High	Median (range) Fasting: 8 (2-14)	Median (range) CHO: 8 (4-11)	
Nausea (0-100) 60 minutes post anesthesia	n=44 Yagmurdur 2011 <sup>110</sup>	High	Median (IQR) Fasting: 9 (5-13)	Median (IQR) CHO: 8 (4-12)	-
Nausea (0-100) 90 minutes post CHO	n=44 Yagmurdur 2011 <sup>110</sup>	High	Median (IQR) Fasting: 8 (4-12)	Median (IQR) CHO: 10 (7-13)	-
Anxiety (postoperative) NRS (0-10)	n=50 Doo 2018 <sup>30</sup>	High	Median (IQR) Fasting: 0 (0-1)	Median (IQR) CHO: 0 (0-0)	0.50

Outcome	Study (no. of participants)	Risk of bias	Comparison results	Intervention results	<i>P</i> value
Anxiety (difference in baseline and preoperative scores) VAS (0-100)	n=29 Melis 2006 <sup>73</sup>	High	Median difference (IQR) Fasting: +3 (51) (increase)	Median difference (IQR) CHOA: -15 (49) (decrease); CHOB: 0 (15) (no difference)	-
Anxiety (preoperative) VAS (0-100)	n=56 Zhang 2019 <sup>115</sup>	High	Median (range) Fasting: 60 (50-70)	Median (range) CHO: 30 (30-30)	-
Anxiety VAS (0-10) Preoperative	n=160 Helminen 2009 <sup>44</sup>	High	Median (IQR) Fasting: 3 (1-5)	Median (IQR) CHO: 2 (1-5)	
Anxiety (0-10) 0-24 hours Postoperatively	n=96 Sada 2014 <sup>98</sup>	High	Median (range) Colorectal patients: Fasting: 2 (1-6) Cholecystectomy patients: Fasting: 2 (1-6)	Median (range) Colorectal patients: CHO: 3 (1-3) Cholecystectomy patients: CHO: 2 (1-3)	>0.05
Anxiety (0-10) 36-48 hours Postoperatively	n=96 Sada 2014 <sup>98</sup>	High	Median (range) Colorectal patients: Fasting: 1.5 (1-5) Cholecystectomy patients: Fasting: 1.5 (1-5)	Median (range) Colorectal patients: CHO: 1 (1-3) Cholecystectomy patients: CHO: 1 (1-3)	>0.05
Anxiety (0-100) 90 minutes post CHO	n=44 Yagmurdur 2011 <sup>110</sup>	High	Median (IQR) Fasting: 48 (43-53)	Median (IQR) CHO: 20 (18-22)	-
Anxiety (0-100) 60 minutes post anesthesia	n=44 Yagmurdur 2011 <sup>110</sup>	High	Median (IQR) Fasting: 46 (44-48)	Median (IQR) CHO: 43 (41-45)	-
Anxiety (1hr preoperative)	n=35 Wang 2010 <sup>107</sup>	High	Median (range) Fasting: 28 (16-61)	Median (range) CHO: 22 (11-47)	

Outcome	Study (no. of participants)	Risk of bias	Comparison results	Intervention results	<i>P</i> value
Anxiety (preoperative) NRS (0-10)	n=50 Doo 2018 <sup>30</sup>	High	Median (IQR) Fasting: 2 (1-2)	Median (IQR) CHO: 2 (1-3)	0.288
Headache VAS (0-100)	n=60 Cakar 2014 <sup>17</sup>	High	Incidence Rate Ratio (range): Fasting: 2.70 (1.69 to 4.32)	Incidence Rate Ratio: CHO: 1.0 (reference)	0
Fatigue (preoperative) NRS (0-10)	n=50 Doo 2018 <sup>30</sup>	High	Median (IQR) Fasting: 2 (1-2)	Median (IQR) CHO: 2 (0-2)	0.512
Fatigue (postoperative) NRS (0-10)	n=50 Doo 2018 <sup>30</sup>	High	Median (IQR) Fasting: 1 (0-2)	Median (IQR) CHO: 1 (0.5-2)	0.630
Malaise (0-10) 40 minutes post CHO drink	n=166 Hausel 2001 <sup>41</sup>	High	Median (IQR) Fasting: 12 (3–30)	Median (IQR) CHO: 8 (4–20)	-
Malaise (0-10) 90 minutes post CHO drink	n=166 Hausel 2001 <sup>41</sup>	High	Median (IQR) Fasting: 10 (3–30)	Median (IQR) CHO: 7 (3–17)	-
Tiredness VAS (0-100)	n=60 Cakar 2014 <sup>17</sup>	High	Incidence Rate Ratio (range): Fasting: 1.18 (0.64 to 2.17)	Incidence Rate Ratio: CHO: 1.0 (reference)	0.592
Tiredness (difference in baseline and preoperative scores) VAS (0-100)	n=29 Melis 2006 <sup>73</sup>	High	Median difference (IQR) Fasting: -19 (27) (decrease)	Median difference (IQR) CHOA: 0 (20) (no difference); CHOB: -7 (29) (decrease)	-
Tiredness (6 hours postoperative) VAS (0-100)	n=56 Zhang 2019 <sup>115</sup>	High	Median (range) Fasting: 30 (20-40)	Median (range) CHO: 30 (20-40)	-

Outcome	Study (no. of participants)	Risk of bias	Comparison results	Intervention results	<i>P</i> value
Tiredness (24 hours postoperative) VAS (0-100)	n=56 Zhang 2019 <sup>115</sup>	High	Median (range) Fasting: 30 (20-30)	Median (range) CHO: 40 (30-40)	-
Tiredness VAS (0- 10) Preoperative	n=160 Helminen 2009 <sup>44</sup>	High	Median (IQR) Fasting: 3 (0-5)	Median (IQR) CHO: 2 (0–5)	-
Tiredness (before induction)	n=113 Helminen 2019 <sup>43</sup>	High	Median (IQR): Fasting: 20 (5-46)	Median (IQR): CHO: 30 (10-54)	-
Tiredness (2 hours post op)	n=113 Helminen 2019 <sup>43</sup>	High	Median (IQR): Fasting: 53 (30-61)	Median (IQR): CHO: 49 (20-70)	-
Tiredness (4 hours post op)	n=113 Helminen 2019 <sup>43</sup>	High	Median (IQR): Fasting: 40 (10-50)	Median (IQR): CHO: 42 (8-70)	-
Tiredness (1hr preoperative)	n=35 Wang 2010 <sup>107</sup>	High	Median (range) Fasting: 23(10-53)	Median (range) CHO: 20 (11-60)	

Outcome	Study (no. of participants)	Risk of bias	Comparison results	Intervention results	<i>P</i> value
Thirst (2 hours postoperative) VAS 0-100	n=95 Gilbert 1995 <sup>37</sup>	High	Median Water: 5	Median Fasting: 21.0	0.0149
Vomiting ( 2 hours postoperative) VAS 0-100	n=95 Gilbert 1995 <sup>37</sup>	High	Median Water: 1.0	Median Fasting: 0	0.21

Outcome	Study (no. of participants)	Risk of bias	Comparison results	Intervention results	<i>P</i> value
Drowsiness (2 hours postoperative) VAS 0-100	n=95 Gilbert 1995 <sup>37</sup>	High	Median Water: 13.0	Median Fasting: 7.0	0.42
Headache ( 2 hours postoperative) VAS 0-100	n=95 Gilbert 1995 <sup>37</sup>	High	Median Water: 2.5	Median Fasting: 2.0	0.99

See appendix F for full GRADE tables.

## 1 1.5 Economic evidence

## 2 1.5.1 Included studies

3 No health economic studies were included.

## 4 1.5.2 Excluded studies

- 5 No relevant health economic studies were excluded due to assessment of limited 6 applicability or methodological limitations.
- 7 See also the health economic study selection flow chart in Appendix G:.

## 8 1.5.3 Unit costs

9 Relevant unit costs of carbohydrate loading drinks are provided below to aid consideration of 10 cost effectiveness.

#### 11 Table 8: UK costs of carbohydrate loading drinks

Brand	Description	Cost per unit
Nutricia	Preop 0.5kcal/ml clear non- carbonated lemon flavoured iso- osmolar carbohydrate drink 200ml carton	£1.50
Polycal	Carbohydrate liquid ready to drink neutral 200ml 2.47kcal/ml plastic bottles	£1.44
Source: NHS	Supply Chain 2018 <sup>77</sup>	

#### 12 13

## 14 **1.6 Evidence statements**

## 15 1.6.1 Clinical evidence statements

16 17

## No evidence was found for mortality; patient, family and carer experience of care; unplanned ICU admission and cancellation of surgery.

- 18 19
- 20 Carbohydrate drinks versus fasting

## 21 Quality of life

- One study showed a clinically important benefit with carbohydrate drinks for postoperative
   patient satisfaction on a scale of 0 10 compared to fasting (1 study, n=58, moderate quality
   evidence)
- 25 One study showed a clinically important harm with carbohydrate drinks when measuring 26 postoperative global QoR-40 score, a quality of life measure, compared to fasting (1 study, 27 n=95, low quality of evidence)
- 28 Two studies found no clinically important difference between carbohydrate drinks and fasting 29 in postoperative wellbeing (2 studies, n=87, moderate quality of evidence).
- 30 One study found no difference in between carbohydrate drinks and fasting in preoperative 31 anxiety (1 study, n=98, moderate quality).
- 32 One study found a clinically important benefit with carbohydrate drinks for postoperative 33 anxiety compared to fasting (1 study, n=50, moderate quality of evidence).

1

2

3

4

5

## Length of stay

Eleven studies looked at length of hospital stay, comparing carbohydrate drinks versus fasting. Overall, there was no clinically important difference between carbohydrate drinks versus fasting. (11 studies, n=673, low quality of evidence).

- 6 Broken down into the different types of surgery types, six studies showed a clinically 7 important benefit for length of stay with carbohydrate drinks in major surgery compared to 8 fasting (6 studies, n=334, very low quality of evidence).
- 9 One study showed a clinically important benefit with carbohydrate drinks for length of stay in 10 orthopaedic surgery compared to fasting (1 study, n=39, low quality of evidence).
- one study showed no clinically important difference between carbohydrate drinks and fasting
   for length of stay in intermediate abdominal surgery (1 study, n=97, low quality of evidence).
- 13Three studies showed no clinically important difference between carbohydrate drinks and14fasting for length of stay in minor abdominal surgery (3 studies, n=203, moderate quality of15evidence).

## 16 Adverse events

Thirst was measured by several studies. One study measured preoperative thirst on a scale
of 0-10 which found no clinically important difference between carbohydrate drinks and
fasting (1 study, n=98, low quality of evidence).

- 20 Three studies found a clinically important benefit with carbohydrate drinks. for postoperative 21 thirst on a scale of 0 - 10 (1 study, n=50, moderate quality), thirst mild (1 study, n=50, low 22 quality) and thirst moderate (1 study, n=50, very low quality)
- 23 One study found a clinically important benefit with carbohydrate drinks for reducing 24 postoperative headache compared to fasting (1 study, n=58, low quality).
- Five studies showed no clinically important difference between carbohydrate drinks and fasting for complication rates (5 studies, n=348, very low quality).
- One study showed a clinically important benefit with carbohydrate drinks when assessing
   postoperative nausea and vomiting measured on a VAS scale of 0 10 compared to fasting
   (1 study, n=58, low quality of evidence).
- Two studies found no clinically important difference between carbohydrate drinks and fasting in nausea and vomiting overall(2 studies, n=138, very low quality evidence).
- One study found no clinically important difference between carbohydrate drinks and fasting
   for nausea (1 study, n=98, very low quality)
- Three studies found no clinically important difference for vomiting with carbohydrate drinks compared to fasting (n=232, low quality evidence)
- 36 One study found no clinically important difference between carbohydrate drinks and fasting in 37 fatigue rates (1 study, n=108, moderate quality evidence)
- 3839 Carbohydrate drinks versus placebo
- 40 Quality of life

Two studies showed no clinically important difference between carbohydrate drinks and
 placebo drinks when measuring postoperative well-being (2 studies, n=205, moderate quality
 of evidence)

## 4 Length of stay

5

6 7

23

28

- Six studies found no clinically important difference between carbohydrate drinks and placebo drinks for length of stay after major abdominal surgery (6 studies, n=441, very low quality of evidence).
- 8 Two studies found no found no clinically important difference between carbohydrate drinks
   9 and placebo drinks for length of stay after minor abdominal surgery (2 studies, n=144,
   10 moderate quality of evidence).
- 11Three studies found no clinically important difference between carbohydrate drinks and12placebo drinks for length of stay after orthopaedic surgery (3 studies, n=89, moderate quality13of evidence).

## 14 Adverse events

- Eight studies found no clinically important difference between carbohydrate drinks and
   placebo drinks when assessing complication rates (8 studies, n=554, low quality evidence).
- Three studies found no clinically important difference between carbohydrate drinks and
   placebo drinks in rates of postoperative fatigue (3 studies, n=268, very low quality evidence).
- 19 Two studies showed no clinically important difference between carbohydrate drinks and 20 placebo drink in postoperative nausea rates (2 studies, n=234, moderate quality evidence)
- Three studies showed no clinically important difference between carbohydrate drinks and placebo drinks in postoperative vomiting (3 studies, n=248, very low quality evidence)

## 24 Water versus fasting

## 25 Adverse events

26 One study found a clinically important benefit with water in postoperative nausea , vomiting 27 and headache, compared to fasting (1 study, n=54, very low quality evidence)

## 29 Evidence not suitable for GRADE

## 30 Carbohydrate drinks versus fasting

- 31 One study showed no notable difference between carbohydrate drinks and fasting for quality 32 of life via the global QoR-40 score (1 study, n=91, high risk of bias)
- Two studies found no notable difference between carbohydrate drink and fasting when assessing length of stay (2 studies, n=156, high risk of bias)
- One study showed no notable difference between carbohydrate drinks and fasting in
   preoperative or postoperative patient satisfaction rates on a scale of one to five (1 study,
   n=50, very high risk of bias)
- Seven studies found no notable difference between carbohydrate drinks and fasting in
   preoperative anxiety (7 studies, n=418, high risk of bias)
- 40 Three studies found no clinically important difference between carbohydrate drinks and 41 fasting for postoperative anxiety (3 studies, n=242, high risk of bias)

- 1 One study showed no notable difference between carbohydrate drinks and fasting in 2 preoperative and postoperative fatigue (1 study, n=50, high risk of bias)
- One study found no notable difference between carbohydrate drinks and fasting for rates of
   headache (1 study, n=60, high risk of bias)
- 5 One study showed no notable difference between carbohydrate drinks and fasting in 6 preoperative malaise (1 study, n=166, high risk of bias)
- One study found no notable difference between carbohydrate drinks and fasting in levels of
   preoperative or postoperative nausea and vomiting (combined) (1 study, n=50, high risk of
   bias)
- 10Two studies showed no notable difference between carbohydrate drinks and fasting in11preoperative nausea (2 studies, n=204, high risk of bias)
- Five studies showed no notable difference between carbohydrate drinks and fasting in postoperative nausea (5 studies, n= 317, high risk of bias)
- 14 One study showed a trend to benefit with carbohydrate drinks in overall thirst rates 15 compared to fasting (1 study, n=60, high risk of bias)
- Four studies showed no notable difference between carbohydrate drinks and fasting in
   preoperative thirst (4 studies, n=315, high risk of bias)
- Five studies showed no notable difference between carbohydrate drinks and fasting for
   postoperative thirst (5 studies, n=431, high risk of bias)
- 20 One study showed no notable difference between carbohydrate drinks and fasting with 21 overall levels of tiredness (1 study, n=60, high risk of bias)
- Four studies showed no notable difference between carbohydrate drinks and fasting in preoperative tiredness (4 studies, n=337, high risk of bias)
- Two studies showed no clinically important difference in postoperative tiredness with carbohydrate drinks compared to fasting (n=169, high risk of bias)
- 26

27 Water versus fasting

- 28 One study showed no statistically significant difference between water and fasting for 29 drowsiness, vomiting or headache (1 study, n=95, high risk of bias)
- 30 One study showed a statistically significant benefit with water for postoperative compared to 31 fasting (1 study, n=95, high risk of bias)
- 32

34

### 33 **1.6.2** Health economic evidence statements

• No relevant economic evaluations were identified.

# **1.7 The committee's discussion of the evidence**

36 Please see recommendations 1.4.1 – 1.4.2 in the guideline.

### 1 1.7.1 Interpreting the evidence

### 2 1.7.1.1 The outcomes that matter most

The committee considered that the focus of this evidence review was to better understand the optimal time and duration of fasting for people undergoing surgery, to improve patient experience while minimising the risk of adverse events from surgery. Subsequently, the committee agreed critical outcomes for decision making to be health related quality of life, mortality, patient, family and carer experience of care and adverse events and complications. The committee also considered length of hospital stay, unplanned ICU admission, thirst, headache and cancellation of surgery to be important outcomes.

10 No evidence was found for mortality, unplanned ICU admission and cancellation of surgery.

### 11 1.7.1.2 The quality of the evidence

12 The quality of evidence that was suitable for GRADE analysis ranged from very low to 13 moderate. The majority of the evidence was graded at low quality. This was mostly due to 14 imprecision of data, reducing the certainty with which the committee could make conclusions 15 from the evidence. The committee felt that the quality of the evidence limited the strength 16 with which they could make any recommendations, particularly given that any 17 recommendation for the use of carbohydrate drinks would have a significant resource impact.

### 18 1.7.1.3 Benefits and harms

19 The committee reviewed the body of evidence comparing preoperative carbohydrate drinks 20 to fasting, carbohydrate drinks to placebo drinks and water to fasting.

### 21 Carbohydrate drinks versus fasting:

Two studies reporting patient satisfaction postoperatively. One study reported patient satisfaction using a 0 - 10 Likert scale which showed better patient satisfaction. The second study using the QoR-40 score showed a reduction in patient satisfaction with a carbohydrate drink. The committee considered the variation may be due to the taste of the carbohydrate drinks given.

- Six studies of patients undergoing major abdominal surgery and one study of patients
   undergoing orthopaedic surgery, showed a reduction in the length of hospital stay when
   preoperatively given a carbohydrate drink. However, one study looking at intermediate
   abdominal surgery and three studies reviewing minor abdominal surgery showed no clinically
   important difference when participants were given carbohydrate drinks.
- When patients were given carbohydrate drinks, the outcome of preoperative thirst showed no
   clinical difference. However, one study which assessed postoperative thirst and another
   study which grouped thirst into mild or moderate postoperative thirst showed a clinically
   important benefit by reducing the number of patients who experienced thirst.
- There was a clinically important benefit with carbohydrate drinks in the reduction of postoperative headache shown by one study. Evidence from five studies showed no difference in complication rate for participants who were given a carbohydrate drink.
- Nausea and vomiting grouped together in one study showed a clinically important benefit
  with carbohydrate drinks. As individual outcomes from six studies, there was no clinically
  important difference with the use of carbohydrate drinks. When assessing postoperative wellbeing, one study showed clinically important benefit with carbohydrate drinks in reducing
  postoperative anxiety. But one study looking at preoperative anxiety and another study
  assessing fatigue showed no clinically important benefit with carbohydrate drinks. Two
  studies assessed wellbeing overall, which showed no clinically important benefit.

The committee agreed that on the balance of evidence carbohydrate drinks preoperatively may have a benefit in the context of major abdominal surgery both for patient comfort with reduced thirst and improved satisfaction and for operative outcomes with a shorter length of stay, The committee noted that there were no observed harms of carbohydrate drinks.

### 5 Carbohydrate drinks versus placebo drinks:

Evidence from eleven studies showed no difference in length of hospital stay and evidence
from eighteen studies showed no difference in complication rate, nausea, vomiting or
postoperative well-being.

### 9 Water versus fasting:

1 2

3 4

- One study showed evidence of clinically important benefit through the reduction of nausea,
   vomiting and headache postoperatively when given water preoperatively.
- No evidence was found for mortality, unplanned ICU admission and cancellation of surgery
   for either of the three comparison groups
- 14 The committee considered that on the balance of all the evidence and considering the 15 increased cost of carbohydrate drinks compared to clear fluids, people should be told that 16 can take clear fluids two hours before surgery and to consider carbohydrate drinks before 17 complex abdominal surgery.

### 18 1.7.2 Cost effectiveness and resource use

- 19 No economic evaluations were identified for this review; therefore, unit costs were presented 20 to aid committee consideration of cost effectiveness.
- There are different types of carbohydrate loading drinks in the NHS but the cost per carton is approximately £1.50. The committee highlighted that these costs can vary across trusts as prices are usually negotiable. Although this is a low cost, if all adults having surgery are prescribed carbohydrate drinks, this affects a large population and therefore the overall costs would be very high.
- The clinical evidence showed that both carbohydrate loading and water were associated with some improvements in comparison to fasting, for example, less people had headaches and felt nauseous. This can temporarily improve the adult's quality of life post-surgery. However, there was no evidence of complications being reduced. For major abdominal surgery, five studies showed a reduction in hospital length of stay of 1.26 days which could have significant cost-savings.
- The committee highlighted that current practice varies but that in recent years more hospitals have been prescribing carbohydrate drinks to adults undergoing surgery.
- As water showed similar effectiveness to carbohydrate drinks when compared to fasting, the 34 35 committee made a recommendation to offer water to people undergoing surgery. The committee highlighted this may lead to cost-savings as some hospitals routinely offer 36 37 carbohydrate drinks to people. A recommendation was also made to consider carbohydrate drinks in adults having abdominal surgery, as there was an indication that postoperative 38 length of stay could be reduced. Also, the committee highlighted that adults are usually 39 unable to eat after major abdominal surgery, therefore carbohydrate drinks may have some 40 clinical benefits in this population. 41

### 42 **1.7.3** Other factors the committee took into account

The committee agreed that the recommendation to offer clear fluids before surgery is
consistent with current practice. Clear fluids can include water, fruit juice without pulp, coffee
or tea without milk, and ice lollies/popsicles. Clear fluids do not include carbonated drinks,

1 milk, or yoghurt. The committee highlighted the importance of preoperative fasting in 2 preventing intraoperative and postoperative complications. Historically, patients have been 3 asked to fast from midnight or up to six hours prior to surgery to prevent such complications. Therefore, the committee suggested that telling patients they can drink water until up to two 4 hours prior to surgery as well as the benefits of doing so will need to be clearly explained. 5 6 The committee also noted that in some units and ahead of certain types of surgery, people 7 are allowed to drink clear fluids less than two hours before surgery. The committee noted that the amount of clear fluid that can be drunk before surgery is not limited but that is should 8 not be excessive. 9

10 The committee noted that the recommendations are applicable to all people undergoing 11 surgery and not just those requiring a general anaesthetic. It also applies to people 12 undergoing dental surgery.

# References

1

2

3 4

5

6

7

8

9

10

11

12

13

14

15

16

17 18

19

20

21

22

23

24 25

26

27 28

29

30

31 32

33

34

35

36 37

38

39

- 1. Adamova Z, Slovacek R. Effects of preoperative carbohydrate drinks on postoperative outcome after colorectal surgery. European Surgery Acta Chirurgica Austriaca. 2017; 49(4):180-186
- 2. Agarwal A, Chari P, Singh H. Fluid deprivation before operation. The effect of a small drink. Anaesthesia. 1989; 44(8):632-4
- 3. Ajuzieogu OV, Amucheazi AO, Nwagha UI, Ezike HA, Luka SK, Abam DS. Effect of routine preoperative fasting on residual gastric volume and acid in patients undergoing myomectomy. Nigerian Journal of Clinical Practice. 2016; 19(6):816-820
  - 4. Amer MA, Smith MD, Herbison GP, Plank LD, McCall JL. Network meta-analysis of the effect of preoperative carbohydrate loading on recovery after elective surgery. British Journal of Surgery. 2017; 104(3):187-197
- Anonymous. Erratum: Randomized controlled trial of liberal versus restricted fluid management in patients undergoing pancreatectomy (Annals of Surgery 264:4 (591-598) DOI: 10.1097/SLA.000000000001846). Annals of Surgery. 2018; 267(3):e61
- Aronsson A, Al-Ani NA, Brismar K, Hedstrom M. A carbohydrate-rich drink shortly before surgery affected IGF-I bioavailability after a total hip replacement. A doubleblind placebo controlled study on 29 patients. Aging-Clinical & Experimental Research. 2009; 21(2):97-101
  - Asakura A, Mihara T, Goto T. The effect of preoperative oral carbohydrate or oral rehydration solution on postoperative quality of recovery: A randomized, controlled clinical trial. PloS One. 2015; 10(8):e0133309
  - 8. Awad S, Varadhan KK, Ljungqvist O, Lobo DN. A meta-analysis of randomised controlled trials on preoperative oral carbohydrate treatment in elective surgery. Clinical Nutrition. 2013; 32(1):34-44
    - Azagury DE, Ris F, Pichard C, Volonte F, Karsegard L, Huber O. Does perioperative nutrition and oral carbohydrate load sustainably preserve muscle mass after bariatric surgery? A randomized control trial. Surgery for Obesity and Related Diseases. 2015; 11(4):920-6
      - Bhaskaran K, Arumugam G, Vinay Kumar PV. A prospective, randomized, comparison study on effect of perioperative use of chloride liberal intravenous fluids versus chloride restricted intravenous fluids on postoperative acute kidney injury in patients undergoing off-pump coronary artery bypass grafting surgeries. Annals of Cardiac Anaesthesia. 2018; 21(4):413-418
  - 11. Bilku DK, Dennison AR, Hall TC, Metcalfe MS, Garcea G. Role of preoperative carbohydrate loading: a systematic review. Annals of the Royal College of Surgeons of England. 2014; 96(1):15-22
  - 12. Bisgaard T, Kristiansen VB, Hjortso NC, Jacobsen LS, Rosenberg J, Kehlet H. Randomized clinical trial comparing an oral carbohydrate beverage with placebo before laparoscopic cholecystectomy. British Journal of Surgery. 2004; 91(2):151-8
- 4113.Bopp C, Hofer S, Klein A, Weigand MA, Martin E, Gust R. A liberal preoperative42fasting regimen improves patient comfort and satisfaction with anesthesia care in43day-stay minor surgery. Minerva Anestesiologica. 2011; 77(7):680-6

1 14. Borges Dock-Nascimento D, Aguilar-Nascimento JE, Caporossi C, Sepulveda 2 Magalhaes Faria M, Bragagnolo R, Caporossi FS et al. Safety of oral glutamine in the abbreviation of preoperative fasting: a double-blind, controlled, randomized clinical 3 4 trial. Nutricion Hospitalaria. 2011; 26(1):86-90 5 15. Brady M, Kinn S, Stuart P, Ness V. Preoperative fasting for adults to prevent perioperative complications. Cochrane Database of Systematic Reviews 2003, Issue 6 4. Art. No.: CD004423. DOI: 10.1002/14651858.CD004423. 7 8 16. Breuer JP, von Dossow V, von Heymann C, Griesbach M, von Schickfus M, Mackh E et al. Preoperative oral carbohydrate administration to ASA III-IV patients undergoing 9 elective cardiac surgery. Anesthesia and Analgesia. 2006; 103(5):1099-108 10 17. Cakar E, Yilmaz E, Cakar E, Baydur H. The effect of preoperative oral carbohydrate 11 solution intake on patient comfort: a randomized controlled study. Journal of 12 13 Perianesthesia Nursing. 2017; 32(6):589-599 14 18. Campos SBG, Barros-Neto JA, Guedes GDS, Moura FA. Pre-operative fasting: Why 15 abbreviate? Arquivos Brasileiros de Cirurgia Digestiva. 2018; 31(2):e1377 19. Canbay O, Adar S, Karagoz AH, Celebi N, Bilen CY. Effect of preoperative 16 consumption of high carbohydrate drink (Pre-Op) on postoperative metabolic stress 17 18 reaction in patients undergoing radical prostatectomy. International Urology and Nephrology. 2014; 46(7):1329-1333 19 20 20. Celiksular MC, Saracoglu A, Yentur E. The influence of oral carbohydrate solution intake on stress response before total hip replacement surgery during epidural and 21 22 general anaesthesia. Turkish Journal of Anaesthesiology and Reanimation. 2016; 23 44(3):117-23 24 21. Chen J. The effect of the preoperative oral intake of 10% glucose solution on 25 postoperative insulin resistance in patients undergoing gastric cancer resection. 26 Journal of Practical Medicine. 2014; 10(12):1562-1565 27 22. Chen J, Cheng L, Xie Z, Li Z. Impact of preoperative oral liquid carbohydrate on 28 postoperative insulin resistance in gastric cancer patients and its associated study. 29 Chinese Journal of Gastrointestinal Surgery. 2015; 18(12):1256-1260 Chinese Clinical Trials Register. Randomized clinical trial of the effect of preoperative 30 23. oral carbohydrate on postoperative cognitive function in elderly patients undergoing 31 32 colorectal surgery. 2018. Available from: 33 http://www.chictr.org.cn/hvshowproject.aspx?id=12495 Last accessed: 20/06/2019 34 24. de Aguilar-Nascimento JE, Caporossi C, Metelo JS, Tanajura GH, Canevari-de-Oliveira M, da Cunha Costa R. Safe intake of an oral supplement containing 35 carbohydrates and whey protein shortly before sedation to gastroscopy; a double 36 blind, randomized trial. Nutricion Hospitalaria. 2014; 29(3):681-6 37 38 25. de Aquilar-Nascimento JE, Dock-Nascimento DB. Reducing preoperative fasting time: A trend based on evidence. World Journal of Gastrointestinal Surgery. 2010; 39 40 2(3):57-60 41 de Aguilar-Nascimento JE, Perrone F, de Assunção Prado LÍ. Preoperative fasting of 26. 42 8 hours or 2 hours: what does evidence reveal? Revista do Colegio Brasileiro 43 Cirurgioes. 2009; 36(4):350-352 44 27. Dilmen OK, Yentur E, Tunali Y, Balci H, Bahar M. Does preoperative oral carbohydrate treatment reduce the postoperative surgical stress response in lumbar 45 46 disc surgery? Clinical Neurology and Neurosurgery. 2017; 153:82-86

1 28. Dock-Nascimento DB, de Aguilar-Nascimento JE, Magalhaes Faria MS, Caporossi C, 2 Slhessarenko N, Waitzberg DL. Evaluation of the effects of a preoperative 2-hour fast with maltodextrine and glutamine on insulin resistance, acute-phase response, 3 4 nitrogen balance, and serum glutathione after laparoscopic cholecystectomy: a 5 controlled randomized trial. Journal of Parenteral & Enteral Nutrition. 2012; 36(1):43-6 52 7 29. Does preoperative oral carbohydrate intake improve postoperative outcomes in patients undergoing coronary artery bypass grafts? Journal of Cardiothoracic and 8 9 Vascular Anesthesia. 2017; Conference: 32nd Annual Meeting of the European 10 Association of Cardiothoracic Anaesthelologists. Germany. 31(Supplement 1):S58-11 S59 12 30. Doo AR, Hwang H, Ki MJ, Lee JR, Kim DC. Effects of preoperative oral carbohydrate 13 administration on patient well-being and satisfaction in thyroid surgery. Korean Journal of Anesthesiology. 2018; 71(5):394-400 14 15 31. Faria MS, de Aguilar-Nascimento JE, Pimenta OS, Alvarenga LC, Jr., Dock-Nascimento DB, Slhessarenko N. Preoperative fasting of 2 hours minimizes insulin 16 resistance and organic response to trauma after video-cholecystectomy: a 17 randomized, controlled, clinical trial. World Journal of Surgery. 2009; 33(6):1158-64 18 19 32. Feguri GR, de Lima PRL, de Cerqueira Borges D, Toledo LR, Batista LN, TC ES et al. Preoperative carbohydrate load and intraoperatively infused omega-3 20 polyunsaturated fatty acids positively impact nosocomial morbidity after coronary 21 22 artery bypass grafting: a double-blind controlled randomized trial. Nutrition Journal. 2017; 16(1):24 23 24 Feng SY, Zhang JR, Chen YL. Three-hour fluid fasting before anesthesia is safe and 33. beneficial to patients. Beijing Medical Journal. 1995; 17(2):92-94 25 26 Gava MG, Castro-Barcellos HM, Caporossi C, Aguilar-Nascimento JE. Enhanced 34. 27 muscle strength with carbohydrate supplement two hours before open cholecystectomy: a randomized, double-blind study. Revista do Colegio Brasileiro de 28 29 Cirurgioes. 2016; 43(1):54-9 35. Ghorashi Z, Ashori V, Aminzadeh F, Mokhtari M. The effects of oral fluid intake an 30 31 hour before cesarean section on regurgitation incidence. Iranian Journal of Nursing 32 and Midwifery Research. 2014; 19(4):439-42 Gianotti L, Biffi R, Sandini M, Marrelli D, Vignali A, Caccialanza R et al. Preoperative 33 36. oral carbohydrate load versus placebo in major elective abdominal surgery (PROCY): 34 A randomized, placebo-controlled, multicenter, phase III trial. Annals of Surgery. 35 36 2018; 267(4):623-630 37 37. Gilbert SS, Easy WR, Fitch WW. The effect of pre-operative oral fluids on morbidity 38 following anaesthesia for minor surgery. Anaesthesia. 1995; 50(1):79-81 39 38. Gonik N, Tassler A, Ow TJ, Smith RV, Shuaib S, Cohen HW et al. Randomized 40 controlled trial assessing the feasibility of shortened fasts in intubated ICU patients 41 undergoing tracheotomy. Otolaryngology - Head & Neck Surgery. 2016; 154(1):87-93 Goodwin AP, Rowe WL, Ogg TW, Samaan A. Oral fluids prior to day surgery. The 42 39. effect of shortening the pre-operative fluid fast on postoperative morbidity. 43 Anaesthesia. 1991; 46(12):1066-8 44 45 40. Harsten A, Hjartarson H, Toksvig-Larsen S. Total hip arthroplasty and perioperative oral carbohydrate treatment: a randomised, double-blind, controlled trial. European 46 47 Journal of Anaesthesiology. 2012; 29(6):271-4

- 41. Hausel J, Nygren J, Lagerkranser M, Hellstrom PM, Hammarqvist F, Almstrom C et al. A carbohydrate-rich drink reduces preoperative discomfort in elective surgery patients. Anesthesia and Analgesia. 2001; 93(5):1344-50
- 42. Hausel J, Nygren J, Thorell A, Lagerkranser M, Ljungqvist O. Randomized clinical trial of the effects of oral preoperative carbohydrates on postoperative nausea and vomiting after laparoscopic cholecystectomy. British Journal of Surgery. 2005; 92(4):415-21
- 43. Helminen H, Branders H, Ohtonen P, Saarnio J. Effect of pre-operative oral carbohydrate loading on recovery after day-case cholecystectomy: A randomised controlled trial. European Journal of Anaesthesiology. 2019; 36(8):605-611
  - 44. Helminen H, Viitanen H, Sajanti J. Effect of preoperative intravenous carbohydrate loading on preoperative discomfort in elective surgery patients. European Journal of Anaesthesiology. 2009; 26(2):123-7
  - 45. Henriksen MG, Hessov I, Dela F, Hansen HV, Haraldsted V, Rodt SA. Effects of preoperative oral carbohydrates and peptides on postoperative endocrine response, mobilization, nutrition and muscle function in abdominal surgery. Acta Anaesthesiologica Scandinavica. 2003; 47(2):191-9
- 46. Hosny H, Ibrahim M, El-Siory W, Abdel-Monem A. Comparative study between conventional fasting versus overnight infusion of lipid or carbohydrate on insulin and free fatty acids in obese patients undergoing elective on-pump coronary artery bypass grafting: a prospective randomized trial. Journal of Cardiothoracic and Vascular Anesthesia. 2018; 32(3):1248-1253
  - 47. Hutchinson A, Maltby JR, Reid CR. Gastric fluid volume and pH in elective inpatients. Part I: Coffee or orange juice versus overnight fast. Canadian Journal of Anaesthesia. 1988; 35(1):12-5
  - 48. Itou K, Fukuyama T, Sasabuchi Y, Yasuda H, Suzuki N, Hinenoya H et al. Safety and efficacy of oral rehydration therapy until 2 h before surgery: a multicenter randomized controlled trial. Journal of Anesthesia. 2012; 26(1):20-7
  - 49. Jones C, Badger SA, Hannon R. The role of carbohydrate drinks in pre-operative nutrition for elective colorectal surgery. Annals of the Royal College of Surgeons of England. 2011; 93(7):504-7
  - 50. Karlsson A, Wendel K, Polits S, Gislason H, Hedenbro JL. Preoperative nutrition and postoperative discomfort in an ERAS setting: A randomized study in gastric bypass surgery. Obesity Surgery. 2016; 26(4):743-8
  - Kaska M, Grosmanová T, Havel E, Hyspler R. Preparation of patients for operation with per-oral intake on the day of the planned surgery. Rozhledy v Chirurgii. 2006; 85(11):554-559
  - 52. Kaska M, Grosmanova T, Havel E, Hyspler R, Petrova Z, Brtko M et al. The impact and safety of preoperative oral or intravenous carbohydrate administration versus fasting in colorectal surgery--a randomized controlled trial. Wiener Klinische Wochenschrift. 2010; 122(1-2):23-30
- 53. Kwon SA, Lee KC, Song YK, Kim TY, Yun JS. Effects of preoperative oral water intake on gastric content and emotional state of patients. Korean Journal of Anesthesiology. 1994; 27(3):220-226
- 45 54. Lagerkranser M, Nygren J, Almström C, Thorell, Hellström. Oral intake of a
  46 carbohydrate rich beverage preoperatively improves safety and well-being.
  47 Anesthesiology. 1997; 87(3A):A952

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

- 55. Lam KK, So HY, Gin T. Gastric pH and volume after oral fluids in the postpartum patient. Canadian Journal of Anaesthesia. 1993; 40(3):218-21
  - 56. Lambert E, Carey S. Practice guideline recommendations on perioperative fasting: A systematic review. Journal of Parenteral & Enteral Nutrition. 2016; 40(8):1158-1165
  - 57. Lauwick SM, Kaba A, Maweja S, Hamoir EE, Joris JL. Effects of oral preoperative carbohydrate on early postoperative outcome after thyroidectomy. Acta Anaesthesiologica Belgica. 2009; 60(2):67-73
- 58. Lee JS, Song Y, Kim JY, Park JS, Yoon DS. Effects of preoperative oral carbohydrates on quality of recovery in laparoscopic cholecystectomy: A randomized, double blind, placebo-controlled trial. World Journal of Surgery. 2018; 18:18
- 59. Li L, Wang Z, Ying X, Tian J, Sun T, Yi K et al. Preoperative carbohydrate loading for elective surgery: a systematic review and meta-analysis. Surgery Today. 2012; 42(7):613-24
  - 60. Li XX, Li YJ, Liu YH, Liu XY. A meta-analysis of preoperative fasting times in elective surgical patients. World Chinese Journal of Digestology. 2015; 23(3):515-520
  - 61. Lidder P, Thomas S, Fleming S, Hosie K, Shaw S, Lewis S. A randomized placebo controlled trial of preoperative carbohydrate drinks and early postoperative nutritional supplement drinks in colorectal surgery. Colorectal Disease. 2013; 15(6):737-45
  - 62. Liu B, Wang Y, Liu S, Zhao T, Zhao B, Jiang X et al. A randomized controlled study of preoperative oral carbohydrate loading versus fasting in patients undergoing elective craniotomy. Clinical Nutrition. 2018; Epublication
  - 63. Ljunggren S, Hahn RG, Nystrom T. Insulin sensitivity and beta-cell function after carbohydrate oral loading in hip replacement surgery: a double-blind, randomised controlled clinical trial. Clinical Nutrition. 2014; 33(3):392-8
  - 64. Ljungqvist O, Nygren J, Thorell A. Preoperative carbohydrates instead of overnight fasting reduces hospital stay following elective surgery. Clinical Nutrition. 1998; 17 (Suppl 1):3
  - Ljungqvist O, Nygren J, Thorell A, Brodin U, Efendic S. Preoperative nutrition -Elective surgery in the fed or the overnight fasted state. Clinical Nutrition. 2001; 20(Suppl 1):167-171
- 66. Ludwig RB, Paludo J, Fernandes D, Scherer F. Lesser time of preoperative fasting and early postoperative feeding are safe? Arquivos Brasileiros de Cirurgia Digestiva. 2013; 26(1):54-8
- 67. Maltby JR. Fasting from midnight--the history behind the dogma. Best Practice & Research Clinical Anaesthesiology. 2006; 20(3):363-78
  - Maltby JR, Sutherland AD, Sale JP, Shaffer EA. Preoperative oral fluids: is a fivehour fast justified prior to elective surgery? Anesthesia and Analgesia. 1986; 65(11):1112-6
- Manchikanti L, Malla Y, Wargo BW, Fellows B. Preoperative fasting before
   interventional techniques: is it necessary or evidence-based? Pain Physician. 2011;
   14(5):459-67
- Mathur S, Plank LD, McCall JL, Shapkov P, McIlroy K, Gillanders LK et al.
  Randomized controlled trial of preoperative oral carbohydrate treatment in major abdominal surgery. British Journal of Surgery. 2010; 97(4):485-94

- 71. McKenna G, Manton S. Pre-operative fasting for intravenous conscious sedation used in dental treatment: are conclusions based on relative risk management or evidence? British Dental Journal. 2008; 205(4):173-6
- 72. Meisner M, Ernhofer U, Schmidt J. Liberalisation of preoperative fasting guidelines: effects on patient comfort and clinical practicability during elective laparoscopic surgery of the lower abdomen. Zentralblatt für Chirurgie. 2008; 133(5):479-485
- 73. Melis GC, van Leeuwen PA, von Blomberg-van der Flier BM, Goedhart-Hiddinga AC, Uitdehaag BM, Strack van Schijndel RJ et al. A carbohydrate-rich beverage prior to surgery prevents surgery-induced immunodepression: a randomized, controlled, clinical trial. Journal of Parenteral & Enteral Nutrition. 2006; 30(1):21-6
  - 74. Miller M, Wishart HY, Nimmo WS. Gastric contents at induction of anaesthesia. Is a 4-hour fast necessary? British Journal of Anaesthesia. 1983; 55(12):1185-8
  - 75. Morimoto Y, Kinugawa T, Hayashi M, Iida T, Yamamoto T. Effects of preoperative oral carbohydrate intake on catabolism, nutrition and adipocytokines during minor surgery: A randomized, prospective, controlled clinical phase II trial. PloS One. 2019; 14(5):e0216525
- 76. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual, updated 2018. London. National Institute for Health and Care Excellence, 2014. Available from: https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview
  - 77. NHS Supply Chain Catalogue. NHS Supply Chain, 2018. Available from: https://my.supplychain.nhs.uk/catalogue
  - 78. Noba L, Wakefield A. Are carbohydrate drinks more effective than preoperative fasting: A systematic review of randomised controlled trials. Journal of Clinical Nursing. 2019; 28(17-18):3096-3116
  - 79. Noblett SE, Watson DS, Huong H, Davison B, Hainsworth PJ, Horgan AF. Preoperative oral carbohydrate loading in colorectal surgery: a randomized controlled trial. Colorectal Disease. 2006; 8(7):563-9
  - Nygren J, Soop M, Thorell A, Sree Nair K, Ljungqvist O. Preoperative oral carbohydrates and postoperative insulin resistance. Clinical Nutrition. 1999; 18(2):117-20
  - 81. Nygren J, Thorell A, Lagerkranser M, Almstrom C, Hammarqvist F, Ljungqvist O. Safety and patient well-being after preoperative oral intake of carbohydrate rich beverage. Clinical Nutrition. 1996; 15 (Suppl 1):30
  - 82. Nygren J, Thorell A, Ljungqvist O. Are there any benefits from minimizing fasting and optimization of nutrition and fluid management for patients undergoing day surgery? Current Opinion in Anaesthesiology. 2007; 20(6):540-544
  - 83. Nygren J, Thorell A, Ljungqvist O. Preoperative oral carbohydrate therapy. Current Opinion in Anaesthesiology. 2015; 28(3):364-9
- 84. Onalan E, Andsoy II, Ersoy OF. The effect of preoperative oral carbohydrate administration on insulin resistance and comfort level in patients undergoing surgery. Journal of Perianesthesia Nursing. 2018; 34(3):539-550
- 43 85. Orbey BC, Alanoglu Z, Yilmaz AA, Erkek B, Ates Y, Ayhan Kuzu M. Do we still need
  44 to restrict preoperative fluid administration in ambulatory anorectal surgery under
  45 spinal anaesthesia? Techniques in Coloproctology. 2009; 13(1):35-40

2

3

4

5

6

7

8

9

10

11

12 13

14

15 16

17

18

19

20

21 22

23

24

25

26

27

28

29

30

31

32

33

34

35

36 37

38

39

- 86. Ozdemir F, Eti Z, Dincer P, Yilmaz Gogus F, Bekiroglu N. The effect of preoperative oral carbohydrate loading on stress response in patients undergoing major or minor surgery. Turkiye Klinikleri Journal of Medical Sciences. 2011; 31(6):1392-1400
  - 87. Ozkan T, Senturk M, Yavru A, Celebi S, Pembeci K. Does preoperative fluid fasting have a benefit on aspiration prophylaxis in obstetric anaesthesia. Turkish Journal of Anaesthesiology and Reanimation. 2000; 28(8):425-429
- 88. Perrone F, da-Silva-Filho AC, Adorno IF, Anabuki NT, Leal FS, Colombo T et al. Effects of preoperative feeding with a whey protein plus carbohydrate drink on the acute phase response and insulin resistance. A randomized trial. Nutrition Journal. 2011; 10:66
  - 89. Pexe-Machado PA, de Oliveira BD, Dock-Nascimento DB, de Aguilar-Nascimento JE. Shrinking preoperative fast time with maltodextrin and protein hydrolysate in gastrointestinal resections due to cancer. Nutrition. 2013; 29(7-8):1054-9
- 90. Pimenta GP, De Aguilar-Nascimento JE. Prolonged preoperative fasting in elective surgical patients: Why should we reduce it? Nutrition in Clinical Practice. 2014; 29(1):22-28
- 91. Popovic M, Schlenker MB, Goldshtein D, Rai A, El-Defrawy S. Preoperative fasting for ambulatory cataract surgery: a systematic review. Canadian Journal of Ophthalmology. 2019; 54(2):145-149
  - 92. Pousman RM, Pepper C, Pandharipande P, Ayers GD, Mills B, Diaz J et al. Feasibility of implementing a reduced fasting protocol for critically ill trauma patients undergoing operative and nonoperative procedures. Journal of Parenteral & Enteral Nutrition. 2009; 33(2):176-80
    - 93. Power S, Kavanagh DO, McConnell G, Cronin K, Corish C, Leonard M et al.
       Reducing preoperative fasting in elective adult surgical patients: a case-control study.
       Irish Journal of Medical Science. 2012; 181(1):99-104
  - 94. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Committee on Standards and Practice Parameters. Anesthesiology. 2011; 114(3):495-511
    - 95. Pu XL. Effect of preoperative carbohydrate supplementation on insulin resistance in patients after scar ectomy. Journal of Anatomy Operating Surgery. 2005; 14:368-70
  - 96. Raksakietisak M, Chinachoti T, Iamaroon A, Thabpenthai Y, Halilamien P, Siriratwarangkul S et al. Oral rehydration with 10% carbohydrate drink for preventing postoperative nausea and vomiting (PONV) after low dose of spinal morphine. Journal of the Medical Association of Thailand. 2014; 97(5):530-535
  - 97. Read MS, Vaughan RS. Allowing pre-operative patients to drink: effects on patients' safety and comfort of unlimited oral water until 2 hours before anaesthesia. Acta Anaesthesiologica Scandinavica. 1991; 35(7):591-5
- 41 98. Sada F, Krasniqi A, Hamza A, Gecaj-Gashi A, Bicaj B, Kavaja F. A randomized trial
  42 of preoperative oral carbohydrates in abdominal surgery. BMC Anesthesiology. 2014;
  43 14:93
- Savluk OF, Kuscu MA, Guzelmeric F, Gurcu ME, Erkilinc A, Cevirme D et al. Do
  preoperative oral carbohydrates improve postoperative outcomesin patients
  undergoing coronary artery bypass grafts? Turkish Journal of Medical Sciences.
  2017; 47(6):1681-1686

1 100. Singh M, Chaudhary M, Vashistha A, Kaur G. Evaluation of effects of a preoperative 2 2-hour fast with glutamine and carbohydrate rich drink on insulin resistance in maxillofacial surgery. Journal of Oral Biology & Craniofacial Research. 2015; 5(1):34-3 4 39 5 101. Smith I, Kranke P, Murat I, Smith A, O'Sullivan G, Soreide E et al. Perioperative fasting in adults and children: Guidelines from the European society of 6 7 anaesthesiology. Romanian Journal of Anaesthesia and Intensive Care. 2012; 8 19(1):65-88 102. Smith M, McCall J, Plank L, Herbison G, Soop M, Nygren J. Preoperative 9 10 carbohydrate treatment for enhancing recovery after elective surgery. Cochrane Database of Systematic Reviews 2014, Issue 8. Art. No.: CD009161. DOI: 11 12 10.1002/14651858.CD009161.pub2. 13 103. Soop M, Myrenfors P, Nygren J, Thorell A, Ljungqvist O. Preoperative oral carbohydrate intake attenuates metabolic changes immediately after hip replacement. 14 15 Clinical Nutrition. 1998; 17(Suppl I):3-4 Soreide E, Hausken T, Soreide JA, Steen PA. Gastric emptying of a light hospital 16 104. breakfast - A study using real time ultrasonography. Acta Anaesthesiologica 17 18 Scandinavica. 1996; 40(5):549-553 Tran S, Wolever TM, Errett LE, Ahn H, Mazer CD, Keith M. Preoperative 19 105. carbohydrate loading in patients undergoing coronary artery bypass or spinal surgery. 20 21 Anesthesia and Analgesia. 2013; 117(2):305-13 22 106. van Ginhoven TM, Dik WA, Mitchell JR, Smits-te Nijenhuis MA, van Holten-Neelen C, Hooijkaas H et al. Dietary restriction modifies certain aspects of the postoperative 23 24 acute phase response. Journal of Surgical Research. 2011; 171(2):582-9 25 107. Wang ZG, Wang Q, Wang WJ, Qin HL. Randomized clinical trial to compare the effects of preoperative oral carbohydrate versus placebo on insulin resistance after 26 27 colorectal surgery. British Journal of Surgery. 2010; 97(3):317-27 28 108. Xu D, Zhu X, Xu Y, Zhang L. Shortened preoperative fasting for prevention of 29 complications associated with laparoscopic cholecystectomy: a meta-analysis. Journal of International Medical Research. 2017; 45(1):22-37 30 Yagci G, Can MF, Ozturk E, Dag B, Ozgurtas T, Cosar A et al. Effects of preoperative 31 109. 32 carbohydrate loading on glucose metabolism and gastric contents in patients 33 undergoing moderate surgery: a randomized, controlled trial. Nutrition. 2008; 34 24(3):212-6 Yagmurdur H, Gunal S, Yildiz H, Gulec H, Topkaya C. The effects of carbohydrate-35 110. 36 rich drink on perioperative discomfort, insulin response and arterial pressure in spinal 37 aesthesia. Journal of Research in Medical Sciences. 2011; 16(11):1483-1489 Yildiz H, Gunal SE, Yilmaz G, Yucel S. Oral carbohydrate supplementation reduces 38 111. 39 preoperative discomfort in laparoscopic cholecystectomy. Journal of Investigative Surgery. 2013; 26(2):89-95 40 41 112. Yilmaz N, Cekmen N, Bilgin F, Erten E, Ozhan MO, Cosar A. Preoperative 42 carbohydrate nutrition reduces postoperative nausea and vomiting compared to 43 preoperative fasting. Journal of Research in Medical Sciences. 2013; 18(10):827-832 44 113. Yuill KA, Richardson RA, Davidson HI, Garden OJ, Parks RW. The administration of an oral carbohydrate-containing fluid prior to major elective upper-gastrointestinal 45 46 surgery preserves skeletal muscle mass postoperatively--a randomised clinical trial. Clinical Nutrition. 2005; 24(1):32-7 47

- 114. Zhan C, Dai X, Shen G, Lu X, Wang X, Lu L et al. Preoperative short-term fasting protects liver injury in patients undergoing hepatectomy. Annals of Translational Medicine. 2018; 6(23):449
- 115. Zhang Y, Min J. Preoperative carbohydrate loading in gynecological patients undergoing combined spinal and epidural anesthesia. Journal of Investigative Surgery. 2019; Epublication

# Appendices

1

2

3

# Appendix A: Review protocols

### Table 9: Review protocol: Preoperative fasting strategy

ID	Field	Content
0.	PROSPERO registration number	Not registered on PROSPERO
1.	Review title	What is the most clinically and cost effective preoperative fasting strategy for adults?
2.	Review question	What is the most clinically and cost effective preoperative fasting strategy for adults?
3.	Objective	To determine the most clinically and cost effective preoperative fasting strategy.
4.	Searches	<ul> <li>Cochrane Central Register of Controlled Trials (CENTRAL)</li> </ul>
		<ul> <li>Cochrane Database of Systematic Reviews (CDSR)</li> </ul>
		• Embase
		MEDLINE
		Epistemonikos
		The searches may be re-run 6 weeks before the final committee meeting and further studies retrieved for inclusion if relevant.
		The full search strategies will be published in the final review.
5.	Condition or domain being studied	Perioperative care
6.	Population	Inclusion: Adults 18 years and over having surgery.
		Exclusion:
		<ul> <li>children and young people aged 17 years and younger</li> </ul>
		<ul> <li>surgery for burns, traumatic brain injury</li> </ul>
		<ul><li>or neurosurgery</li><li>cardiac surgery</li></ul>
		<ul> <li>parenteral feeding</li> </ul>
		emergency surgery     prognant wampan
		<ul><li>pregnant women</li><li>gastroparesis</li></ul>
7.	Intervention/Exposure/Test	no food for <4 hours
		<ul> <li>no food for 4-6 hours</li> <li>no food for &gt;6 hours</li> </ul>
		<ul> <li>no fluids for &lt;2 hours</li> </ul>

© NICE 2019. All rights reserved. Subject to Notice of rights.

		no fluids for 2-4 hours     no fluids for 4 6 hours
		<ul> <li>no fluids for 4-6 hours</li> <li>no fluids for &gt;6 hours</li> <li>maintaining clear fluids (non-milk, non-particulate drinks) before surgery</li> <li>combinations of food and fluid restriction strategies</li> </ul>
8.	Comparator/Reference standard/Confounding factors	each other
9.	Types of study to be included	Randomised controlled trials (RCTs), systematic reviews of RCTs.
		Observational studies if no RCT evidence is identified.
10.	Other exclusion criteria	<ul><li>Exclusions:</li><li>non-English language studies</li><li>studies published before 2000</li></ul>
11.	Context	An extended fasting period can be unpleasant for the person undergoing surgery. This review aims to determine the most clinically and cost effective fasting strategy.
12.	Primary outcomes (critical outcomes)	<ul> <li>health-related quality of life</li> <li>mortality</li> <li>patient, family and carer experience of care</li> <li>adverse events and complications (Clavien- Dindo, postoperative morbidity score (POMS), aspiration – pulmonary complications, acute kidney injury)</li> <li>The committee did not agree to on any established minimal clinically important differences, therefore the default MIDs will be used and any difference in mortality will be considered clinically important.</li> </ul>
13.	Secondary outcomes (important outcomes)	<ul> <li>length of hospital stay</li> <li>unplanned ICU admission</li> <li>thirst</li> <li>headache</li> <li>cancellation of surgery</li> <li>The committee did not agree to on any established minimal clinically important differences, therefore the default MIDs will be used and any difference in mortality will be considered clinically important.</li> </ul>
14.	Data extraction (selection and coding)	EndNote will be used for reference management, sifting, citations and bibliographies. All references identified by the searches and from other sources will be screened for inclusion. 10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer. The full text of potentially eligible studies will be

 $\ensuremath{\textcircled{\sc online \sc on$ 

		retrieved and will be assessed in line with the
		criteria outlined above.
		Data extractions performed using EviBase, a platform designed and maintained by the National Guideline Centre (NGC)
15.	Risk of bias (quality) assessment	Risk of bias will be assessed using the appropriate checklist as described in Developing NICE guidelines: the manual.
		<ul> <li>Systematic reviews: Risk of Bias in Systematic Reviews (ROBIS)</li> </ul>
		<ul> <li>Randomised Controlled Trial: Cochrane RoB (2.0)</li> </ul>
		<ul> <li>Non randomised study, including cohort studies: Cochrane ROBINS-I</li> </ul>
		<ul> <li>Case control study: CASP case control checklist</li> </ul>
		<ul> <li>Controlled before-and-after study or Interrupted time series: Effective Practice and Organisation of Care (EPOC) RoB Tool</li> </ul>
		<ul> <li>Cross sectional study: JBI checklist for cross sectional study</li> </ul>
		<ul> <li>Case series: Institute of Health Economics (IHE) checklist for case series</li> </ul>
		10% of all evidence reviews are quality assured by a senior research fellow. This includes checking:
		• papers were included /excluded appropriately
		<ul> <li>a sample of the data extractions</li> </ul>
		<ul> <li>correct methods are used to synthesise data</li> </ul>
		<ul> <li>a sample of the risk of bias assessments</li> </ul>
		Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary.
16.	Strategy for data synthesis	Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5).
		GRADEpro will be used to assess the quality of evidence for each outcome, taking into account individual study quality and the meta-analysis results. The 4 main quality elements (risk of bias, indirectness, inconsistency and imprecision) will be appraised for each outcome. Publication bias is tested for when there are more than 5 studies for an outcome.
		The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group

 $\ensuremath{\textcircled{\sc online \sc on$ 

		http://www	.gradewor	kinggroup.o	rg/
		be prese		quality asse	ssible, data will ssed
			l will be us re studies.		esise data from
				used for netweet a set of the set	work meta- data identified.
		List any	other softv	vare planne	d to be used.
		measures and visuall 50% will be heterogene conducted using strati heterogene not explain	will be ass y inspecte e consider eity. Sensi based on ified meta- eity in effe the heter	ed. An I <sup>2</sup> valued ed indicative tivity analys pre-specifie analysis to ct estimates	g the l <sup>2</sup> statistic ue greater than e of substantial es will be ed subgroups explore the s. If this does e results will be
17.	Analysis of sub-groups	Subgroups		0	
		<ul> <li>older adu</li> </ul>			
40		<ul> <li>people w</li> </ul>	vith diabete	es	
18.	Type and method of review	$\boxtimes$	Intervent	tion	
			Diagnos	tic	
			Prognos	tic	
			Qualitati	ve	
			Epidemi	ologic	
			Service	Delivery	
			Other (p	lease specif	y)
19.	Language	English			
20.	Country	England			
21.	Anticipated or actual start date	[To be add	ed 1		
22.	Anticipated completion date	[To be add			
23.	Stage of review at time of this	Review sta	_	Started	Completed
	submission	Preliminary searches	/		
		Piloting of selection p			
		Formal scr of search r against elig criteria	esults		
		Data extra	ction		

© NICE 2019. All rights reserved. Subject to Notice of rights.

-	1	1		,
		Risk of bias (quality) assessment		
		Data analysis		
24.	Named contact	5a. Named contact		
		National Guideline C	entre	
		5b Named contact e-	mail	
		perioperativecare@n	ice.org.uk	
		5e Organisational aff	iliation of th	e review
		National Institute for Excellence (NICE) ar Centre		
25.	Review team members	From the National Gu	uideline Cer	ntre:
		Ms Kate Ashmore		
		Ms Kate Kelley		
		Ms Sharon Swain		
		Mr Ben Mayer		
		Ms Maria Smyth		
		Mr Vimal Bedia		
		Mr Audrius Stonkus		
		Ms Madelaine Zucke	r	
		Ms Margaret Constar	nti	
		Ms Annabelle Davis		
		Ms Lina Gulhane		
26.	Funding sources/sponsor	This systematic revie the National Guidelin funding from NICE.		
27.	Conflicts of interest	All guideline committe who has direct input i (including the evidence witnesses) must decl of interest in line with for declaring and dea interest. Any relevant interests, will also be start of each guidelin Before each meeting interest will be consid committee Chair and development team. A person from all or par documented. Any cha declaration of interess minutes of the meeting	into NICE g ce review te are any pot NICE's coo ling with co c interests, c declared pot e committee , any potent dered by the a senior mo a senior mo any decision rt of a meet anges to a r ts will be re	uidelines eam and expert ential conflicts de of practice inflicts of or changes to ublicly at the e meeting. tial conflicts of e guideline ember of the is to exclude a ing will be member's corded in the

		interests v guideline.	vill be published with the final
28.	Collaborators	overseen use the re evidence- section 3 o <u>manual</u> . M	tent of this systematic review will be by an advisory committee who will view to inform the development of based recommendations in line with of <u>Developing NICE guidelines: the</u> Members of the guideline committee ble on the NICE website.
29.	Other registration details	n/a	
30.	Reference/URL for published protocol	n/a	
31.	Dissemination plans	raise awai	v use a range of different methods to reness of the guideline. These include approaches such as:
		<ul> <li>notifying publication</li> </ul>	registered stakeholders of ion
			ng the guideline through NICE's ter and alerts
		appropri	a press release or briefing as iate, posting news articles on the ebsite, using social media channels, licising the guideline within NICE.
32.	Keywords	Periopera	tive care, preoperative, fasting
33.	Details of existing review of same topic by same authors	n/a	
34.	Current review status		Ongoing
			Completed but not published
			Completed and published
			Completed, published and being updated
			Discontinued
35	Additional information	n/a	
36.	Details of final publication	www.nice.	.org.uk

2

### Table 10: Health economic review protocol

Review question	All questions – health economic evidence
Objectives	To identify health economic studies relevant to any of the review questions.
Search criteria	• Populations, interventions and comparators must be as specified in the clinical review protocol above.
	• Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis).
	• Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The

bibliographies will be checked for relevant studies, which will then be ordered.) · Unpublished reports will not be considered unless submitted as part of a call for evidence. Studies must be in English. Search A health economic study search will be undertaken using population-specific terms and a health economic study filter - see appendix B below. strategy Review Studies not meeting any of the search criteria above will be excluded. Studies strategy published before 2003, abstract-only studies and studies from non-OECD countries or the USA will also be excluded. Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).<sup>76</sup> Inclusion and exclusion criteria • If a study is rated as both 'Directly applicable' and with 'Minor limitations' then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile. • If a study is rated as either 'Not applicable' or with 'Very serious limitations' then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile. • If a study is rated as 'Partially applicable', with 'Potentially serious limitations' or both then there is discretion over whether it should be included. Where there is discretion The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological guality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below. The health economist will be guided by the following hierarchies. Setting: • UK NHS (most applicable). OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden). OECD countries with predominantly private health insurance systems (for example, Switzerland). Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations. Health economic study type: Cost-utility analysis (most applicable). • Other type of full economic evaluation (cost-benefit analysis, cost-effectiveness analysis, cost-consequences analysis). Comparative cost analysis. Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations. Year of analysis:

• The more recent the study, the more applicable it will be.

- Studies published in 2003 or later but that depend on unit costs and resource data entirely or predominantly from before 2003 will be rated as 'Not applicable'.
- Studies published before 2003 will be excluded before being assessed for applicability and methodological limitations.

Quality and relevance of effectiveness data used in the health economic analysis:

• The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline. For example, economic evaluations based on observational studies will be excluded, when the clinical review is only looking for RCTs,

# **Appendix B: Literature search strategies**

The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual 2014, updated 2018.<sup>76</sup>

4 For more detailed information, please see the Methodology Review.

# 5 B.1 Clinical search literature search strategy

Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies for interventions as these concepts may not be well described in title, abstract or indexes and therefore difficult to retrieve. Search filters were applied to the search where appropriate.

# 11 Table 11: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 31 May 2019	Exclusions Randomised controlled trials Systematic review studies
Embase (OVID)	1974 – 31 May 2019	Exclusions Randomised controlled trials Systematic review studies
The Cochrane Library (Wiley)	Cochrane Reviews to 2019 Issue 5 of 12 CENTRAL to 2019 Issue 5 of 12 DARE, and NHSEED to 2015 Issue 2 of 4 HTA to 2016 Issue 4 of 4	None
Epistemonikos (Epistemonikos Foundation)	Inception - 19 February 2019	Systematic review studies

1

2

3

6

7

8 9

10

# Medline (Ovid) search terms

1
exp Preoperative Care/ or Preoperative Period/
(pre-operat* or preoperat* or pre-surg* or presurg*).ti,ab.
((before or prior or advance or pre or prepar*) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.
or/1-3
limit 4 to English language
(exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/)
5 not 6
letter/
editorial/
news/
exp historical article/
Anecdotes as Topic/
comment/
case report/
(letter or comment*).ti.

© NICE 2019. All rights reserved. Subject to Notice of rights.

	or/8-15
16.	randomized controlled trial/ or random*.ti,ab.
17.	16 not 17
18.	animals/ not humans/
19.	exp Animals, Laboratory/
20.	exp Animal Experimentation/
21.	exp Models, Animal/
22.	exp Rodentia/
23.	(rat or rats or mouse or mice).ti.
24.	or/18-24
25.	7 not 25
26.	Fasting/ or Food deprivation/
27.	Water deprivation/
28.	hunger/ or thirst/
29.	(meal* or solid or solids or drink* or water or liquid* or milk or beverage* or hydrat* or eat* or ate or food* or feed* or carbohyrate* or fasting or fasted or starv* or hung* or thirst*).ti,ab.
30.	((fluid* or oral* or consume or consumption) adj4 (restrict* or limit* or stop* or abstinence or abstain* or deprive* or deprivation or lack* or fast* or starve* or hung* or thirst* or intake or intaking or ingest*)).ti,ab.
31.	("nil by mouth" or "nothing by mouth" or NBM or "nil per os" or "nihil per os" or "nulla per os" or "non per os" or NPO).ti,ab.
32.	or/27-32
33.	26 and 33
34.	randomized controlled trial.pt.
35.	controlled clinical trial.pt.
36.	randomi#ed.ab.
37.	placebo.ab.
38.	randomly.ab.
39.	clinical trials as topic.sh.
40.	trial.ti.
41.	or/35-41
42.	Meta-Analysis/
43.	Meta-Analysis as Topic/
44.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
45.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
46.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
47.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
48.	(search* adj4 literature).ab.
49.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
50.	cochrane.jw.
51.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
52.	or/43-52
53.	34 and (42 or 53)

1.	*preoperative care/ or *preoperative period/
2.	(pre-operat* or preoperat* or pre-surg* or presurg*).ti,ab.
3.	((before or prior or advance or pre or prepar*) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.
4.	or/1-3
5.	limit 4 to English language
6.	(exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/)
7.	5 not 6
8.	letter.pt. or letter/
9.	note.pt.
10.	editorial.pt.
11.	case report/ or case study/
12.	(letter or comment*).ti.
13.	or/8-12
14.	randomized controlled trial/ or random*.ti,ab.
15.	13 not 14
16.	animal/ not human/
17.	nonhuman/
18.	exp Animal Experiment/
19.	exp Experimental Animal/
20.	animal model/
21.	exp Rodent/
22.	(rat or rats or mouse or mice).ti.
23.	or/15-22
24.	7 not 23
25.	*diet restriction/ or food deprivation/
26.	water deprivation/
27.	*hunger/ or thirst/
28.	(meal* or solid or solids or drink* or water or liquid* or milk or beverage* or hydrat* or eat* or ate or food* or feed* or carbohyrate* or fasting or fasted or starv* or hung* or thirst*).ti,ab.
29.	((fluid* or oral* or consume or consumption) adj4 (restrict* or limit* or stop* or abstinence or abstain* or deprive* or deprivation or lack* or fast* or starve* or hung* or thirst* or intake or intaking or ingest*)).ti,ab.
30.	("nil by mouth" or "nothing by mouth" or NBM or "nil per os" or "nihil per os" or "nulla per os" or "non per os" or NPO).ti,ab.
31.	or/25-30
32.	24 and 31
33.	random*.ti,ab.
34.	factorial*.ti,ab.
35.	(crossover* or cross over*).ti,ab.
36.	((doubl* or singl*) adj blind*).ti,ab.
37.	(assign* or allocat* or volunteer* or placebo*).ti,ab.
38.	crossover procedure/
39.	single blind procedure/

 $\ensuremath{\textcircled{\sc online \sc on$ 

40.	randomized controlled trial/
41.	double blind procedure/
42.	or/33-41
43.	systematic review/
44.	Meta-Analysis/
45.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
46.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
47.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
48.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
49.	(search* adj4 literature).ab.
50.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
51.	cochrane.jw.
52.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
53.	or/43-52
54.	32 and (42 or 53)

### Cochrane Library (Wiley) search terms

#1.	MeSH descriptor: [Preoperative Care] this term only
#2.	MeSH descriptor: [Preoperative Period] this term only
#3.	MeSH descriptor: [Perioperative Nursing] this term only
#4.	(pre-operative* or preoperative* or preop* or pre-op* or pre-surg* or presurg*):ti,ab
#5.	(before or prior or advance) near/3 (surg* or operat* or anaesthes* or anesthes*):ti,ab
#6.	(or #1-#5)
#7.	MeSH descriptor: [Fasting] this term only
#8.	MeSH descriptor: [Food Deprivation] this term only
#9.	MeSH descriptor: [Water Deprivation] this term only
#10.	MeSH descriptor: [Hunger] this term only
#11.	MeSH descriptor: [Thirst] this term only
#12.	(meal* or solid or solids or drink* or water or liquid* or milk or beverage* or hydrat* or eat* or ate or food* or feed* or carbohyrate* or fasting or fasted or starv* or hung* or thirst*):ti,ab
#13.	((fluid* or oral* or consume or consumption) near/4 (restrict* or limit* or stop* or abstinence or abstain* or deprive* or deprivation or lack* or fast* or starve* or hung* or thirst* or intake or intaking or ingest*)):ti,ab
#14.	("nil by mouth" or "nothing by mouth" or NBM or "nil per os" or "nihil per os" or "nulla per os" or "non per os" or NPO):ti,ab
#15.	(or #7-#14)
#16.	#6 and #15

2

1

### Epistemonikos (Epistemonikos Foundation) search terms

1.	(pre-operative* OR preoperative* OR preop* OR pre-op* OR pre-surg* OR presurg*)
	AND (fasting OR fasted OR starv* OR hung* OR thirst* OR "nil by mouth" OR "nothing
	by mouth" OR NBM OR "nil per os" OR "nihil per os" OR "nulla per os" OR "non per os"
	OR NPO) [Filters: protocol=no, classification=systematic-review]

# **B.2** Health Economics literature search strategy

Health economic evidence was identified by conducting a broad search relating to the perioperative care population in NHS Economic Evaluation Database (NHS EED – this ceased to be updated after March 2015) and the Health Technology Assessment database (HTA) with no date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD). Additional health economics searches were run on Medline and Embase.

#### Table 12: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline	2014 – 30 May 2019	Exclusions Health economics studies
Embase	2014 – 30 May 2019	Exclusions Health economics studies
Centre for Research and Dissemination (CRD)	HTA - Inception – 02 May 2019 NHSEED - Inception to 02 May 2019	None

9

2

3

4

5

6

7

8

#### Medline (Ovid) search terms

1.	exp Preoperative Care/ or exp Perioperative Care/ or exp Perioperative Period/ or exp Perioperative Nursing/
2.	((pre-operative* or preoperative* or preop* or pre-op* or pre-surg* or presurg*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine)).ti,ab.
3.	((perioperative* or peri-operative* or intraoperative* or intra-operative* or intrasurg* or intra-surg* or peroperat* or per-operat*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine)).ti,ab.
4.	((postoperative* or postop* or post-op* or post-surg* or postsurg*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine)).ti,ab.
5.	((care* or caring or treat* or nurs* or recover* or monitor*) adj3 (before or prior or advance or during or after) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.
6.	1 or 2 or 3 or 4 or 5
7.	(intraoperative* or intra-operative* or intrasurg* or intra-surg* or peroperat* or per- operat* or perioperat* or peri-operat*).ti,ab.
8.	((during or duration) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.
9.	7 or 8
10.	postoperative care/ or exp Postoperative Period/ or exp Perioperative nursing/
11.	(postop* or post-op* or post-surg* or postsurg* or perioperat* or peri-operat*).ti,ab.
12.	(after adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.
13.	(post adj3 (operat* or anaesthes* or anesthes*)).ti,ab.
14.	10 or 11 or 12 or 13
15.	exp Preoperative Care/ or Preoperative Period/
16.	(pre-operat* or preoperat* or pre-surg* or presurg*).ti,ab.
17.	((before or prior or advance or pre or prepar*) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.
18.	15 or 16 or 17
19.	6 or 9 or 14 or 18
20.	letter/
21.	editorial/

22.	news/
23.	exp historical article/
24.	Anecdotes as Topic/
25.	comment/
26.	case report/
27.	(letter or comment*).ti.
28.	or/20-27
29.	randomized controlled trial/ or random*.ti,ab.
30.	28 not 29
31.	animals/ not humans/
32.	exp Animals, Laboratory/
33.	exp Animal Experimentation/
34.	exp Models, Animal/
35.	exp Rodentia/
36.	(rat or rats or mouse or mice).ti.
37.	or/30-36
38.	19 not 37
39.	limit 38 to English language
40.	(exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/)
41.	39 not 40
42.	economics/
43.	value of life/
44.	exp "costs and cost analysis"/
45.	exp Economics, Hospital/
46.	exp Economics, medical/
47.	Economics, nursing/
48.	economics, pharmaceutical/
49.	exp "Fees and Charges"/
50.	exp budgets/
51.	budget*.ti,ab.
52.	cost*.ti.
53.	(economic* or pharmaco?economic*).ti.
54.	(price* or pricing*).ti,ab.
55.	(cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
56.	(financ* or fee or fees).ti,ab.
57.	(value adj2 (money or monetary)).ti,ab.
58.	or/42-57
59.	41 and 58

## Embase (Ovid) search terms

1.	*preoperative period/ or *intraoperative period/ or *postoperative period/ or *perioperative nursing/ or *surgical patient/
2.	((pre-operative* or preoperative* or preop* or pre-op* or pre-surg* or presurg*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine)).ti,ab.
3.	((perioperative* or peri-operative* or intraoperative* or intra-operative* or intrasurg* or intra-surg* or peroperat* or per-operat*) adj3 (care* or caring or treat* or nurs* or

	monitor* or recover* or medicine)).ti,ab.	
4.	((care* or caring or treat* or nurs* or recover* or monitor*) adj3 (before or prior or advance or during or after) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.	
5.	1 or 2 or 3 or 4	
6.	peroperative care/ or exp peroperative care/ or exp perioperative nursing/	
7.	(intraoperative* or intra-operative* or intrasurg* or intra-surg* or peroperat* or per- operat* or perioperat* or peri-operat*).ti,ab.	
8.	((during or duration) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.	
9.	6 or 7 or 8	
10.	postoperative care/ or exp postoperative period/ or perioperative nursing/	
11.	(postop* or post-op* or post-surg* or postsurg* or perioperat* or peri-operat*).ti,ab.	
12.	(after adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.	
13.	(post adj3 (operat* or anaesthes* or anesthes*)).ti,ab.	
14.	10 or 11 or 12 or 13	
15.	exp preoperative care/ or preoperative period/	
16.	(pre-operat* or preoperat* or pre-surg* or presurg*).ti,ab.	
17.	((before or prior or advance or pre or prepar*) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.	
18.	15 or 16 or 17	
19.	5 or 9 or 14 or 18	
20.	letter.pt. or letter/	
21.	note.pt.	
22.	editorial.pt.	
23.	case report/ or case study/	
24.	(letter or comment*).ti.	
25.	or/20-24	
26.	randomized controlled trial/ or random*.ti,ab.	
27.	25 not 26	
28.	animal/ not human/	
29.	nonhuman/	
30.	exp Animal Experiment/	
31.	exp Experimental Animal/	
32.	animal model/	
33.	exp Rodent/	
34.	(rat or rats or mouse or mice).ti.	
35.	or/27-34	
36.	19 not 35	
37.	limit 36 to English language	
38.	(exp child/ or exp pediatrics/) not (exp adult/ or exp adolescent/)	
39.	37 not 38	
40.	health economics/	
41.	exp economic evaluation/	

42.	exp health care cost/
43.	exp fee/
44.	budget/
45.	funding/
46.	budget*.ti,ab.
47.	cost*.ti.
48.	(economic* or pharmaco?economic*).ti.
49.	(price* or pricing*).ti,ab.
50.	(cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
51.	(financ* or fee or fees).ti,ab.
52.	(value adj2 (money or monetary)).ti,ab.
53.	or/40-52
54.	39 and 53

# NHS EED and HTA (CRD) search terms


#1.	MeSH DESCRIPTOR Preoperative Care EXPLODE ALL TREES
#2.	MeSH DESCRIPTOR Perioperative Care EXPLODE ALL TREES
#3.	MeSH DESCRIPTOR Perioperative Period EXPLODE ALL TREES
#4.	MeSH DESCRIPTOR Perioperative Nursing EXPLODE ALL TREES
#5.	(((perioperative* or peri-operative* or intraoperative* or intra-operative* or intrasurg* or intra-surg* or peroperat* or per-operat*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine)))
#6.	(((care* or caring or treat* or nurs* or recover* or monitor*) adj3 (before or prior or advance or during or after) adj3 (surg* or operat* or anaesthes* or anesthes*)))
#7.	(((pre-operative* or preoperative* or preop* or pre-op* or pre-surg* or presurg*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine)))
#8.	(((postoperative* or postop* or post-op* or post-surg* or postsurg*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine)))
#9.	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
#10.	(* IN HTA)
#11.	(* IN NHSEED)
#12.	#9 AND #10
#13.	#9 AND #11
#14.	MeSH DESCRIPTOR Intraoperative Care EXPLODE ALL TREES
#15.	#1 OR #2 OR #3 OR #4 OR #14
#16.	((intraoperative* or intra-operative* or intrasurg* or intra-surg* or peroperat* or per- operat* or perioperat* or peri-operat*))
#17.	(((during or duration) adj3 (surg* or operat* or anaesthes* or anesthes*)))
#18.	((postop* or post-op* or post-surg* or postsurg* or perioperat* or peri-operat*))
#19.	((after adj3 (surg* or operat* or anaesthes* or anesthes*)))
#20.	((post adj3 (operat* or anaesthes* or anesthes*)))
#21.	((pre-operat* or preoperat* or pre-surg* or presurg*))
#22.	(((before or prior or advance or pre or prepar*) adj3 (surg* or operat* or anaesthes* or anesthes*)))
#23.	#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
#24.	#10 AND #23

© NICE 2019. All rights reserved. Subject to Notice of rights.

#25.	#11 AND #23
#26.	#12 OR #13 OR #24 OR #25

# Appendix C: Clinical evidence selection

Figure 1: Flow chart of clinical study selection for the review of preoperative fasting



2 3

# **Appendix D: Clinical evidence tables**

Study	Ajuzieogu 2016 <sup>3</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=90)
Countries and setting	Conducted in Nigeria; Setting: Hospital
Line of therapy	Unclear
Duration of study	Intervention + follow up: 24 hours
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: People scheduled for abdominal myomectomy
Stratum	Overall
Subgroup analysis within study	Stratified then randomised
Inclusion criteria	Ninety American Society of Anesthesiologists (ASA) physical status I and II patients aged 18–42 years scheduled for abdominal myomectomy were studied after obtaining a written informed consent from them.
Exclusion criteria	Patients with a history of any gastrointestinal disorder, receiving antacids, or H2 receptor blockers, or those who refused general anesthesia were excluded. Other exclusion criteria were a history of diabetes mellitus, body mass index >30 kg/m2 and pregnancy.
Age, gender and ethnicity	Age - Range: 18-42 years of age. Gender (M:F): Not specified.
Further population details	1. Age: <60 years 2. People with diabetes: Non-diabetic
Indirectness of population	No indirectness
Interventions	(n=30) Intervention 1: Combination of food and fluid restrictions - To be reported. Fasting from midnight until the surgery Duration 24 hours. Concurrent medication/care: Not stated. Indirectness: No indirectness (n=30) Intervention 2: Maintaining clear fluids before surgery - Non-milk, non-particulate drinks. 800 mL of oral carbohydrate solution containing 12.5% glucose, 50 kcal/100 mL (Nutricia preop®; Nutricia, Zoetermeer, The Netherlands) the night before surgery and an additional 400 mL 2 h before induction of anesthesia Duration 24 hours. Concurrent medication/care: Not stated. Indirectness: No indirectness
Funding	No funding

#### RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FASTING versus CARBOHYDRATE DRINK

Protocol outcome 1: Adverse events and complications

- Actual outcome: Postoperative nausea and vomiting-VAS at 24 hours; Group 1: mean 6 (SD 1.25); n=29, Group 2: mean 4 (SD 1); n=29; VAS 1-10 Top=High is poor outcome; Comments: 2 People dropped out in the overall population due to faulty aspiration techniques, however which groups had these drop-outs is not mentioned. 1 per group has therefore been assumed.

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 2 People dropped out in the overall population due to faulty aspiration techniques, however which groups had these drop-outs is not mentioned. 1 per group has therefore been assumed. ; Indirectness of outcome: No indirectness ;

- Actual outcome: Postoperative nausea and vomiting-VAS at Postoperative score; Group 1: mean 7 (SD 1); n=29, Group 2: mean 7.5 (SD 0.75); n=29; VAS 1-10 Top=High is poor outcome; Comments: 2 People dropped out in the overall population due to faulty aspiration techniques, however which groups had these drop-outs is not mentioned. 1 per group has therefore been assumed.

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 2 People dropped out in the overall population due to faulty aspiration techniques, however which groups had these drop-outs is not mentioned. 1 per group has therefore been assumed. ; Indirectness of outcome: No indirectness ;

Protocol outcome 2: Patient, family and carer experience of care

- Actual outcome: Patient satisfaction at 24 hours; Group 1: mean 6 (SD 0.5); n=29, Group 2: mean 8 (SD 0.75); n=29; VAS 1-10 Top=High is good outcome; Comments: 2 People dropped out in the overall population due to faulty aspiration techniques, however which groups had these drop-outs is not mentioned. 1 per group has therefore been assumed.

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 2 People dropped out in the overall population due to faulty aspiration techniques, however which groups had these drop-outs is not mentioned. 1 per group has therefore been assumed. ; Indirectness of outcome: No indirectness ;

Protocol outcomes not reported by the	Quality of life; Mortality; Unplanned ICU admission; Thirst; Headache; Cancellation of surgery
study	

Study	Asakura 2015 <sup>7</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=134)
Countries and setting	Conducted in Hong Kong (China); Setting: Yokohama City University Hospital in Yokohama, Japan
Line of therapy	Unclear
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients ASA physical status 1 and 2 adults, age 20 to 79 years, who were scheduled to undergo a surgical procedure of body surface
Exclusion criteria	Patients with impaired gastrointestinal motility, poor comprehension of Japanese, or with psychiatric disorders were excluded from enrolment
Recruitment/selection of patients	scheduled to undergo a surgical procedure of body surface
Age, gender and ethnicity	Age - Mean (SD): CHO:63.4 ±13.6; Fasting: 64.5 ± 10.4. Gender (M:F): 33/28.
Further population details	1. Age: >60 years (CHO:63.4 ±13.6; Fasting: 64.5 ± 10.4). 2. People with diabetes: Not stated / Unclear
Indirectness of population	No indirectness
Interventions	<ul> <li>(n=46) Intervention 1: Combination of food and fluid restrictions - To be reported. received 250ml of preoperative CHO (Arginaid Water™, 18% carbohydrates, Nestle Health Science, Tokyo, Japan) between 6.00–6:30 a.m. on the morning of surgery. This is because 250ml of Arginaid Water are approved as a mea Duration preoperative. Concurrent medication/care: na. Indirectness: No indirectness</li> <li>(n=45) Intervention 2: Combination of food and fluid restrictions - To be reported. Control group, did not</li> </ul>
	receive any preoperative CHO, and were fasted starting at midnight on the day of surgical procedure. Duration preoperative. Concurrent medication/care: na. Indirectness: No indirectness
Funding	No funding

Perioperative care: DRAFT FOR CONSULTATION Preoperative fasting strategy - Actual outcome: Global QoR-40 score at 24 hours postoperative; Median (IQR): CHO: 196 (191–198); Fasting: 197 (189.5–200)); Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: lost to follow up; Group 2 Number missing: 5, Reason: lost to follow up

Protocol outcome 2: Adverse events and complications

- Actual outcome: Length of stay at postoperative; median (IQR):: CHO: 3 (2–3); Fasting: 3 (2–6) days);

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: lost to follow up; Group 2 Number missing: 5, Reason: lost to follow up

Protocol outcomes not reported by the study Mortality; Patient, family and carer experience of care; Unplanned ICU admission; Thirst; Headache; Cancellation of surgery

Study	Cakar 2017 <sup>17</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=95)
Countries and setting	Conducted in Turkey; Setting: Medical university hospital, Turkey
Line of therapy	Unclear
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	adult patients undergoing an elective thyroid operation and American Society of Anesthesiologists (ASA) physical status I or II.
Exclusion criteria	The exclusion criteria were aged below 18 or above 80 years, pregnancy, history of delayed gastric emptying, gastrointestinal obstruction, liver cirrhosis, diabetes mellitus, hypertension, severe hepatic or renal failure, or any endocrine disorder that might influence the metabolic parameters and patients requiring urgent or emergent surgery.
Recruitment/selection of patients	undergoing an elective thyroid operation
Age, gender and ethnicity	Age - Mean (SD): CHO: 48.17 ± 9.81; Fasting: 50.07 ± 9.95. Gender (M:F): 28/32.
Further population details	1. Age: <60 years (CHO: 48.17 ± 9.81; Fasting: 50.07 ± 9.95). 2. People with diabetes: Non-diabetic
Indirectness of population	No indirectness
Interventions	(n=30) Intervention 1: Combination of food and fluid restrictions - To be reported. These patients were given an oral carbohydrate solution (PreOp-Nutricia-12.5% carbohydrate, 50 kcal 100 mL21, 290 mOsm kg21,pH: 5.0); 800 mL at 12:00 a.m. and 400 mL 2 hours before surgery . Duration preoperative. Concurrent medication/care: na. Indirectness: No indirectness
	(n=33) Intervention 2: Combination of food and fluid restrictions - To be reported. The routine fasting procedure was implemented, in which patients were instructed not to take any fluid or food by mouth after midnight (12:00 a.m.) preoperatively and were not given an intravenous (IV) injection. Duration preoperative. Concurrent medication/care: NA. Indirectness: No indirectness

Funding	Funding not stated	
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING		
<ul> <li>Protocol outcome 1: Adverse events and complications</li> <li>- Actual outcome: Tiredness at 6am POD 1; Incidence Rate Ratio (range):: CHO: 1.0 (reference); Fasting: 1.18 (0.64 to 2.17) VAS 0-100 Top=High is poor outcome, Comments: p value 0.592;</li> <li>Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 3, Reason: lost to follow up</li> </ul>		
outcome, Comments: p value 0.0; Risk of bias: All domain - High, Selection - L	idence rate ratio (range): CHO: 1.0 (reference); Fasting: 11.23 (9.41 to 3.40) VAS 0-100 Top=High is poor .ow, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 3, Reason: lost to follow up	
Protocol outcome 3: Headache - Actual outcome: Headache at 6am POD 1; Incidence Rate Ratio (range):: CHo: 1.0 (reference): Fasting: 2.70 (1.69 to 4.32) VAS 0-100 Top=High is poor outcome, Comments: p value 0.0; Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 3, Reason: lost to follow up		
Protocol outcomes not reported by the	Quality of life ; Mortality ; Patient, family and carer experience of care ; Unplanned ICU admission ;	

Protocol outcomes not reported by the Study Quality of life ; Mortality ; Patient, family and carer experience of care ; Unplanned ICU admission ; Cancellation of surgery

Study	Canbay 2014 <sup>19</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=50)
Countries and setting	Conducted in Turkey; Setting: Department of Anesthesiology, Faculty of Medicine, Hacettepe University, Turkey
Line of therapy	Unclear
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	ASA I–II group and would undergo open radical retropubic prosta- tectomy surgery under elective conditions.
Exclusion criteria	Patients with metabolic, endocrine, or hepatic disease, fever, and infection were excluded.
Recruitment/selection of patients	Undergoing open radical retropubic prostatectomy surgery
Age, gender and ethnicity	Age - Mean (SD): CHO: 60.00 ± 10.37; Fasting: 58.36 ± 11.19. Gender (M:F): all male.
Further population details	1. Age: >60 years (CHO: 60.00 ± 10.37; Fasting: 58.36 ± 11.19). 2. People with diabetes: Non-diabetic
Indirectness of population	No indirectness
Interventions	(n=25) Intervention 1: Combination of food and fluid restrictions - To be reported. Received 800 ml oral glucose solution containing 12.5 % glucose (Nutricia preop) at 24:00 h before surgery and 400 ml at 04:00 h, 2 h prior to the surgery
	. Duration preoperative. Concurrent medication/care: NA
	(n=25) Intervention 2: Combination of food and fluid restrictions - To be reported. oral intake was restricted starting from 24:00h . Duration preoperative. Concurrent medication/care: NA
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING

Protocol outcome 1: Thirst

- Actual outcome: Thirst (Mild) at Unclear; Group 1: 6/25, Group 2: 13/25; Comments: 4 point Likert scale (0 = no sense, 1: mild, 2: moderate, 3: severe)

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low,
Crossover - Low; Indirectness of outcome: No indirectness;
- Actual outcome: Thirst (Moderate) at Unclear; Group 1: 0/25, Group 2: 5/25; Comments: 4-point likert scale (0 = no sense, 1: mild, 2: moderate, 3:
severe)
Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low,

Crossover - Low; Indirectness of outcome: No indirectness ;

Protocol outcomes not reported by the study Quality of life ; Mortality ; Adverse events and complications ; Patient, family and carer experience of care ; Unplanned ICU admission ; Headache ; Cancellation of surgery

Study	Celiksular 2016 <sup>20</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=80)
Countries and setting	Conducted in Turkey; Setting:
Line of therapy	Not applicable
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	ASA I-II patients undergoing total hip replacement surgery due to coxarthrosis
Exclusion criteria	The exclusion criteria consisted of patients using steroids and/or beta-ad- renergic blockers and those with rheumatologic, endocrine, metabolic, renal and liver disease; tumours; obesity; fever and infection.
Recruitment/selection of patients	undergoing total hip replacement surgery due to coxarthrosis
Age, gender and ethnicity	Age - Mean (SD): CHO: 53 (14.96); Fasting: 52.8 (17.86). Gender (M:F): 23/57.
Further population details	1. Age: <60 years (CHO: 53 (14.96); Fasting: 52.8 (17.86)). 2. People with diabetes: Non-diabetic
Indirectness of population	
Interventions	<ul> <li>(n=40) Intervention 1: Combination of food and fluid restrictions - To be reported. The patients were given 800 mL and 400 mL (12.5%) of oral carbohydrate solution (PreopQ, Nutricia, Holland) 8h and two hours before their elective surgery . Duration preoperative. Concurrent medication/care: General anesthesia or epidural anesthesia. Indirectness: No indirectness</li> <li>(n=40) Intervention 2: Combination of food and fluid restrictions - To be reported. This group of patients</li> </ul>
	underwent surgery under general anaesthesia or epidural after an 8-h preoperative fasting period . Duration preoperative. Concurrent medication/care: general anesthesia or epidural. Indirectness: No indirectness
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING

Protocol outcome 1: Adverse events and complications

- Actual outcome: Nausea & Vomiting at Unclear; Group 1: 2/40, Group 2: 1/40 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcomes not reported by the Quality of life ; Mortality ; Patient, family and carer experience of care ; Unplanned ICU admission ; Thirst ; Headache ; Cancellation of surgery study

Study	Doo 2018 <sup>30</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=50)
Countries and setting	
Line of therapy	Unclear
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged 20–65 years with American Society of Anesthesiologists physical status I or II, who were scheduled to undergo open thyroidectomy under general anaesthesia
Exclusion criteria	mellitus, gastric emptying disorders including gastroesophageal reflux disease, contraindications for ketorolac or nefopam, or emergency surgery were excluded. Patients with fasting blood glucose $\geq$ 126 mg/dl or glycosylated hemoglobin $\geq$ 6.5% on pre- operative laboratory test, suggestive of hidden diabetes mellitus, were also excluded.
Recruitment/selection of patients	scheduled to undergo open thyroidectomy under general anaesthesia
Age, gender and ethnicity	Age - Mean (SD): CHO:49.8 ± 7.1 ; Fasting: 51.0 ± 7.5. Gender (M:F): 11/39.
Further population details	1. Age: <60 years (CHO:49.8 ± 7.1 ; Fasting: 51.0 ± 7.5). 2. People with diabetes: Non-diabetic
Indirectness of population	
Interventions	(n=25) Intervention 1: Combination of food and fluid restrictions - To be reported. Subjects in the carbohydrate group fasted, but received 400 ml of carbohydrate-rich drink (12.8% carbohydrates, 50 kcal/100 ml; Nucare NONPO®, Daesang Wellife, Korea) 2 hours before induction of anesthesia. Duration preoperative. Concurrent medication/care: General anesthesia with postoperative PCA
	(n=25) Intervention 2: Combination of food and fluid restrictions - To be reported. Subjects in the control group were requested to obey traditional preoperative fasting after midnight prior to the day of surgery

	Duration preoperative. Concurrent medication/care: general anesthesia with postoperative PCA. Indirectness: No indirectness	
Funding	Equipment / drugs provided by industry (This research received carbohydrate beverages (Nucare NONPO $\ensuremath{\mathbb{R}}$ ORCID)	
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING		
Protocol outcome 1: Adverse events and complications - Actual outcome: Nausea & Vomiting at preoperative; Median (IQR): : CHO: 0 (0-1); Fasting: 0 (0-0) NRS 0-10 Top=High is poor outcome, Comments: p value 0.192;		

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low: Indirectness of outcome: No indirectness :

- Actual outcome: Nausea & Vomiting at postoperative; Median (IQR):: CHO: 1 (0.5-2) ; Fasting: 1 (1-2) NRS 0-10 Top=High is poor outcome, Comments: p value 0.926;

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

- Actual outcome: Fatigue at preoperative; Median (IQR): CHO: 2 (0-2); Fasting: 2 (1-2) NRS 0-10 Top=High is poor outcome, Comments: p value 0.512; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

- Actual outcome: Fatigue at postoperative: Median (IQR):: CHO: 1 (0.5-2); Fasting: 1 (0-2) NRS 0-10 Top=High is poor outcome, Comments: p value 0.630:

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

- Actual outcome: Anxiety at preoperative; Median (IQR): CHO: 2 (1-3); Fasting: 2 (1-2) NRS 0-10 Top=High is poor outcome, Comments: p value 0.288; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

- Actual outcome: Anxiety at postoperative; median (IQR):: CHo: 0 (0-0); Fasting: 0 (0-1) NRS 0-10 Top=High is poor outcome, Comments: p value 0.50; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

Protocol outcome 2: Patient, family and carer experience of care

- Actual outcome: Patient Satisfaction at preoperative; Mean; (Median (IQR):: CHO: 4 (3-4); Fasting: 4 (3-4)) 5-point scale 0-5 Top=High is good outcome. Comments: p value 1

(5: very satisfied, 4: somewhat satisfied, 3: neutral, 2: somewhat dissatisfied, 1: very dissatisfied);

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ;

- Actual outcome: Patient Satisfaction at postoperative; Median (IQR) : CHO: 4 (3-4); Fasting: 4 (3-4) 5 point scale 1-5 Top=High is good outcome,

Comments: p value 0.715 5-point scale (5: very satisfied, 4: somewhat satisfied, 3: neutral, 2: somewhat dissatisfied, 1: very dissatisfied); Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcome 3: Thirst

- Actual outcome: Thirst at preoperative; Median (IQR): CHO: 1 (0-2); Fasting: 2 (1-2) NRS 0-10 Top=High is poor outcome, Comments: p value 0.099; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Thirst at postoperative; Median (IQR) : CHO: 2 (1-3); Fasting: 3 (1.5-4) NRS 0-10 Top=High is poor outcome, Comments: p value 0.456;

Risk of bias: All domain - ; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the	Quality of life ; Mortality ; Unplanned ICU admission ; Headache ; Cancellation of surgery
study	

Study	Faria 2009 <sup>31</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=21)
Countries and setting	Conducted in Brazil; Setting: Medical centre, Brazil
Line of therapy	Not applicable
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Adult women scheduled to undergo elective laparoscopic cholecystectomy
Exclusion criteria	ASA score above II, diabetes mellitus, age below 18 or above 65 years old, renal failure, gastroesophageal reflux, acute cholecystitis, use of corticosteroids up to 6 months previously, and any noncompliance or violation on the assigned protocol of preoperative fasting.
Recruitment/selection of patients	scheduled to undergo elective laparoscopic cholecystectomy
Age, gender and ethnicity	Age - Median (range): CHO: 47 (19–65); Fasting: 48 (29–65). Gender (M:F): all female.
Further population details	1. Age: <60 years (CHO: 47 (19–65); Fasting: 48 (29–65)). 2. People with diabetes: Non-diabetic
Indirectness of population	No indirectness
Interventions	(n=11) Intervention 1: Combination of food and fluid restrictions - To be reported. receive 200 ml of a carbohydrate beverage containing 12.5% (25 g, 50 kcal per 100 ml and approximately 285 mOsm) of maltodextrine (Nidex, Nestle, Brazil) 2 h before operation. Duration preoperative. Concurrent medication/care: All patients were submitted to general anesthesia without epidural blockage. They received a single dose of 1 g of intravenous cefazolin. A routine prescription of 1,000–1,500 ml of intravenous saline was administered to all patients postoperatively. Postoperative fasting was prescribed until 5:00 p.m., 12 h after the patients had or had not received the carbohydrate drink. After that, all patients received a liquid diet unless they had nausea or vomiting, in which case an antiemetic was prescribed. Postoperative analgesia was provided with both 50 mg of subcutaneous tramadol cloridrate and 500 mg of intravenous dipyrone every 6h Indirectness: No indirectness
	(n=12) Intervention 2: Combination of food and fluid restrictions - To be reported. conventional preoperative fasting of 8 h. Duration preoperative. Concurrent medication/care: All patients were submitted to general

	anesthesia without epidural blockage. They received a single dose of 1 g of intravenous cefazolin. A routine prescription of 1,000–1,500 ml of intravenous saline was administered to all patients postoperatively. Postoperative fasting was prescribed until 5:00 p.m., 12 h after the patients had or had not received the carbohydrate drink. After that, all patients received a liquid diet unless they had nausea or vomiting, in which case an antiemetic was prescribed. Postoperative analgesia was provided with both 50 mg of subcutaneous tramadol cloridrate and 500 mg of intravenous dipyrone every 6h Indirectness: No indirectness
Funding	(CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnologico) funding the study (grant 401943/2005-4))
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING	

Protocol outcome 1: Adverse events and complications

- Actual outcome: Vomiting at Postoperative; Group 1: 3/11, Group 2: 7/10 Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 2

Protocol outcomes not reported by the	Quality of life ; Mortality ; Patient, family and carer experience of care ; Unplanned ICU admission ; Thirst
study	; Headache ; Cancellation of surgery

Study	Gilbert 1995 <sup>37</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=95)
Countries and setting	Conducted in United Kingdom; Setting: The Vale of Leven Hospital, Alexandria, Dunbartonshire
Line of therapy	Unclear
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients scheduled for minor operations who were ASA I or II
Exclusion criteria	Patients with gastrointestinal disease, undergoing emergency procedures, pregnant women, children and patients with mental handicap were not studied.
Recruitment/selection of patients	Patients scheduled for minor operations who were ASA I or II
Age, gender and ethnicity	Age - Mean (SD): Water: 45.6 (15.6); Fasting: 48.3 (16.6). Gender (M:F): 35/60.
Further population details	1. Age: <60 years (Water: 45.6 (15.6); Fasting: 48.3 (16.6)). 2. People with diabetes: Not stated / Unclear
Indirectness of population	
Interventions	(n=46) Intervention 1: Combination of food and fluid restrictions - To be reported. Patients in group A (water were asked to drink 500 ml- 1L of water over 2 h, before a 3 h pre-operative fast Duration preoperative. Concurrent medication/care: All patients received premedication with temazepam 20mg and ranitidine 150 mg by mouth, 2 h before the scheduled time of operation.
	(n=49) Intervention 2: Combination of food and fluid restrictions - To be reported. Group B (fasting) followed the standard regimen of fasting from midnight for the morning list or 'tea and toast' before 08.00 h for the afternoon session. Duration preoperative. Concurrent medication/care: All patients received premedication with temazepam 20mg and ranitidine 150 mg by mouth, 2 h before the scheduled time of operation Indirectness: No indirectness
Funding	Funding not stated

Perioperative care: DRAFT Preoperative fasting strategy

FOR CONSULTATION

Protocol outcome 1: Adverse events and complications

- Actual outcome: Nausea at 2 hours post operative; Median: Water: 1.0; FAsting: 0 0-100 Top=High is poor outcome, Comments: p value 0.32; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low, Comments - Only median value given; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: not enough water taken or given IV fluids; Group 2 Number missing: 1, Reason: given IV fluids

- Actual outcome: Vomiting at 2 hours post operative; Median : Water: 1.0; Fasting: 0 0-100 Top=High is poor outcome, Comments: p value 0.21; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low, Comments - Only median value given; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: not enough water taken or given IV fluids; Group 2 Number missing: 1, Reason: given IV fluids

- Actual outcome: Drowsiness at 2 hours post operative; Mean; ;

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low, Comments - Only median value given; Indirectness of outcome: No indirectness; Group 1 Number missing: 5, Reason: not enough water taken or given IV fluids; Group 2 Number missing: 1, Reason: given IV fluids

#### Protocol outcome 2: Thirst

- Actual outcome: Thirst at 2 hours post operative; Median: Water: 5.0; Fasting: 21.0 VAS 0-100 Top=High is poor outcome, Comments: P value 0.0149; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low, Comments - Only median value given; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: not enough water taken or given IV fluids; Group 2 Number missing: 1, Reason: given IV fluids

#### Protocol outcome 3: Headache

- Actual outcome: Headache at 2 hours post operative; Median : Water: 2.5; Fasting: 2.0 0-100 Top=High is poor outcome, Comments: p value 0.99; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low, Comments - Only median value given; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: not enough water taken or given IV fluids; Group 2 Number missing: 1, Reason: given IV fluids

Protocol outcomes not reported by the study

Quality of life ; Mortality ; Patient, family and carer experience of care ; Unplanned ICU admission ; Cancellation of surgery

Study	Hausel 2001 <sup>41</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=252)
Countries and setting	Conducted in Sweden; Setting: Three hospitals in the Stockholm area took part in the study.
Line of therapy	Not applicable
Duration of study	Intervention time:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients who were eligible for intake of preoperative clear fluids, according to the guidelines from the Swedish Association of Anaesthetists (1), were considered for inclusion. These guidelines are similar to the present recommendations given by the American Society of Anesthesiologists (ASA)
Exclusion criteria	conditions (including pharmacologic treatments) that might impair gastrointestinal motility, gastroesophageal reflux, pregnancy, and the potential for difficult airway management. In addition, patients with diabetes mellitus and patients in ASA physical status classes ≥III were excluded.
Recruitment/selection of patients	patients scheduled for elective laparoscopic cholecystectomy or elective major colorectal surgery
Age, gender and ethnicity	Age - Median (IQR): Laparoscopic cholecystectomy - Fasted: 48 (37–59); CHO: 49 (36–58); Colorectal surgery: Fasted 52 (34–66); CHO 56 (50–67). Gender (M:F): 84/168.
Further population details	1. Age: <60 years (Laparoscopic cholecystectomy - Fasted: 48 (37–59); CHO: 49 (36–58); Colorectal surgery: Fasted 52 (34–66); CHO 56 (50–67)). 2. People with diabetes: Non-diabetic
Indirectness of population	No indirectness
Interventions	(n=80) Intervention 1: Combination of food and fluid restrictions - To be reported. During the evening before surgery, the CHO group consumed 800 mL of an iso-osmolar carbohydrate-rich drink (12.5% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg, pH 5.0, Nutricia Preop®; Numico, Zoetermeer, the Netherlands). After midnight, nothing by mouth was allowed, except a single morning dose of 400 mL of the CHO drink. Duration preoperative. Concurrent medication/care: Premedication was standardized to morphine 10 mg IM or ketobemidone 5 mg IM. Epidural analgesia was initiated before general anesthesia (GA) by using bupivacaine with epinephrine. GA was induced IV with fentanyl and thiopental after the administration of glycopyrrolate.

Perioperative care: DRAFT FOR CONSULTATION Preoperative fasting strategy

	(n=86) Intervention 2: Combination of food and fluid restrictions - To be reported. patients were fasted from midnight. Duration preoperative. Concurrent medication/care: Premedication was standardized to morphine 10 mg IM or ketobemidone 5 mg IM. Epidural analgesia was initiated before general anesthesia (GA) by using bupivacaine with epinephrine. GA was induced IV with fentanyl and thiopental after the administration of glycopyrrolate Indirectness: No indirectness		
Funding	Funding not stated		
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING Protocol outcome 1: Adverse events and complications			
- Actual outcome: Malaise at 40 minutes pos	st morning drink; Median (IQR): Fasted: 12 (3–30); CHO: 8 (4–20) visual analogue scale 0-100 Top=High is		
Risk of bias: All domain - High, Selection - H	poor outcome; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;		
<ul> <li>Actual outcome: Malaise at 90 minutes pos poor outcome;</li> </ul>	st morning drink; Median (IQR): Fasted: 10 (3–30); CHO: 7 (3–17) visual analogue scale 0-100 Top=High is		
	ligh, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, to indirectness :		
- Actual outcome: Nausea at 40 minutes pos	st morning drink; Median (IQR): Fasting: 3 (2–10); CHO: 4 (2–6) visual analogue scale 0-100 Top=High is poor		
outcome; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low,			
Crossover - Low; Indirectness of outcome: No indirectness ; - Actual outcome: Nausea at 90 minutes post morning drink; Median (IQR): Fasting: 4 (2–12); CHO:3 (2–7) visual analogue scale 0-100 Top=High is poor			
outcome; Risk of bias: All domain - High, Selection - H Crossover - Low; Indirectness of outcome: N	ligh, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Io indirectness ;		
Protocol outcomes not reported by the study	Quality of life ; Mortality ; Patient, family and carer experience of care ; Unplanned ICU admission ; Thirst ; Headache ; Cancellation of surgery		

Study	Helminen 2009 <sup>44</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=240)
Countries and setting	Conducted in Finland; Setting: Department of Surgery and bDepartment of Anaesthesia, Seinajoki Central Hospital, Finland
Line of therapy	Not applicable
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	adult patients undergoing elective abdominal, anal, thyroid or parathyroid operations and ASA physical status I–III.
Exclusion criteria	Patients who were pregnant or who had dementia, impairment of gastrointestinal motility or diabetes mellitus were excluded from the study.
Recruitment/selection of patients	patients undergoing elective abdominal, anal, thyroid or parathyroid operations
Age, gender and ethnicity	Age - Mean (SD): CHO: 60±15; Fasting: 58±4. Gender (M:F): 68/137.
Further population details	1. Age: >60 years (CHO: 60±15; Fasting: 58±4). 2. People with diabetes: Not stated / Unclear
Indirectness of population	
Interventions	(n=80) Intervention 1: Combination of food and fluid restrictions - To be reported. Patients in the CHO group were given nothing after midnight and a 12.5%CHD(Nutricia Preop; Numici, The Netherlands), that is 400ml (=200 kcal), between 6 and 7 a.m Duration preoperative. Concurrent medication/care: Patients were premedicated and anaesthetized according to the normal practice of our hospital. Oral premedication of hydroxyzine hydrochloride (Atarax; UCB, Belgium) 25–50mg with a small amount of water was given at 7 a.m. in the morning Indirectness: No indirectness
	(n=80) Intervention 2: Combination of food and fluid restrictions - To be reported. Patients in the fasting group were given nothing by mouth after midnight Duration preoperative. Concurrent medication/care: Patients were premedicated and anaesthetized according to the normal practice of our hospital. Oral premedication of hydroxyzine hydrochloride (Atarax; UCB, Belgium) 25–50mg with a small amount of water was given at 7 a.m. in the morning Indirectness: No indirectness
Funding	Funding not stated

## RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING

Protocol outcome 1: Thirst

- Actual outcome: Thirst at Before anesthesia; Median (IQR): CHO: 1 (0-4.5); Fasting: 3 (0-5) visual analogue scale 0-10 Top=High is poor outcome; Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 10; Group 2 Number missing: 7

- Actual outcome: Tiredness at Before anesthesia; median (IQR): CHO: 2 (0–5); Fasting: 3 (0-5) visual analogue scale 0-10 Top=High is poor outcome; Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 10; Group 2 Number missing: 7

- Actual outcome: Anxiety at Before anesthesia; median (IQR): CHO: 2 (1-5); Fasting: 3 (1-5) visual analogue scale 0-10 Top=High is poor outcome; Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 10; Group 2 Number missing: 7

Protocol outcomes not reported by the study Quality of life ; Mortality ; Adverse events and complications ; Patient, family and carer experience of care ; Unplanned ICU admission ; Headache ; Cancellation of surgery

Study	Helminen 2019 <sup>43</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=113)
Countries and setting	Conducted in Finland; Setting: Seinajoki Central hospital, Oulu University hospital, Finland
Line of therapy	Not applicable
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Adults aged between 18 - 70 with ASA I to II scheduled for day case cholecystectomy.
Exclusion criteria	bleeding or coagulation disorders, BMI > 40kg/m <sup>2</sup> , insulin dependent diabetes, dementia, migraine or menieres disease or with a history of alcohol or drug abuse
Recruitment/selection of patients	scheduled for day case cholecystectomy.
Age, gender and ethnicity	Age - Mean (SD): CHO: 47 (13); Fasting: 46 (11). Gender (M:F): Define.
Further population details	1. Age: <60 years (CHO: 47 (13); Fasting: 46 (11)). 2. People with diabetes: Diabetic patients (non insulin dependent diabetes patients were included. 5 in each group.).
Indirectness of population	No indirectness
Interventions	(n=57) Intervention 1: Combination of food and fluid restrictions - To be reported. 200ml of carbohydrate rick drink (Providextra; Fresineus Kabi Ab; Bad Homburg Vor der Hohe, Germany) containing 300kcal, 67g carbohydrate and 8g protein at home before leaving for the hospital or by 6am for surgery scheduled at 9am or 8pm at the latest for later surgery. Duration preoperative. Concurrent medication/care: NA
	(n=56) Intervention 2: Combination of food and fluid restrictions - To be reported. Patients were instructed to take nothing by mouth after midnight on the night before surgery. Duration preoperative. Concurrent medication/care: NA. Indirectness: No indirectness
Funding	No funding

Preoperative fasting strategy

Perioperative care:

DRAFT

FOR CONSULTATION

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING

Protocol outcome 1: Quality of life - Actual outcome: Tiredness at before induction; Median (IQR): CHO: 30 (10-54); Fasting: 20 (5-46) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 4, Reason: questionnaire not completed; Group 2 Number missing: 1, Reason: questionnaire not completed

- Actual outcome: Tiredness at 2 hours postoperative; Mean; (Median (IQR): CHO: 49 (20-70); Fasting: 53 (30-61)) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 4, Reason: questionnaire not completed; Group 2 Number missing: 1, Reason: questionnaire not completed

- Actual outcome: Tiredness at 4 hours postoperative; Median (IQR) : CHO: 42 (8-70); Fasting: 40 (10-50) VAS 0-100 Top=High is poor outcome; Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: questionnaire not completed; Group 2 Number missing: 1, Reason: questionnaire not completed

Protocol outcome 2: Adverse events and complications

- Actual outcome: Nausea at before induction; Median (IQR): CHO: 0 (0-0); Fasting: 0 (0-2) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low,

Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: questionnaire not completed; Group 2 Number missing: 1, Reason: questionnaire not completed

- Actual outcome: Nausea at 2 hours postoperative; Median (IQR): CHO: 0 (0-14); Fasting: 0 (0-6) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: questionnaire not completed; Group 2 Number missing: 1, Reason: questionnaire not completed

- Actual outcome: Nausea at 4 hours postoperative; Median (IQR) : CHO: 0 (0-4); Fasting: 0 (0-10) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low,

Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: questionnaire not completed; Group 2 Number missing: 1, Reason: questionnaire not completed

Protocol outcome 3: Thirst

- Actual outcome: Thirst at before induction; Median (IQR): CHO: 22 (6 - 50); Fasting: 40 (8 - 63));

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low,

Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: questionnaire not completed; Group 2 Number missing:

1, Reason: questionnaire not completed

- Actual outcome: Thirst at 2 hours postoperative; Median (IQR): : CHO: 41 (20 - 61); Fasting: 46 (24-70));

Risk of bias: All domain - ; Indirectness of outcome: No indirectness

- Actual outcome: Thirst at 4 hours postoperative; Median (IQR) : CHO: 28 (9-61); Fasting: 20(0-50));

Risk of bias: All domain - ; Indirectness of outcome: No indirectness

NICE 2019. All rights reserved. Subject to Notice of rights.

 $\bigcirc$ 

	study	Cancellation of surgery	Pe
			riop
1			era
			tive /e fa
>			car
5.			e: E g st
			)RA rate
1			gy gy
3			FO
)			2 C
0			ON (
2. )			SUL
÷ )			TA.
			Perioperative care: DRAFT FOR CONSULTATION Preoperative fasting strategy
			Z
) 5.			
2			

Study	Lee 2018 <sup>58</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=153)
Countries and setting	
Line of therapy	Not applicable
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients ASA I – II adults who had a Karnofsky performance status scale greater than 70 undergoing laparoscopic cholecystectomy
Exclusion criteria	fasting glucose level greater than 120 mg/dL, type I or II diabetes, gastroesophageal reflux disease, history of previous Gi surgery or ASA IV/V
Recruitment/selection of patients	undergoing laparoscopic cholecystectomy
Age, gender and ethnicity	Age - Mean (SD): CHO: 50 (13); Fasting: 49 (12). Gender (M:F): 49/48.
Further population details	1. Age: <60 years (CHO: 50 (13); Fasting: 49 (12)). 2. People with diabetes: Non-diabetic
Indirectness of population	No indirectness
Interventions	(n=51) Intervention 1: Combination of food and fluid restrictions - To be reported. Received 800ml of a clear carbohydrate beverage (12.8% carbohydrates, 50kcal/100ml, 290 mOsm/kg, Daesang WelLife Co, Korea). Patients were instructed to ingest 400ml of this beverage on the evening before surgery (400ml) 2h before any anesthetic medication was administered. Duration preoperative. Concurrent medication/care: General anesthesia with IV postoperative pain relief
	(n=51) Intervention 2: Combination of food and fluid restrictions - To be reported. Patients within this group were not allowed to drink any solution or fluid after midnight before surgery. Duration preoperative. Concurrent medication/care: General anesthesia with IV postoperative pain relief
Funding	Equipment / drugs provided by industry (Nos-NPO were provided by the Daesang Corporation, Korea)

Protocol outcome 1: Quality of life

- Actual outcome: Postoperative QoR-40 score at POD 1; Group 1: mean 187.7 (SD 17.5); n=46, Group 2: mean 194.5 (SD 5.6); n=51; QoR-40 40-200 Top=High is good outcome

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 5, Reason: prolonged fasting time; Group 2 Number missing: 2, Reason: refusal to complete postoperative data

Protocol outcome 2: Adverse events and complications

- Actual outcome: Length of stay (days) at postoperative; Group 1: mean 2.59 days (SD 1.61); n=46, Group 2: mean 2.38 days (SD 2.05); n=51 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 5, Reason: prolonged fasting time; Group 2 Number missing: 2, Reason: refusal to complete postoperative data

Protocol outcomes not reported by the study Mortality; Patient, family and carer experience of care; Unplanned ICU admission; Thirst; Headache; Cancellation of surgery

Study	Melis 2006 <sup>73</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=29)
Countries and setting	Conducted in Netherlands; Setting: VU University Medical Centre, Netherlands
Line of therapy	Not applicable
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Adult patients undergoing elective orthopaedic surgery
Exclusion criteria	inability to give informed consent, decreased consciousness, and circumstancex increasing the chance of a full stomach at the moment of induction (diabetes, sliding hernia of the stomach, rolling diaphragmatic hernia, obstruction of GI tract, pregnancy, increased intracranial pressure, obesity and use of medication affecting gastric emptying)
Recruitment/selection of patients	Adult patients undergoing elective orthopaedic surgery
Age, gender and ethnicity	Age - Mean (SD): Drink A: 59 (9); Drink B: 47 (17); Fasting: 56 (13). Gender (M:F): 15/14.
Further population details	1. Age: <60 years (Drink A: 59 (9); Drink B: 47 (17); Fasting: 56 (13)). 2. People with diabetes: Non-diabetic
Indirectness of population	No indirectness
Interventions	(n=19) Intervention 1: Combination of food and fluid restrictions - To be reported. CHO Drink A: Drink was poured out into a class 4 hours before surgery and had to be consumed 3 hours before surgery. Drink A was Nutricia preOp (Nutricia, Zoetermeer, the Netherlands), which contained 50.4g of the carbohydrates; consisting of 0.8g glucose, 5.2g polysaccharides and a small amount of organic acids and 200mg sodium, 488mg Potassium, 24mg chloride, 24mg calcium, 4mg of phosphor, and 4mg of Magnesium in a solution of 400ml with an osmolality of 260mOsm/kg CHO drink B: Drink was poured out into a class 4 hours before surgery and had to be consumed 3 hours before surgery. Drink B was Roosvicee vruchtenmix (Heinz, Zeist, the Netherlands), a syrup of rosehip and

	other fruits, which was diluted in water (70ml syrup : 330ml water) and contained 48mg of carbohydrates, consisting of 6.2g fructose, 6.2g of glucose and furthermore carbohydrate with unidentified chemical structure of 0.2g fiber, 0.2g protein, 6.4mg sodium, 73mg potassium, 6.9mg calcium, 7.mg phosphor, 0.1mg iron and 41mg Vitamin C in a solution of 400ml with an osmolality of 574 mOsm/kg . Duration preoperative. Concurrent medication/care: NA. Indirectness: No indirectness (n=10) Intervention 2: Combination of food and fluid restrictions - To be reported. Fasted after midnight on the day of surgery. Duration preoperative. Concurrent medication/care: NA. Indirectness: No indirectness
Funding	Funding not stated

# RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO DRINK A / CHO DRINK B versus FASTING

Protocol outcome 1: Quality of life

- Actual outcome: Anxiety at day before surgery up to preoperative; Median increase/decrease (IQR): CHOA: -15 (49); CHOB: 0 (15) ; Fasting: +3 (51) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcome 2: Adverse events and complications

- Actual outcome: Nausea at day before surgery up to preoperative; Median increase / decrease (IQR): CHOA: 0 (6); CHOB: +1 (6); Fasting: 0 (7) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Tiredness at day before surgery up to preoperative; Mean; (median increase/decrease (IQR): CHOA: 0 (20); CHOB: -7 (29); Fasting: - 19 (27)) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcome 3: Thirst

- Actual outcome: Feeling of thirst at day before surgery up to preoperative; Median Increase/Decrease (IQR): CHOA: -7 (39); CHOB: 0 (18); Fasting: +34 (34) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcomes not reported by the Mortality; Patient, family and carer experience of care; Unplanned ICU admission; Headache;

	study	Cancellation of surgery	Pe
		·	riop
			erat
			tive /e fa
>			car Istin
5.			e: D g sti
			)RA
5			Perioperative care: DRAFT FOR CONSULTATION Preoperative fasting strategy
5			0 H
			200
			NO
			ŰL.
+ ) 7			TAT
) ;			NOI.
) )			~
5. )			

Study	Onalan 2018 <sup>84</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=53)
Countries and setting	Conducted in Turkey; Setting: Karabuk University Health Sciences Institute, Karabuk, Turkey;
Line of therapy	Unclear
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Scheduled for LC, Age more than 18 years and less than 65 years. Agreeing to participate in the study and signing the informed consent form.
Exclusion criteria	Those with a history of diabetes (type 1 and 2). Those who have ahistory of gestational diabetes. Body mass index (BMI)of 40 kg/m2 or more (BMI 5 body weight/height2). ASA group III or IV. Those who were administered intravenous fluid before surgery. Those with liver and kidney failure. Drug users whose blood glucose levels will be impacted. Those who have previously undergone abdominal surgery. Those with a history of acute cholecystitis or acute pancreatitis. Patients for whom CO2 insufflation is inconvenient in terms of anesthesia (heart failure, chronic obstructive pulmonary disease, and so forth). Those who have bleeding diathesis. Those receiving immuno suppressive treatment. Patients with any infectious disease.
Recruitment/selection of patients	elective laparoscopic cholecystectomy (LC)
Age, gender and ethnicity	Age - Median (IQR): CHO: 53 (16); Fasting: 54 (14). Gender (M:F): 13/37.
Further population details	1. Age: <60 years (CHO: 53 (16); Fasting: 54 (14)). 2. People with diabetes: Non-diabetic
Indirectness of population	No indirectness
Interventions	(n=26) Intervention 1: Combination of food and fluid restrictions - To be reported. the patients were given an oral glucose solution (Nutricia preop) containing 12.5% glucose, first 800 mL at 12 a.m., and then 400 mL at 6 a.m., 2 hours before the surgery. The solution was ingested in 10 minutes. Nutricia preop, one of the

	OCSs containing maltodextrin and electrolytes, contains 12.5% glucose. It passes through the stomach in 90 minutes. Its osmolality is 285 mosm/kg/H2O and it has 50 kcal/100 mL. In addition, it contains 0.46 mg/mL sodium and 1.93 mg/mL potassium.
	. Duration preoperative . Concurrent medication/care: To provide the standardization of treatment after surgery, both groups were treated with 2,000 mL 5% dextrose plus 1,500 mL saline solution, cefazolin sodium (according to our country's infection control committee suggestion) 1 g 2 x 1, tenoxicam 20 mg 2 x 1, ranitidine 50 mg 3 x 1, and metocloramide HCL Indirectness: No indirectness
	(n=27) Intervention 2: Combination of food and fluid restrictions - To be reported. Food and water were cut off in the control group as of 12 a.m. the night before surgery. Duration Preoperative. Concurrent medication/care: To provide the standardization of treatment after surgery, both groups were treated with 2,000 mL 5% dextrose plus 1,500 mL saline solution, cefazolin sodium (according to our country's infection control committee suggestion) 1 g 2 x 1, tenoxicam 20 mg 2 x 1, ranitidine 50 mg 3 x 1, and metocloramide HCL Indirectness: No indirectness
Funding	Academic or government funding (This study was carried out as the Scientific Research Project of Karabuk University
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING	

Protocol outcome 1: Thirst

- Actual outcome: Thirst at 3 hours postoperative; Group 1: mean 0.64 (SD 0.91); n=25, Group 2: mean 7.8 (SD 2.5); n=25; VAS 0-10 Top=High is poor outcome; Comments: P value <0.001

Low values from the visual analog scale are indicative

of recovery.

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low,

Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 1, Reason: prolonged procedure; Group 2 Number missing: 2, Reason: prolonged procedure / change of surgery

- Actual outcome: Anxiety at 3 hours postoperative; Group 1: mean 0.12 (SD 0.44); n=25, Group 2: mean 5.12 (SD 2.77); n=25; VAS 0-10 Top=High is poor outcome; Comments: P value <0.001

Low values from the visual analog scale are indicative of recovery.

Risk of bias: All domain - ; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the Quality of life; Mortality; Adverse events and complications; Patient, family and carer experience of care

-
0
NICE
N
2
2019.
$\geq$
$\leq$
Ţ.
ЧD
Il rights reserved. S
F
S
er
<ul> <li>S</li> </ul>
d
d
je
유
Subject to N
0 <del>-</del> 0
ωŚ
tic
otice
0
f
D.
ght
ŝ

## study

# ; Unplanned ICU admission ; Headache ; Cancellation of surgery

Study	Raksakietisak 2014 <sup>96</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=100)
Countries and setting	Conducted in Thailand; Setting: Faculty of Medicine Siriraj Hospital, Mahidol Unviersity, Thailand
Line of therapy	Unclear
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged 50 – 80 years with unilateral total knee replacement
Exclusion criteria	Revision TKR or bilateral TKR, BMI > 30kg/m2, Gi diseases or Gi affecting drugs, diabetes, CKD, and CHF
Recruitment/selection of patients	unilateral total knee replacement
Age, gender and ethnicity	Age - Mean (SD): CHO: 69.8 (7.3); Fasting: 70.8 (8.5). Gender (M:F): 10/88.
Further population details	1. Age: >60 years (CHO: 69.8 (7.3); Fasting: 70.8 (8.5)). 2. People with diabetes: Non-diabetic
Indirectness of population	No indirectness
Interventions	(n=48) Intervention 1: Combination of food and fluid restrictions - To be reported. Assigned to drink 400ml of 10% carbohydrate rich orange juice (Greenmate) between 18:00 and 24:00 and another 400ml at about 2 hour before anaesthesia (6:00 to 7:00am). Duration preoperative. Concurrent medication/care: Single shot spinal anesthesia
	(n=50) Intervention 2: Combination of food and fluid restrictions - To be reported. The control group had to starve from midnight. Duration preoperative. Concurrent medication/care: Single shot spinal anesthesia. Indirectness: No indirectness
Funding	(Siriraj research development fund)

Protocol outcome 1: Adverse events and complications

Actual outcome: Nausea at postoperative; Group 1: 9/48, Group 2: 10/50
Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 2, Reason: inadequate spinal block; Group 2 Number missing: 0
Actual outcome: Vomiting at postoperative; Group 1: 8/48, Group 2: 12/50
Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low, Comments - ; Indirectness of outcome: No indirectness; Group 1 Number missing: 2, Reason: inadequate spinal block; Group 2 Number missing: 0
Protocol outcome 2: Patient, family and carer experience of care

- Actual outcome: Anxiety at Preoperative; Group 1: mean 3.6 (SD 3); n=48,

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 2, Reason: inadequate spinal block; Group 2 Number missing: 0

Protocol outcome 3: Thirst

- Actual outcome: Thirst at Preoperative; Group 1: mean 2.4 (SD 2.2); n=48,

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 2, Reason: inadequate spinal block; Group 2 Number missing: 0

Protocol outcomes not reported by the Quality of life; Mortality; Unplanned ICU admission; Headache; Cancellation of surgery study

 $\odot$ 

Study	Read 1991 <sup>97</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=54)
Countries and setting	Conducted in United Kingdom; Setting: University Hospital of Wales
Line of therapy	Not applicable
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients ASA I or II, between the ages of 18-60 and scheduled to have elective surgery normally requiring tracheal intubation
Exclusion criteria	Pregnant, GI abnormality, or any medications known to affect gastric emptying
Recruitment/selection of patients	scheduled to have elective surgery normally requiring tracheal intubation
Age, gender and ethnicity	Age - Median (range): Water: 30 (17-56); Fasting: 32 (18-50). Gender (M:F): 18/36.
Further population details	1. Age: <60 years (Water: 30 (17-56); Fasting: 32 (18-50)). 2. People with diabetes: Not stated / Unclear
Indirectness of population	No indirectness
Interventions	<ul> <li>(n=25) Intervention 1: Preoperative food restriction for - 4-6 hours. Permitted to drink water up until 2 hours before the operation. Duration preoperative. Concurrent medication/care: Premedication of oral temazepam 20mg given 2h preoperatively. Indirectness: No indirectness</li> <li>(n=29) Intervention 2: Combination of food and fluid restrictions - To be reported. Abstain from eating and drinking from midnight (morning operation) or after a light breakfast at 6:30am (afternoon operation). Duration preoperative. Concurrent medication/care: Premedication of oral temazepam 20mg given 2h preoperatively. Indirectness</li> </ul>

Perioperative care: DRAFT FOR CONSULTATION Preoperative fasting strategy

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: WATER versus FASTING

Protocol outcome 1: Adverse events and complications - Actual outcome: Nausea at POD1; Group 1: 5/25, Group 2: 15/29 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; - Actual outcome: Vomiting at POD1; Group 1: 3/25, Group 2: 10/29 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Protocol outcome 2: Headache

- Actual outcome: Headache at POD1; Group 1: 6/25, Group 2: 12/29 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

Protocol outcomes not reported by the study Quality of life ; Mortality ; Patient, family and carer experience of care ; Unplanned ICU admission ; Thirst ; Cancellation of surgery

Study	Sada 2014 <sup>98</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=142)
Countries and setting	
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 48 hours postoperative
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	patients were older than 18 years, undergoing an operation of the colon and rectum for benign and malignant diseases, or open abdominal cholecystectomy for chronic cholecystitis
Exclusion criteria	type 1 or 2 diabetes mellitus, stomach emptying disorders or documented gastric esophageal reflex disease, emergency surgery interventions, or refusal of the patient to participate in the trial
Recruitment/selection of patients	undergoing an operation of the colon and rectum
Age, gender and ethnicity	Age - Mean (SD): CHO: 56.85 (12.8); Fasting: 56.45 (14.28). Gender (M:F): 53/89.
Further population details	1. Age: <60 years (CHO: 56.85 (12.8); Fasting: 56.45 (14.28)). 2. People with diabetes: Non-diabetic (Type 1 and 2 diabetes an exclusion criterion).
Indirectness of population	No indirectness
Interventions	<ul> <li>(n=44) Intervention 1: Combination of food and fluid restrictions - To be reported. The study group received 800 mL (per os) of carbohydrate beverage in the evening before surgery (22:00) and an additional 400 mL 2 h before anesthesia induction Duration preoperative. Concurrent medication/care: General anesthesia for surgery. Indirectness: No indirectness</li> <li>(n=52) Intervention 2: Combination of food and fluid restrictions - To be reported. The control group did not receive any of these drinks and were subject to the traditional preoperative fasting Duration preoperative.</li> </ul>
Funding	Concurrent medication/care: General anesthesia for surgery. Indirectness: No indirectness
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CARBOHYDRATE DRINK versus FASTING

Protocol outcome 1: Adverse events and complications

- Actual outcome: Thirst at 0-24h postoperatively; Mean; (Median (range): see below) visual analogue scale 0-10 Top=High is poor outcome, Comments: Colorectal patients: CHO: 3 (1-5): Fasting: 4 (1-7) p value >0.05

Cholecystectomy patients: CHO: 3 (1-5): Fasting: 4 (1-7) p value >0.05;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 1, Reason: excluded from analysis/lost to follow up; Group 2 Number missing: 2, Reason: excluded from analysis/lost to follow up

- Actual outcome: Anxiety at 0-24h postoperatively; median (range): see below visual analogue scale 0-10 Top=High is poor outcome, Comments: Colorectal patients: CHO: 3 (1-3): Fasting: 2 (1-6) p value >0.05

Cholecystectomy patients: CHO: 2 (1-3): Fasting: 2 (1-6) p value >0.05;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 1, Reason: excluded from analysis/lost to follow up; Group 2 Number missing: 2, Reason: excluded from analysis/lost to follow up

- Actual outcome: Nausea at 0-24h postoperatively; median (range): see below visual analogue scale 0-10 Top=High is poor outcome, Comments: Colorectal patients: CHO: 1 (1-5): Fasting: 3 (1-6) p value >0.05

Cholecystectomy patients: CHO: 1 (1-5): Fasting: 3 (1-6) p value >0.05;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 1, Reason: excluded from analysis/lost to follow up; Group 2 Number missing: 2, Reason: excluded from analysis/lost to follow up

Protocol outcome 2: Thirst

- Actual outcome: Thirst at 36-48h postoperatively; median (range): see below visual analogue scale 0-10 Top=High is poor outcome, Comments: Colorectal patients: CHO: 2 (1-3): Fasting: 2 (1-5) p value <0.05

Cholecystectomy patients: CHO: 2 (1-3): Fasting: 2 (1-5) p value >0.05;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 1, Reason: excluded from analysis/lost to follow up; Group 2 Number missing: 2, Reason: excluded from analysis/lost to follow up

- Actual outcome: Anxiety at 36-48h postoperatively; median (range): see below visual analogue scale 0-10 Top=High is poor outcome, Comments: Colorectal patients: CHO: 1 (1-3): Fasting: 1.5 (1-5) p value >0.05

Cholecystectomy patients: CHO: 1 (1-3): Fasting: 1.5 (1-5) p value >0.05;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 1, Reason: excluded from analysis/lost to follow up; Group 2 Number missing: 2, Reason: excluded from analysis/lost to follow up

- Actual outcome: Nausea at 36-48h postoperatively; median (range): see below visual analogue scale 0-10 Top=High is poor outcome, Comments: Colorectal patients: CHO: 1 (1-3): Fasting: 2 (1-5) p value >0.05

Cholecystectomy patients: CHO: 1 (1-3): Fasting: 2 (1-5) p value >0.05;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 1, Reason: excluded from analysis/lost to follow up; Group 2

 $\odot$ 

Number missing: 2, Reason: excluded from analysis/lost to follow up	,

Protocol outcomes not reported by the	Quality of life; Mortality; Patient, family and carer experience of care; Unplanned ICU admission;
study	Headache ; Cancellation of surgery

Study	Smith 2014 <sup>102</sup>
Study type	Cochrane Review
Number of studies (number of participants)	27 (n=1976)
Line of therapy	preoperative carbohydrate supplementation
Method of assessment of guideline condition	Adequate method of assessment/diagnosis. Cochrane review of randomised controlled trials (RCTs) that compared the effects on postoperative recovery and well-being when preoperative carbohydrate treatment was used versus placebo or preoperative fasting in adults (18 years of age or older)
Stratum	Overall
Selection of studies	Assessed RCTs evaluating the effects of preoperative carbohydrate treatment was used versus placebo or preoperative fasting, and included: a clearly defined clinical question details of inclusion and exclusion criteria details of databases searched and relevant search strategies length of hospital stay, complication rate, patient reported well-being scores and adverse events summary results for at least one desired outcome
Inclusion criteria	Included adult patients (18 years of age or older) undergoing any type of elective surgical procedure while under general, spinal or epidural anaesthesia. We included patients who underwent spinal or epidural blockade in addition to general anaesthesia.
Exclusion criteria	Excluded patients who required urgent or emergency surgery (cases in which surgery is required within 24 hours after the first physician contact for a potentially life-threatening condition).
Indirectness of population	No indirectness
Interventions	Intervention 1: The intervention group included all participants who were given at least 45 g of carbohydrate by oral beverage or by the intravenous route. To be included, studies must have planned to administer the carbohydrates within four hours of surgery start time, or induction of anaesthesia. Co-intervention with other oral substances in the four hours before surgery was permitted so long as the dose of carbohydrate was at least 45 g (n=935) Intervention 2: The intervention group was compared with a control group consisting of participants who
	received less than 45 g of carbohydrate in the four hours before anaesthesia. Control participants may have received a placebo drink containing less than 45 g of carbohydrate, clear liquids or nothing by mouth during this time. The control group may have received intravenous fluid therapy during the four hours before surgery start time, so long as the total combined dose of carbohydrates given by oral and intravenous routes remained less than 45 g (n=1041)

Outcomes reported	Length of hospital stay: measured in days.
	Postoperative complication rate
	Fatigue: measured by such instruments as ordinal or visual analogue scales.
	General well-being: measured by such instruments as ordinal, visual analogue or composite scales.
	Nausea 24 hours postoperatively: measured by such instruments as ordinal, visual analogue or composite scales.
	Vomiting within 24 hours postoperatively: measured as an incidence rate.

Evidence included for 21 studies:

An 2008; Bisgaard 2004; Braga 2012; Harsten 2012; Hausel 2005; Henriksen 2003; Kaska 2010; Lidder 2013; Ljunggren 2012; Ljunggvist 1994; Mathur 2010; Noblett 2006; Ozdemir 2011; Pexe-Machado 2013; Soop 2001; Soop 2004; Wang 2010; Yang 2012; Yildiz 2013; Yuill 2005; Zelic 2012

Six studies from this Cochrane review were not included for analysis as they included populations or interventions not suitable for this review :

Breuer 2006 – cardiac surgeryJarvela 2008 – cardiac surgeryLauwick 2009 – comparison with water onlyPerrone 2011 – comparison with water onlyRapp-Kasek 2007 – cardiac surgeryTran 2013 – cardiac surgeryRisk of bias assessmentOverall risk of bias – low risk

Overall risk of bias – low risk of bias, Study eligibility criteria – low concern, Identification and selection of studies – low concern, Data collection and study appraisal – low concern, Synthesis and findings – low concern

Study	Wang 2010 <sup>107</sup>
Study type	RCT (Patient randomised; Parallel) – Included in Smith 2014 <sup>102</sup>
Number of studies (number of participants)	(n=48)
Countries and setting	Conducted in China; Setting: Departments of general surgery at Medical University Hospitals in China
Line of therapy	Unclear
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients undergoing elective open colorectal cancer resection surgery
Exclusion criteria	Diabetes Mellitus or impaired glucose tolerance, medication affecting insulin sensitivity, weight loss greater than 10 per cent during the previous 6 months, presence of distant metastasis on CT, renal insufficiency, hepatic insufficiency, GORD, gastrointestinal obstruction or conditions known to affect gastric emptying rate and age more than 75 or less than 25 years
Recruitment/selection of patients	Patients undergoing elective open colorectal cancer resection surgery
Age, gender and ethnicity	Age - Median (range): CHO 66 (48 - 74); Fasting 63 (37 - 74);. Gender (M:F): 28/20.
Further population details	1. Age: >60 years (CHO 66 (48 - 74); Fasting 63 (37 - 74);). 2. People with diabetes: Non-diabetic
Indirectness of population	
Interventions	(n=18) Intervention 1: Combination of food and fluid restrictions - To be reported. Patients in the CHO group consumed 400ml Nutricia PreOp (12.5% carbohydrate, 0.5kcal/ml, 240mOsm/kg, pH 4 - 9, Nutricia Zoetermeer, Netherlands) 3h before induction of anesthesia completing CHO ingestion within 1h. Patients were nil by mouth after 2100 hours apart from single morning dose of 400ml carbohydrate drink Duration perioperative. Concurrent medication/care: Oral bowel preparation with polyethylene glycol electrolyte solution administered to all patients. All patients received a low residue liquid diet freely before 2100 hours on the day before surgery.
	(n=17) Intervention 2: Combination of food and fluid restrictions - To be reported. Patients were fasted from midnight before surgery. Duration perioperative. Concurrent medication/care: Oral bowel preparation with polyethylene glycol electrolyte solution administered to all patients. All patients received a low residue liquid diet freely before 2100 hours on the day before surgery.
Funding	Funding not stated

© NICE 2019. All rights reserved. Subject to Notice of rights. 109

#### RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING

Protocol outcome 1: Quality of life

- Actual outcome: Anxiety at 1 hour preoperative; Median (range): CHO: 22 (11-47); Fasting: 28 (16-61) VAS 0-100 Top=High is poor outcome; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2, Reason: complications found during surgery; Group 2 Number missing: 1, Reason: complications found during surgery

#### Protocol outcome 2: Adverse events and complications

- Actual outcome: Nausea at 1 hour preoperative; Median (range): CHO: 8 (4-11); Fasting: 8 (2-14) VAS 0-100 Top=High is poor outcome; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 2, Reason: complications found during surgery; Group 2 Number missing: 1, Reason: complications found during surgery

- Actual outcome: Tiredness at 1 hour preoperative; Median (range): CHO: 20 (11-60); Fasting: 23(10-53) VAs 0-100 Top=High is poor outcome; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2, Reason: complications found during surgery; Group 2 Number missing: 1, Reason: complications found during surgery

#### Protocol outcome 3: Thirst

- Actual outcome: Thirst at 1 hour preoperative; Median (range) : CHO: 20 (8-59); Fasting: 24 (19-60) VAS 0-100 Top=High is poor outcome; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2, Reason: complications found during surgery; Group 2 Number missing: 1, Reason: complications found during surgery

Protocol outcomes not repo	orted by the Mortality	; Patient, family and carer experience of care	; Unplanned ICU admission ; Headache ;
study	Cancellat	tion of surgery	

Study	Yagmurdur 2011 <sup>110</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=44)
Countries and setting	Conducted in Turkey; Setting: The Ministry of Health Ankara Research and Training Hospital, Ankara, Turkey.
Line of therapy	Not applicable
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients ASA classes I-II adult patients scheduled for elective inguinal hernia repair surgery under spinal anesthesia
Exclusion criteria	not specified
Recruitment/selection of patients	scheduled for elective inguinal hernia repair surgery under spinal anesthesia
Age, gender and ethnicity	Age - Mean (SD): CHO: 45 (7); Fasting: 43 (8). Gender (M:F): 26/18.
Further population details	1. Age: <60 years (CHO: 45 (7); Fasting: 43 (8)). 2. People with diabetes: Not stated / Unclear
Indirectness of population	
Interventions	(n=22) Intervention 1: Combination of food and fluid restrictions - To be reported. During the evening before surgery, patients in the CHO group ingested 800 mL of an iso-osmolar carbohydrate-rich drink [12.5% carbohydrates (glucose: 0.2 g, maltose: 0.7 g, polysaccharides: 10 g), 50 kcal/100 ml, 290 mOsm/kg, pH 5.0; Nutricia Preop ; Numico, Zoetermeer, The Netherlands]. Nothing per os was allowed from midnight except another 400 mL of CHO in the morning at least 90 minutes before spinal anesthesia in the CHO group Duration preoperative. Concurrent medication/care: spinal anesthesia
	(n=22) Intervention 2: Combination of food and fluid restrictions - To be reported. The patients in the control group underwent spinal anesthesia after the routine fast from midnight Duration preoperative. Concurrent medication/care: spinal anesthesia
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO DRINK versus FASTING

Protocol outcome 1: Thirst

- Actual outcome: Thirst at 90 minutes post ingestion of CHO drink; median (IQR): CHO: 20 (16-24); Fasting: 60 (56-64) visual analogue scale 0-100 Top=High is poor outcome;

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

- Actual outcome: Thirst at 60 minutes post anesthesia; median (IQR): CHO: 18 (13-23): Fasting: 64 (59-69) visual analogue scale 0-100 Top=High is poor outcome;

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

- Actual outcome: Nausea at 90 minutes post ingestion of CHO drink; Median (IQR) : CHO: 10 (7-13); Fasting: 8 (4-12) visual analogue scale 0-100 Top=High is poor outcome;

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

- Actual outcome: Nausea at 60 minutes post anesthesia; Median (IQR): CHO: 8 (4-12); Fasting: 9 (5-13) visual analogue scale 0-100 Top=High is poor outcome;

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Anxiety at 90 minutes post ingestion of CHO drink; Median (IQR): CHO: 20 (18-22); Fasting: 48 (43-53) visual analgoue scale 0-100 Top=High is poor outcome;

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Anxiety at 60 minutes post anesthesia; Median (IQR): CHO: 43 (41-45); Fasting: 46 (44-48) visual analogue scale 0-100 Top=High is poor outcome;

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

Protocol outcomes not reported by the	Quality of life ; Mortality ; Adverse events and complications ; Patient, family and carer experience of care
study	; Unplanned ICU admission ; Headache ; Cancellation of surgery

Number of studies (number of participants) Countries and setting Line of therapy Duration of study Method of assessment of guideline condition Stratum	RCT (Patient randomised; Parallel) – Included in Smith 2014 <sup>102</sup> (n=35)         Conducted in Netherlands; Setting: Royal infirmary of Edinburgh         Unclear         Intervention + follow up:         Adequate method of assessment/diagnosis
Countries and setting Line of therapy Duration of study Method of assessment of guideline condition Stratum	Conducted in Netherlands; Setting: Royal infirmary of Edinburgh Unclear Intervention + follow up:
Line of therapy Duration of study Method of assessment of guideline condition Stratum	Unclear Intervention + follow up:
Duration of study Method of assessment of guideline condition Stratum	Intervention + follow up:
Method of assessment of guideline condition Stratum	· · · · · · · · · · · · · · · · · · ·
condition Stratum	Adequate method of assessment/diagnosis
Subgroup analysis within study	Overall
g , , ,	Not applicable
Inclusion criteria	Patients undergoing elective abdominal surgery
	Existing impaired renal function, liver cirrhosis, diabetes, metabolic abnormalities, or gastric stasis / obstruction were excluded as were all patients undergoing emergency or laparoscopic procedures
Recruitment/selection of patients	Patients undergoing elective abdominal surgery
Age, gender and ethnicity	Age - Mean (SD): CHO: 52.1 (2.4); Fasting: 52.8 (2.5). Gender (M:F): 39/26.
Further population details	1. Age: <60 years (CHO: 52.1 (2.4); Fasting: 52.8 (2.5)). 2. People with diabetes: Non-diabetic
Indirectness of population	-
	(n=34) Intervention 1: Combination of food and fluid restrictions - To be reported. Placebo drink (fluid and electrolytes; potassium; sodium; chloride; calcium; magnesium) of 800ml on the evening prior to surgery approximately 12 hours before anesthesia and a further 400ml 2 - 3 hours before the induction of anesthesia. It was stipulated that the 400ml drink on the morning of surgery should be consumed over 20 minutes Duration preoperative. Concurrent medication/care: NA (n=31) Intervention 2: Combination of food and fluid restrictions - To be reported. Carbohydrate drink
	(containing 12.6g carbohydrates 100ml with electrolytes, potassium, sodium, chloride, calcium and magnesium) of 800ml on the evening prior to surgery approximately 12 hours before anesthesia and a further 400ml 2 - 3 hours before the induction of anesthesia. It was stipulated that the 400ml drink on the morning of surgery should be consumed over 20 minutes. Duration preoperative. Concurrent medication/care: NA
Funding	Study funded by industry (Study supported by Numico research, Wageningen, Netherlands)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PLACEBO versus CHO

- Actual outcome: Length of stay at Perioperative period; Median (IQR) : CHO: 10 (6); Fasting: 8 (4) days );

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcomes not reported by the study Quality of life ; Mortality ; Patient, family and carer experience of care ; Unplanned ICU admission ; Thirst ; Headache ; Cancellation of surgery

Perioperative care: DRAFT FOR CONSULTATION Preoperative fasting strategy

Study	Zhang 2019 <sup>115</sup>							
Study type	RCT (Patient randomised; Parallel)							
Number of studies (number of participants)	(n=58)							
Countries and setting	Conducted in China; Setting: First affiliated Hospital of Nanchang University, China							
Line of therapy	Not applicable							
Duration of study	Intervention + follow up:							
Method of assessment of guideline condition	Adequate method of assessment/diagnosis							
Stratum	Overall							
Subgroup analysis within study	Not applicable							
Inclusion criteria	Patients aged 18 – 55, ASA I – II scheduled to undergo elective open gynaecological surgery							
Exclusion criteria	Not specified							
Recruitment/selection of patients	scheduled to undergo elective open gynaecological surgery							
Age, gender and ethnicity	Age - Mean (SD): CHO: 42.64 (5.26); Fasting: 43.57 (5.60). Gender (M:F): all female.							
Further population details	1. Age: <60 years (CHO: 42.64 (5.26); Fasting: 43.57 (5.60)). 2. People with diabetes: Not stated / Unclear							
Indirectness of population	No indirectness							
Interventions	(n=29) Intervention 1: Combination of food and fluid restrictions - To be reported. Patients in the CHO group consumed CHO (12.5g of carbohydrate per 100ml, 285 mOsm/kg; Nutricia Preop, Nutricia, Zoetermeer, The Netherlands) in doses of 800ml on the evening before surgery (between 8pm and 10pm) and 400ml 2h before their scheduled operation. Duration preoperative . Concurrent medication/care: combined spinal epidural anesthesia for the procedure							
	(n=29) Intervention 2: Combination of food and fluid restrictions - To be reported. Patients in the fasting group were forbidden from eating anything after midnight before the induction of anaesthesia. Duration preoperative. Concurrent medication/care: combined spinal epidural anesthesia for the procedure. Indirectness: No indirectness							
Funding	Funding not stated							

Perioperative care: DRAFT FOR CONSULTATION Preoperative fasting strategy

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING

Protocol outcome 1: Adverse events and complications

- Actual outcome: Nausea & vomiting at Postoperative; Group 1: 8/29, Group 2: 12/29; Comments: p value 0.2646

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

- Actual outcome: Tiredness at 6h postoperative; median (range): CHO: 30 (20-40); Fasting: 30 (20-40) VAS 0-100 Top=High is poor outcome; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Tiredness at 24h postoperative; median (range): CHO: 40 (30-40); Fasting: 30 (20-30) VAS 0-100 Top=High is poor outcome; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Anxiety at Preoperative; median (range): CHO: 30 (30-30); Fasting: 60 (50-70) VAS 0-100 Top=High is poor outcome, Comments: p value <0.001;

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

Protocol outcome 2: Patient, family and carer experience of care

- Actual outcome: Length of hospital stay at Postoperative; Group 1: mean 3.82 days (SD 0.67); n=29, Group 2: mean 4.36 days (SD 0.78); n=29; Comments: 0.0079

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcome 3: Thirst

- Actual outcome: Thirst at 6h postoperative; Median (range):: CHO: 20 (10-30); Fasting: 40 (20-55) VAS 0-100 Top=High is poor outcome, Comments: p value < 0.001;

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Thirst at 24h postoperative; median (range): CHO: 30 (25-40); Fasting: 40 (20-50) VAS 0-100 Top=High is poor outcome; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcome 4: Headache

- Actual outcome: Headache at Postoperative; Group 1: 3/29, Group 2: 9/29; Comments: P value 0.0507

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

Protocol outcomes not reported by the Quality of life ; Mortality ; Unplanned ICU admission ; Cancellation of surgery study

#### Table 13: Risk of bias summary from Cochrane review

Study: Smith 2014 <sup>102</sup>	
Domain	Outcome
Study eligibility criteria	Low concern
Identification and selection of studies	Low concern
Data collection and study appraisal	Low concern
Synthesis and findings	Low concern
Overall risk of bias	Low risk of bias

# Appendix E: Forest plots

## 2 E.1 Carbohydrate drinks versus Fasting

#### Figure 2: Patient Satisfaction (0-10) (24 hours postoperative)

		сно	Fasting					Mean Difference	Mean Difference						
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI			IV, Fixe	d, 95%	CI		
Ajuzieogu 2016	8	0.75	29	6	0.5	29	100.0%	2.00 [1.67, 2.33]						-	
Total (95% CI)			29			29	100.0%	2.00 [1.67, 2.33]						$\blacklozenge$	
Heterogeneity: Not ap Test for overall effect:	-2 Fa	vours	1 Fasting	l 0 Favou	1 Is Ch	2 10									

1

#### Figure 3: Postoperative global QoR-40 score

СНО				Fa	sting	g		Mean Difference	Mean Difference							
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixed, 95% CI				IV, Fixed, 95% CI		
Lee 2018	186.7	17.5	46	194.5	5.6	49	100.0%	-7.80 [-13.09, -2.51]								
Total (95% CI)			46			49	100.0%	-7.80 [-13.09, -2.51]								
Heterogeneity: Not ap Test for overall effect:		(P = 0	).004)						-20	-10 Favours Fasting	0 10 Favours CH	) 20 10				

#### Figure 4: Length of hospital stay (days)

		ohydrate			sting			Mean Difference		Mean Difference
Study or Subgroup		SD [days]	Total	Mean [days]	SD [days]	Total	Weight	IV, Random, 95% CI [days]	Year	IV, Random, 95% CI [days]
2.3.1 Major abdomina	l surgery									
Noblett 2006	7.5	2.81	12	10	2.74	12	1.8%	-2.50 [-4.72, -0.28]		←
An 2008	11	1.2	27	15.1	3.8	24	3.2%	-4.10 [-5.69, -2.51]	2008	•
Kaska 2010	11	2.22	74	11	2.96	75	7.8%	0.00 [-0.84, 0.84]		
Ozdemir 2011	3.86	2.17	15	3.39	1.795	15	3.8%	0.47 [-0.96, 1.90]	2011	
Pexe-Machado 2013	8.1	3.82	10	15.6	8.72	12	0.3%	-7.50 [-12.97, -2.03]	2013	•
Zhang 2019 Subtotal (95% CI)	3.82	0.67	29 167	4.36	0.78	29 167	14.4% <b>31.3%</b>	-0.54 [-0.91, -0.17] - <b>1.43 [-2.68, -0.18]</b>	2019	
Heterogeneity: Tau <sup>2</sup> = 1	1.68; Chi <sup>2</sup> = 31.6	83, df = 5 (P	< 0.00	001); I² = 84%						
Test for overall effect: 2	Z = 2.24 (P = 0.0	13)								
2.3.2 Intermediate Ab	-									
Lee 2018 Subtotal (95% CI)	2.59	1.61	46 <b>46</b>	2.38	2.05	51 51	9.1% <b>9.1%</b>	0.21 [-0.52, 0.94] 0.21 [-0.52, 0.94]	2018	
Heterogeneity: Not app	olicable									
Test for overall effect: 2	Z = 0.56 (P = 0.5	i7)								
2.3.3 Minor abdomina	l surgery									
Hausel 2005	1.2	0.7	55	1.3	0.9	58	15.6%	-0.10 [-0.40, 0.20]	2005	
Ozdemir 2011	0.96	0.085	15	1.09	0.277	15	17.5%	-0.13 [-0.28, 0.02]	2011	
Yildiz 2013	1	0.32	30	1	0.32	30	17.4%	0.00 [-0.16, 0.16]	2013	
Subtotal (95% CI)			100			103	50.5%	-0.07 [-0.18, 0.03]		
Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2			: 0.50);	I <sup>2</sup> = 0%						
2.3.4 Orthopaedic sur	gery									
Ljunggren 2012 Subtotal (95% CI)	5	0.74	19 <b>1</b> 9	6	1.48	20 20	9.1% <b>9.1%</b>	-1.00 [-1.73, -0.27] - <b>1.00 [-1.73, -0.27]</b>	2012	<b>←</b>
Heterogeneity: Not app Test for overall effect: 2		107)								
Total (95% CI)			332			341	100.0%	-0.37 [-0.68, -0.06]		
Heterogeneity: Tau <sup>2</sup> = I	0.14: Chi≊ = 49.	80 df=10/		0001) <sup>,</sup> P= 80%	,	211				
Test for overall effect: 2			0.01	5001), 1 = 00 X	,					-0.5 -0.25 0 0.25 0.5
Test for subaroup diffe			/P = 0	01) 12 - 72 0%						Favours carbohydrates Favours fasting

#### Figure 5: Thirst (0-10) (preoperative)

	СНО			Fasting				Mean Difference		е			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixe	ed, 95% (	CI	
Raksakietisak 2014	2.4	2.4	48	2.2	2.2	50	100.0%	0.20 [-0.71, 1.11]					
Total (95% CI)			48			50	100.0%	0.20 [-0.71, 1.11]					
Heterogeneity: Not app Test for overall effect: 2		(P =	0.67)						-2	-1 Favours CHO	0 Favou	1 rs Fastin	2 g

1

#### Figure 6: Thirst (0-10) (postoperative)

0	•	<u></u>		·				Maan Difference				Havanaa
		сно			sting	,		Mean Difference		IV	lean D	fference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		1	V, Fixe	d, 95% Cl
Onalan 2018	0.64	0.91	25	7.8	2.5	25	100.0%	-7.16 [-8.20, -6.12]				
Total (95% CI)			25			25	100.0%	-7.16 [-8.20, -6.12]	•			
Heterogeneity: Not ap										-4	-2	
Test for overall effect:	Z = 13.4	l6 (P <	0.0000	01)						Favours	S CHO	Favours Fasting

#### Figure 7: Thirst (mild)

5	СНС	5	Fastir	ng		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Canbay 2014	6	25	13	25	100.0%	0.46 [0.21, 1.02]	
Total (95% CI)		25		25	100.0%	0.46 [0.21, 1.02]	
Total events	6		13				
Heterogeneity: Not ap Test for overall effect:		P = 0.0	6)				0.1 0.2 0.5 1 2 5 10 Favours CHO Favours Fasting

#### Figure 8: Thirst (moderate)

-	СНС	)	Fasti	ng		Risk Ratio	I	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H	Fixed, 95% CI	
Canbay 2014	0	25	5	25	100.0%	0.09 [0.01, 1.56]		<u> </u>	
Total (95% CI)		25		25	100.0%	0.09 [0.01, 1.56]			
Total events	0		5						
Heterogeneity: Not app Test for overall effect:		P = 0.1	0)				0.002 0.1 Favours C	1 10 HO Favours Fasting	500 g

#### 4

#### Figure 9: Headache (postoperative)

	CHC	)	Fastir	ng		Risk Ratio	F	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	М-Н,	Fixed, 95% CI	
Zhang 2019	3	29	9	29	100.0%	0.33 [0.10, 1.11]		l−-†	
Total (95% CI)		29		29	100.0%	0.33 [0.10, 1.11]			
Total events	3		9						
Heterogeneity: Not app Test for overall effect:		P = 0.0	7)				0.01 0.1 Favours C	1 10 HO Favours Fasting	100

#### Figure 10: Complication rate

	Carbohy	drate	Fastir	ng		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
Hausel 2005	0	55	0	58		Not estimable	2005	
Noblett 2006	2	12	1	12	6.6%	2.00 [0.21, 19.23]	2006	
Kaska 2010	7	74	11	75	42.4%	0.64 [0.26, 1.57]	2010	
Zelic 2012	4	20	3	20	18.1%	1.33 [0.34, 5.21]	2012	
Pexe-Machado 2013	5	10	4	12	32.9%	1.50 [0.55, 4.13]	2013	
Total (95% CI)		171		177	100.0%	1.05 [0.59, 1.87]		
Total events	18		19					
Heterogeneity: Tau <sup>2</sup> = 0	).00; Chi <b></b> =	2.08, d	f= 3 (P =	0.56);	I <b>2</b> = 0%			
Test for overall effect: Z	:= 0.15 (P	= 0.88)						Favours carbohydrates Favours fasting

#### Figure 11: Well-being (postoperative)

	Carb	ohydra	ate	F	asting			Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Henriksen 2003	2.97	3.16	32	3.4	3.33	16	52.4%	-0.13 [-0.73, 0.47]	2003	
Ljunggren 2012	26	5.19	19	25	3.7	20	47.6%	0.22 [-0.41, 0.85]	2012	
Total (95% CI)			51			36	100.0%	0.04 [-0.40, 0.47]		
Heterogeneity: Tau <sup>2</sup> =				= 1 (P =	0.43);	I <sup>2</sup> = 0%				-1 -0.5 0 0.5 1
Test for overall effect:	2 = 0.16	0 (P = 0	1.87)							Favours fasting Favours carbohydrates

#### Figure 12: Nausea & Vomiting (0-10) (postoperative)

	0	сно		Fa	asting			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Ajuzieogu 2016	5.75	2	29	6.5	1.24	29	100.0%	-0.75 [-1.61, 0.11]	
Total (95% CI)			29			29	100.0%	-0.75 [-1.61, 0.11]	
Heterogeneity: Not ap Test for overall effect:		: (P =	0.09)					-	-2 -1 0 1 2 Favours CHO Favours Fasting

#### 4

#### Figure 13: Nausea & Vomiting

	CHO	)	Fastir	ng		Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl	
2.12.1 Nausea & Vom	niting								
Celiksular 2016	2	40	1	40	7.7%	2.00 [0.19, 21.18]			-
Zhang 2019	8	29	12	29	92.3%	0.67 [0.32, 1.39]			
Subtotal (95% CI)		69		69	1 <b>00.0</b> %	0.77 [0.38, 1.54]			
Total events	10		13						
Heterogeneity: Chi <sup>2</sup> =	0.78, df = 1	I (P = 0	).38); l² =	0%					
Test for overall effect:	Z = 0.74 (F	P = 0.4	6)						
2.12.2 Nausea									
Raksakietisak 2014	9	48	10	50	100.0%	0.94 [0.42, 2.10]			
Subtotal (95% CI)		48		50	1 <b>00.0</b> %	0.94 [0.42, 2.10]		$\bullet$	
Total events	9		10						
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 0.16 (F	P = 0.8	8)						
2.12.3 Vomiting									
Faria 2009	3	11	7	10	31.9%	0.39 [0.14, 1.11]			
Hausel 2005	3	55	4	58	16.9%	0.79 [0.19, 3.37]			
Raksakietisak 2014	8	48	12	50	51.1%	0.69 [0.31, 1.55]			
Subtotal (95% CI)		114		118	1 <b>00.0%</b>	0.61 [0.34, 1.10]		$\bullet$	
Total events	14		23						
Heterogeneity: Chi <sup>2</sup> =	0.93, df = 2	2 (P = 0	).63); l² =	0%					
Test for overall effect:	Z = 1.64 (F	P = 0.1	D)						
							L		
							0.01 0.	1 1 10	10

Test for subgroup differences: Chi<sup>2</sup> = 0.73, df = 2 (P = 0.69), l<sup>2</sup> = 0%

© NICE 2019. All rights reserved. Subject to Notice of rights.

Favours CHO Favours Fasting

#### Figure 14: Anxiety (0-10) (preoperative)

•	(	сно	•	Fa	asting	9	,	Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Raksakietisak 2014	3.6	3	48	3.3	3.8	50	100.0%	0.30 [-1.05, 1.65]	
Total (95% CI)			48			50	100.0%	0.30 [-1.05, 1.65]	
Heterogeneity: Not ap Test for overall effect:		8 (P =	0.66)						-1 -0.5 0 0.5 1 Favours CHO Favours Fasting

#### Figure 15: Anxiety (0-10) (postoperative) CHO Fasting Mean Difference

		сно		Fa	asting			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Onalan 2018	0.12	0.44	25	5.12	2.77	25	100.0%	-5.00 [-6.10, -3.90]	
Total (95% CI)			25			25	100.0%	-5.00 [-6.10, -3.90]	◆
Heterogeneity: Not ap Test for overall effect:		(P < 0	).00001	)					-4 -2 0 2 4 Favours CHO Favours Fasting

#### 2

Henriksen 2003 6.58 3.74 32 6.6 2.89 16 41.6% -0.01 [-	m, 95% CI Year IV, Random, 95% CI
Yildiz 2013 9 29.15 30 13 29.45 30 58.4% -0.13 [-	.61, 0.59] 2003
	.64, 0.37] 2013
Total (95% CI) 62 46 100.0% -0.08 [-	.47, 0.31]

### 3 4

5

6 7 Evidence includes data from Smith M, McCall J, Plank L, Herbison G, Soop M, Nygren J. Preoperative carbohydrate treatment for enhancing recovery after elective surgery. Cochrane Database of Systematic Reviews 2014, Issue 8. Copyright Cochrane Collaboration, reproduced with permission.

8

## 1 E.2 Carbohydrate drinks versus placebo drinks

#### Figure 17: Length of hospital stay (days)

0	Carbo	ohydrate		Pla	cebo		,	Mean Difference		Mean Difference
Study or Subgroup	Mean [days]	SD [days]	Total	Mean [days]	SD [days]	Total	Weight	IV, Random, 95% CI [days]	Year	IV, Random, 95% CI [days]
3.1.1 Major abdomina	al surgery									
Yuill 2005	8	2.96	31	10	4.44	34	0.9%	-2.00 [-3.82, -0.18]	2005	
Mathur 2010	8.68	6.68	69	9.93	11.89	73	0.3%	-1.25 [-4.40, 1.90]	2010	•
Ozdemir 2011	3.86	2.17	15	2.78	1.27	15	1.8%	1.08 [-0.19, 2.35]	2011	+
Braga 2012	14.2	3.145	18	14.3	4.44	18	0.5%	-0.10 [-2.61, 2.41]	2012	
Yang 2012	9.7	13.72	24	10.2	18.13	24	0.0%	-0.50 [-9.60, 8.60]	2012	•
Lidder 2013 Subtotal (95% CI)	7	3.477	59 <b>216</b>	8.25	4.906	61 225	1.3% <mark>4.8%</mark>	-1.25 [-2.77, 0.27] -0.59 [-1.82, 0.64]	2013	
Heterogeneity: Tau <sup>2</sup> =	1.02; Chi <sup>2</sup> = 9.1	70, df = 5 (P	= 0.08)	); I² = 48%						
Test for overall effect:	Z = 0.94 (P = 0	.35)								
3.1.2 Minor abdomina	al surgery									
Hausel 2005	1.2	0.7	55	1.2	0.6	59	27.8%	0.00 [-0.24, 0.24]		+
Ozdemir 2011	0.96	0.085	15	1.02	0.115	15	54.0%	-0.06 [-0.13, 0.01]	2011	-
Subtotal (95% CI)			70			74	81.8%	-0.06 [-0.12, 0.01]		•
Heterogeneity: Tau <sup>2</sup> = Test for overall effect:			= 0.64)	); I² = 0%						
3.1.3 Orthopaedic su	rgery									
Soop 2001	5.5	1.41	8	5.1	1.85	7	1.0%	0.40 [-1.28, 2.08]	2001	
Soop 2004	5	0	8	6	0	6		Not estimable	2004	
Harsten 2012 Subtotal (95% CI)	3.33	0.71	30 <b>46</b>	3.25	1	30 <b>43</b>	12.4% <b>13.4%</b>	0.08 [-0.36, 0.52] 0.10 [-0.32, 0.53]	2012	
Heterogeneity: Tau <sup>2</sup> =			= 0.72)	); I² = 0%						
Test for overall effect:	Z = 0.46 (P = 0	.64)								
Total (95% CI)			332			342	100.0%	-0.04 [-0.21, 0.14]		<b>+</b>
Heterogeneity: Tau <sup>2</sup> =	0.01; Chi <sup>2</sup> = 11	.25, df = 9 (	P = 0.2	6); I² = 20%						-4 -2 0 2
Test for overall effect:	Z = 0.42 (P = 0	.67)								-4 -2 U 2 Favours carbohydrates Favours placebo
	erences: Chi <sup>2</sup> =									

#### Figure 18: Complication rate

-									
	Carbohy	drate	Placel	00		Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI Y	ar	M-H, Random, 95% Cl	
Soop 2001	1	8	0	7	0.6%	2.67 [0.13, 56.63] 2	01		
Soop 2004	0	8	0	6		Not estimable 2	)4		
Hausel 2005	0	55	0	59		Not estimable 2	05		
Yuill 2005	6	31	6	34	5.3%	1.10 [0.39, 3.05] 2	05		
Mathur 2010	23	69	30	73	29.4%	0.81 [0.53, 1.25] 2	10		
Braga 2012	13	18	12	18	29.1%	1.08 [0.70, 1.67] 2	12		
Yang 2012	5	24	5	24	4.5%	1.00 [0.33, 3.01] 2	12		
Lidder 2013	23	59	28	61	31.2%	0.85 [0.56, 1.29] 2	13		
Total (95% CI)		272		282	100.0%	0.92 [0.73, 1.17]		•	
Total events	71		81						
Heterogeneity: Tau <sup>2</sup> =	0.00; Chi <sup>2</sup> =	= 1.63, d	f = 5 (P =	0.90);	$l^2 = 0\%$				-
Test for overall effect:	,		(	- , ,			0.1 0.1 Favours o	2 0.5 1 2 5 carbohydrates Favours placebo	10

#### 3

#### Figure 19: Fatigue (postoperative)

	Carb	ohydr	ate	PI	acebo	•	:	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI Year	IV, Random, 95% Cl
Bisgaard 2004	6	2.25	43	6	2	43	33.9%	0.00 [-0.42, 0.42] 2004	<b>_</b>
Mathur 2010	44.6	28.3	58	43.4	30.6	64	36.4%	0.04 [-0.31, 0.40] 2010	<b></b>
Harsten 2012	39	25	30	15	28	30	29.7%	0.89 [0.36, 1.42] 2012	<b>_</b>
Total (95% CI)			131			137	100.0%	0.28 [-0.22, 0.78]	
Heterogeneity: Tau <sup>2</sup> =	0.15; Ch	i <sup>2</sup> = 8.1	13, df =	2 (P = 0	0.02);	l² = 75%	6		-1 -0.5 0 0.5 1
Test for overall effect:	Z = 1.09	(P = 0	.28)						Favours carbohydrates Favours placebo

#### Figure 20: Well-being (postoperative)


Bisgaard 2004         65         23         43         63         22.5         43         42.0%         0.09 [-0.34, 0.51]         2004           Mathur 2010         24.1         15.4         56         25         14.8         63         58.0%         -0.06 [-0.42, 0.30]         2010	Std. Mean Difference	Std. Mean Difference	5		acebo	PI	ate	ohydra	Carb	
Mathur 2010 24.1 15.4 56 25 14.8 63 58.0% -0.06 [-0.42, 0.30] 2010	IV, Random, 95% CI	IV, Random, 95% CI Year	Weight	Total	SD	Mean	Total	SD	Mean	Study or Subgroup
		0.09 [-0.34, 0.51] 2004	42.0%	43	22.5	63	43	23	65	Bisgaard 2004
		-0.06 [-0.42, 0.30] 2010	58.0%	63	14.8	25	56	15.4	24.1	Mathur 2010
10tal (95% Cl) 99 106 100.0% 0.00 [-0.27, 0.26]		0.00 [-0.27, 0.28]	100.0%	106			99			Total (95% CI)

#### Figure 21: Nausea (mm) (postoperative)

	Carb	ohydrate		Pla	acebo			Mean Difference	Mean Difference
Study or Subgroup	Mean [mm]	SD [mm]	Total	Mean [mm]	SD [mm]	Total	Weight	IV, Random, 95% CI [mm] Year	IV, Random, 95% CI [mm]
Hausel 2005	8	6.67	55	10	6.67	59	92.2%	-2.00 [-4.45, 0.45] 2005	
Mathur 2010	17.8	24.5	57	16.1	22.3	63	7.8%	1.70 [-6.71, 10.11] 2010	
Total (95% CI)			112			122	100.0%	-1.71 [-4.06, 0.64]	-
Heterogeneity: Tau <sup>2</sup> = Test for overall effect			P = 0.4	1); I <sup>2</sup> = 0%					-10 -5 0 5 10 Favours carbobydrates Favours placebo

1

#### Figure 22: Postoperative vomiting



2 3

4

5

6

Evidence includes data from Smith M, McCall J, Plank L, Herbison G, Soop M, Nygren J. Preoperative carbohydrate treatment for enhancing recovery after elective surgery. Cochrane Database of Systematic Reviews 2014, Issue 8. Copyright Cochrane Collaboration, reproduced with permission.

## 7 E.3 Water versus Fasting

Figure 23:	Nausea	a PO	D 1				
-	Wate	er	Fastir	ng		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Read 1991	5	25	15	29	100.0%	0.39 [0.16, 0.91]	<b></b>
Total (95% CI)		25		29	100.0%	0.39 [0.16, 0.91]	
Total events	5		15				
Heterogeneity: Not a Test for overall effect		P = 0.0	3)			-	0.2 0.5 1 2 5 Favours Water Favours Fasting

#### Figure 24: Vomiting POD 1

0	Wate	r	Fasti	ng		Risk Ratio			Ris	k Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		N	I-H, Fix	xed, 95% (		
Read 1991	3	25	10	29	100.0%	0.35 [0.11, 1.13]				+		
Total (95% CI)		25		29	100.0%	0.35 [0.11, 1.13]				-		
Total events	3		10									
Heterogeneity: Not ap Test for overall effect:		P = 0.0	8)				0.1	1 0.2 Favours	0.5 Water	1 2 r Favours	5 Fasting	10

9

#### Figure 25: **Headache POD 1** Water **Risk Ratio Risk Ratio** Fasting Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI M-H, Fixed, 95% CI Read 1991 6 25 12 29 100.0% 0.58 [0.26, 1.32] Total (95% CI) 25 29 100.0% 0.58 [0.26, 1.32] Total events 12 6 Heterogeneity: Not applicable 2 0.5 5 0.2 Test for overall effect: Z = 1.30 (P = 0.19) Favours Water Favours Fasting

# **Appendix F: GRADE tables**

Table 14: Clinical evidence profile: Carbohydrate drinks versus fasting

			Quality as	sessment			No of par	tients		Effect		
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	CHO versus fasting	Control	Relative (95% Cl)	Absolute	Quality	Importance
Patient Sa	atisfaction (0-	10) (follov	v-up 24 hours; Be	tter indicated by	higher values)							
	randomised trials	serious <sup>1</sup>	no serious inconsistency		no serious imprecision	none	29	29	-	MD 2 higher (1.67 to 2.33 higher)	⊕⊕⊕O MODERATE	CRITICAL
Postopera	ative global Q	oR-40 sco	ore (follow-up 24 ł	nours; Better ind	licated by highe	r values)		<u> </u>				
	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	46	49	-	MD 7.8 lower (13.09 to 2.51 lower)	⊕⊕OO LOW	CRITICAL
Length of	hospital stay	(Better ir	ndicated by lower	values)				<u> </u>				
	randomised trials	serious <sup>1</sup>	serious <sup>3</sup>	no serious indirectness	no serious imprecision	none	332	341	-	MD 0.37 lower (0.68 lower to 0.06 higher)	⊕⊕OO LOW	CRITICAL
Length of	Length of hospital stay - Major abdominal surgery (Better indicated by lower values)											
	randomised trials	serious <sup>1</sup>	very serious <sup>3</sup>	no serious indirectness	serious <sup>2</sup>	none	167	167	-	MD 1.43 lower (2.68 to 0.18 lower)	⊕OOO VERY LOW	CRITICAL

Length	of hospital sta	y - Interme	ediate Abdominal	Surgery (Better	indicated by lov	wer values)	1	r			1	Γ
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	46	51	-	MD 0.21 higher (0.52 lower to 0.94 higher)	⊕⊕OO LOW	CRITICAI
Length	of hospital sta	y - Minor a	abdominal surger	y (Better indicate	ed by lower valu	ies)	•				•	•
3	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	100	103	-	MD 0.07 lower (0.18 lower to 0.03 higher)	⊕⊕⊕O MODERATE	CRITICAL
Length	of hospital sta	y - Orthop	aedic surgery (Be	etter indicated by	v lower values)		•				•	•
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	19	20	-	MD 1.00 lower (1.73 to 0.27 lower)	⊕⊕OO LOW	CRITICAL
Thirst	(0-10) (preopera	tive) (Bett	er indicated by lo	ower values)							•	<u> </u>
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	48	50	-	MD 0.2 higher (0.71 lower to 1.11 higher)	⊕⊕OO LOW	IMPORTAN
Thirst	(0-10) (postoper	ative) (Be	tter indicated by	lower values)							•	•
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	25	25	-	MD 7.16 lower (8.2 to 6.12 lower)	⊕⊕⊕O MODERATE	IMPORTAN
Thirst	(mild)							•			•	
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	6/25 (24%)	52%	RR 0.46 (0.21 to 1.02)	281 fewer per 1000 (from 411 fewer to 10 more)	⊕⊕OO LOW	IMPORTAN

Perioperative care: DRAFT FOR CONSULTATION Preoperative fasting strategy

Thirst (I	noderate)	_	-			-						
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	0/25 (0%)	20%	RR 0.09 (0.01 to 1.56)	182 fewer per 1000 (from 198 fewer to 112 more)	⊕⊕OO LOW	IMPORTAN
Headac	he (postoperat	ive)										
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	3/29 (10.3%)	31%	RR 0.33 (0.1 to 1.11)	208 fewer per 1000 (from 279 fewer to 34 more)	⊕⊕OO LOW	IMPORTAN
Compli	cation rate											
5	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	18/171 (10.5%)	14.8%	RR 1.05 (0.59 to 1.87)	7 more per 1000 (from 61 fewer to 129 more)	⊕OOO VERY LOW	IMPORTAN
Well-be	ing (postopera	tive) (Bette	er indicated by lo	wer values)								
2	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	51	36	-	SMD 0.04 higher (0.4 lower to 0.47 higher)	⊕⊕⊕O MODERATE	IMPORTAN
Nausea	& Vomiting 0-1	0 (postop	erative) (Better in	dicated by lower	values)							
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	29	29	-	MD 2.0 lower (2.58 to 1.42 lower)	⊕⊕OO LOW	IMPORTAN
Nausea	& Vomiting											

2	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	10/69 (14.5%)	21.9%		50 fewer per 1000 (from 136 fewer to 118 more)		IMPORTAN
Nause	a & Vomiting - N	lausea			-		1	1			1	
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	9/48 (18.8%)	20%	RR 0.94 (0.42 to 2.1)	12 fewer per 1000 (from 116 fewer to 220 more)		IMPORTAI
Nause	a & Vomiting - V	omiting		-	-	-	-			•	•	
3	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	14/114 (12.3%)	24%	RR 0.61 (0.34 to 1.1)	94 fewer per 1000 (from 158 fewer to 24 more)	⊕⊕OO LOW	IMPORTAI
Anxie	y (0-10) (preope	rative) (Be	etter indicated by	lower values)	-1		1	4		l	1	
											1	
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	48	50	-	MD 0.3 higher (1.05 lower to 1.65 higher)	⊕⊕⊕O MODERATE	CRITICA
1 Anxie	trials			indirectness		none	48	50	-	5 (		
1 <b>Anxie</b> 1	trials		inconsistency	indirectness		none	48 25	25	-	5 (		CRITICA
1	trials y (0-10) (postop randomised	erative) (E	inconsistency Better indicated b no serious inconsistency	indirectness y lower values) no serious	imprecision no serious					lower to 1.65 higher) MD 5 lower (6.1 to 3.9	MODERATE ⊕⊕⊕O	CRITICA

<sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias <sup>2</sup> Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

© NICE 2019. All rights reserved. Subject to Notice of rights. 128

<sup>3</sup> Downgraded by 1 or 2 increments because: The point estimate varies widely across studies, unexplained by subgroup analysis. The confidence intervals across studies show minimal or no overlap, unexplained by subgroup analysis. Heterogeneity, I2=50%, p=0.04, unexplained by subgroup analysis.

#### Table 15: Clinical evidence profile: Carbohydrate drinks versus Placebo

			Quality as	sessment			No of pati	ents		Effect	Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	CHO versus placebo	Control	Relative (95% CI)	Absolute	Quality	Importance
Length of	hospital stay	(Better ir	ndicated by lower	values)	•						•	
10	randomised trials	serious <sup>1</sup>	serious <sup>2</sup>	no serious indirectness	no serious imprecision	none	332	342	-	MD 0.04 lower (0.21 lower to 0.14 higher)	⊕⊕OO LOW	CRITICAL
Length of	hospital stay	- Major a	bdominal surgery	(Better indicate	d by lower value	es)					•	
6	randomised trials	serious <sup>1</sup>	very serious <sup>2</sup>	no serious indirectness	no serious imprecision	none	216	225	-	MD 0.59 lower (1.82 lower to 0.64 higher)	⊕OOO VERY LOW	CRITICAL
Length of	hospital stay	- Minor a	bdominal surgery	(Better indicate	d by lower value	es)						
2	randomised trials		no serious inconsistency	no serious indirectness	no serious imprecision	none	70	74	-	MD 0.06 lower (0.12 lower to 0.01 higher)	⊕⊕⊕O MODERATE	CRITICAL
Length of	hospital stay	- Orthopa	aedic surgery (Bet	ter indicated by	lower values)							
3	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	46	43	-	MD 0.1 higher (0.32 lower to 0.53 higher)	⊕⊕⊕O MODERATE	CRITICAL
Complica	tion rate											

8	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>3</sup>	none	71/272 (26.1%)	19.2%	RR 0.92 (0.73 to 1.17)	15 fewer per 1000 (from 52 fewer to 33 more)	⊕⊕OO LOW	IMPORTAN'
Fatigu	e (postoperative	e) (Better i	ndicated by lowe	r values)		,		1	1		1	<u> </u>
3	randomised trials	serious <sup>1</sup>	very serious <sup>2</sup>	no serious indirectness	no serious imprecision	none	131	137	-	SMD 0.28 higher (0.22 lower to 0.78 higher)	⊕OOO VERY LOW	IMPORTAN
Well-b	eing (postopera	tive) (Bett	er indicated by lo	ower values)					<u> </u>		<u> </u>	
2	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	99	106	-	SMD 0 higher (0.27 lower to 0.28 higher)	⊕⊕⊕O MODERATE	CRITICAL
Nause	a (24 h) (Better i	ndicated I	by lower values)		-1		1	1	ł		ł	<u> </u>
2	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	112	122	-	MD 1.71 lower (4.06 lower to 0.64 higher)	⊕⊕⊕O MODERATE	IMPORTAN
Vomiti	ng (postoperativ	/e)	1					1	L		L	L
3	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>3</sup>	none	19/122 (15.6%)	8.5%	RR 1.18 (0.65 to 2.12)	15 more per 1000 (from 30 fewer to 95 more)	⊕OOO VERY LOW	IMPORTAN

<sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias <sup>2</sup> Downgraded by 1 or 2 increments because: The point estimate varies widely across studies, unexplained by subgroup analysis. The confidence intervals across studies show minimal or no overlap, unexplained by subgroup analysis Heterogeneity, I2=50%, p=0.04, unexplained by subgroup analysis. <sup>3</sup> Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

#### Table 16: Clinical evidence profile: Clear fluids (water) versus fasting

Quality assessment	No of patients	Effect	Quality	Importance	
--------------------	----------------	--------	---------	------------	--


No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Clear fluids (Water)	Fasting	Relative (95% CI)	Absolute		
Nausea (P	Nausea (POD1)											
	randomised trials			no serious indirectness	serious <sup>2</sup>	none	5/25 (20%)	51.7%	RR 0.39 (0.16 to 0.91)	315 fewer per 1000 (from 47 fewer to 434 fewer)	⊕⊕OO LOW	IMPORTANT
Vomiting (I	Vomiting (POD1)											
	randomised trials			no serious indirectness	serious <sup>2</sup>	none	3/25 (12%)	34.5%	RR 0.35 (0.11 to 1.13)	224 fewer per 1000 (from 307 fewer to 45 more)	⊕⊕OO LOW	IMPORTANT
Headache (POD1)												
	randomised trials			no serious indirectness	very serious <sup>2</sup>	none	6/25 (24%)	41.4%	RR 0.58 (0.26 to 1.32)	174 fewer per 1000 (from 306 fewer to 132 more)	⊕OOO VERY LOW	IMPORTANT

<sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias <sup>2</sup> Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs 1

2

# Appendix G: Health economic evidence selection

Figure 26: Flow chart of health economic study selection for the guideline



\* Non-relevant population, intervention, comparison, design or setting; non-English language

© NICE 2019. All rights reserved. Subject to Notice of rights.

# Appendix H: Health economic evidence tables

None.

# Appendix I: Excluded studies

## 2 I.1 Excluded clinical studies

1

3

Adamova 20171Incorrect study designAgarwal 19892Unclear outcomes – how outcomes measured unclear and not specifiedAguilar-Nascimento 200926Not in EnglishAmer 20174Systematic Review : references screenedAmerican Society of Anesthesiologists 201124Incorrect study designAnonymous 20175Incorrect comparisonAnonymous 20176Not availableAnonymous 20176Incorrect comparisonAvad 20138Systematic Review : references screenedAzagury 20159Not availableBhaskaran 201810Incorrect comparisonBilku 201411Systematic Review : references screenedBigsard 200412Incorrect comparisonBorge Dock-Nascimento 201113No relevant outcomesBorges Dock-Nascimento 201114No relevant outcomesBreuer 200616 Chen 20155Incorrect study designChen 201427Incorrect study designChen 201547Nor relevant outcomesBreuer 200616 Chen 201424Incorrect study designChen 201427No relevant outcomesBreuer 200616 Chen 201424Incorrect study designChen 201425Not in EnglishChen 201426No relevant outcomes201055Systematic Review : references screenedBreuer 200616 Chen 201426Incorrect study designChen 201427No in EnglishChen 201427No relevant outcomesChen 201427No relevant outcomesChen 2014278No relevant outcomesDilmen 201777No relevant outcomes <t< th=""><th>Reference</th><th>Reason for exclusion</th></t<>	Reference	Reason for exclusion			
Agarwan 1989specifiedAguilar-Nascimento 2009 <sup>26</sup> Not in EnglishAmer 2017 <sup>4</sup> Systematic Review : references screenedAmerican Society of Anesthesiologists 2011 <sup>34</sup> Incorrect study designAnonymous 2018 <sup>5</sup> Not availableAnonymous 2017 <sup>29</sup> Incorrect comparisonAronsson 2009 <sup>6</sup> Incorrect comparisonAvad 2013 <sup>8</sup> Systematic Review : references screenedAzagury 2015 <sup>9</sup> Not availableBhaskaran 2018 <sup>10</sup> Incorrect comparisonAgarwa 2014 <sup>11</sup> Systematic Review : references screenedBisgaard 2004 <sup>12</sup> Incorrect comparisonBisgaard 2004 <sup>12</sup> Incorrect comparisonBorges Dock-Nascimento 2011 <sup>14</sup> No relevant outcomesBready 2003 <sup>15</sup> Systematic Review : references screenedBready 2003 <sup>15</sup> Systematic Review : references screenedBready 2003 <sup>15</sup> Incorrect populationCampos 2018 <sup>18</sup> Incorrect study designChen 2014 <sup>21</sup> Not in EnglishChen 2014 <sup>21</sup> Not in EnglishChen 2015 <sup>22</sup> Not in EnglishChictr 2018 <sup>23</sup> Citation onlyde Aguilar-Nascimento 2014 <sup>24</sup> No relevant outcomes2014 <sup>25</sup> No relevant outcomes	Adamova 2017 <sup>1</sup>	Incorrect study design			
Amer 20174Systematic Review : references screenedAmerican Society of Anesthesiologists 201194Incorrect study designAnonymous 20185Not availableAnonymous 201729Incorrect comparisonAronsson 20096Incorrect comparisonAwad 20138Systematic Review : references screenedAzagury 20159Not availableBhaskaran 201810Incorrect comparisonBilku 201411Systematic Review : references screenedBisgaard 200412Incorrect comparisonBorges Dock-Nascimento 201184No relevant outcomesBreuer 200616Incorrect study designCampos 201818Incorrect study designChen 201421No relevant outcomesBreuer 200616Incorrect study designChen 201421No relevant outcomesChen 201421No tin EnglishChen 201421No tin EnglishChen 201421No tin EnglishChen 201421No relevant outcomes2010053Citation onlyde Aguilar-Nascimento 2010053No relevant outcomes2010053No tin EnglishChen 201422No relevant outcomes201434No relevant outcomes201053Citation onlyde Aguilar-Nascimento 2010735No relevant outcomes201434No relevant outcomes201434No relevant outcomes201435No relevant outcomes201436No relevant outcomes201437No relevant outcomes201437No relevant outcomes201437No re	Agarwal 1989 <sup>2</sup>				
American Society of Anesthesiologists 2011 <sup>34</sup> Incorrect study designAnonymous 2018 <sup>8</sup> Not availableAnonymous 2017 <sup>29</sup> Incorrect comparisonAronsson 2009 <sup>6</sup> Incorrect comparisonAwad 2013 <sup>8</sup> Systematic Review : references screenedAzagury 2015 <sup>9</sup> Not availableBhaskaran 2018 <sup>10</sup> Incorrect comparisonBilku 2014 <sup>11</sup> Systematic Review : references screenedBisgaard 2004 <sup>12</sup> Incorrect comparisonBorges Dock-NascimentoNo relevant outcomesBorges Dock-NascimentoNo relevant outcomesBreuer 2006 <sup>16</sup> Incorrect study designChen 2014 <sup>21</sup> Not in EnglishChen 2014 <sup>22</sup> Not in EnglishChen 2014 <sup>23</sup> Citation onlyde Aguilar-Nascimento 2010 <sup>25</sup> No relevant outcomesDilmen 2017 <sup>27</sup> No relevant outcomesDock-Nascimento 2010 <sup>25</sup> No relevant outcomesDilmen 2017 <sup>27</sup> No relevant outcomesDock-Nascimento 2014 <sup>24</sup> No relevant outcomesDilmen 2017 <sup>27</sup> No relevant outcomesDock-Nascimento 2014 <sup>24</sup> No relevant outcomesDock-Nascimento 2014 <sup>24</sup> No relevant outcomesFeguri 2017 <sup>32</sup> Incorrect populationFeng 1995 <sup>33</sup> Not in EnglishGava 2016 <sup>34</sup> No relevant outcomesGava 2016 <sup>34</sup> No relevant outcomesGava 2016 <sup>34</sup> No relevant outcomesGava 2016 <sup>34</sup> Incorrect population	Aguilar-Nascimento 2009 <sup>26</sup>	•			
Anesthesiologists 2011 <sup>94</sup> Anonymous 2018 <sup>8</sup> Not availableAnonymous 2017 <sup>29</sup> Incorrect comparisonAronsson 2009 <sup>6</sup> Incorrect comparisonAwad 2013 <sup>8</sup> Systematic Review : references screenedAzagury 2015 <sup>9</sup> Not availableBhaskaran 2018 <sup>10</sup> Incorrect comparisonBilku 2014 <sup>11</sup> Systematic Review : references screenedBisgaard 2004 <sup>12</sup> Incorrect comparisonBorges Dock-NascimentoNo relevant outcomesBorges Dock-NascimentoNo relevant outcomesBreuer 2006 <sup>16</sup> Incorrect sudy designChen 2014 <sup>21</sup> Not in EnglishChen 2014 <sup>22</sup> Not in EnglishChen 2014 <sup>23</sup> Citation onlyde Aquilar-NascimentoIncorrect study design2010 <sup>25</sup> No relevant outcomes2010 <sup>25</sup> No relevant outcomes2010 <sup>25</sup> No relevant outcomes2010 <sup>25</sup> Not in EnglishChiCtr 2018 <sup>23</sup> Citation onlyde Aquilar-Nascimento 2014 <sup>24</sup> No relevant outcomes2014 <sup>24</sup> No relevant outcomes2014 <sup>24</sup> No relevant outcomes2014 <sup>24</sup> No relevant outcomes2014 <sup>24</sup> No relevant outcomesDilmen 2017 <sup>27</sup> No relevant outcomesFeguri 2017 <sup>32</sup> Incorrect populationFeng 1995 <sup>33</sup> Not in EnglishGava 2016 <sup>34</sup> No relevant outcomesGava 2016 <sup>34</sup> No relevant outcomesGhorashi 2014 <sup>35</sup> Incorrect population	Amer 2017 <sup>4</sup>	Systematic Review : references screened			
Anonymous 2018 <sup>5</sup> Not availableAnonymous 2017 <sup>29</sup> Incorrect comparisonAronsson 2009 <sup>6</sup> Incorrect comparisonAwad 2013 <sup>8</sup> Systematic Review : references screenedAzagury 2015 <sup>9</sup> Not availableBhaskaran 2018 <sup>10</sup> Incorrect comparisonBilku 2014 <sup>11</sup> Systematic Review : references screenedBisgaard 2004 <sup>12</sup> Incorrect comparisonBorpe 2011 <sup>13</sup> No relevant outcomesBorges Dock-Nascimento 2011 <sup>45</sup> Systematic Review : references screenedBreuer 2006 <sup>16</sup> Incorrect populationCampos 2018 <sup>18</sup> Incorrect study designChen 2014 <sup>21</sup> Not in EnglishChen 2015 <sup>22</sup> Not in EnglishChen 2015 <sup>23</sup> Citation onlyde Aguilar-Nascimento 2010 <sup>43</sup> No relevant outcomesDilmen 2017 <sup>27</sup> No relevant outcomesDock-Nascimento 2014 <sup>24</sup> No relevant outcomesDilmen 2017 <sup>27</sup> No relevant outcomesDilmen 2017 <sup>27</sup> No relevant outcomesDock-Nascimento 2014 <sup>24</sup> No relevant outcomesDilmen 2017 <sup>27</sup> No relevant outcomesFeguri 2017 <sup>32</sup> Incorrect populationFeguri 2017 <sup>32</sup> No relevant outcomesFeguri 2017 <sup>34</sup> No relevant outcomesFeguri 2017 <sup>35</sup> No relevant outcomesFeguri 2017 <sup>34</sup> No relevant outcomesFeguri 2017 <sup>35</sup> No relevant outcomesFeguri 2017 <sup>34</sup> No relevant outcomesFeguri 2017 <sup>35</sup> Incorrect populationFerguri 2017 <sup>36</sup> No relevant outcomesFeguri 2017 <sup>36</sup> <	American Society of Anesthesiologists 2011 <sup>94</sup>	Incorrect study design			
Aronsson 2009 <sup>6</sup> Incorrect comparisonAwad 2013 <sup>8</sup> Systematic Review : references screenedAzagury 2015 <sup>9</sup> Not availableBhaskaran 2018 <sup>10</sup> Incorrect comparisonBilku 2014 <sup>11</sup> Systematic Review : references screenedBisgaard 2004 <sup>12</sup> Incorrect comparisonBopp 2011 <sup>13</sup> No relevant outcomesBorges Dock-Nascimento 2011 <sup>14</sup> No relevant outcomesBreuer 2006 <sup>16</sup> Incorrect study designChen 2014 <sup>21</sup> Not in EnglishChen 2014 <sup>22</sup> Not in EnglishChirt 2018 <sup>23</sup> Citation onlyde Aguilar-Nascimento 2010 <sup>25</sup> No relevant outcomesDilmen 2017 <sup>27</sup> No relevant outcomesDock-Nascimento 2012 <sup>28</sup> No relevant outcomesDilmen 2017 <sup>27</sup> No relevant outcomesDilmen 2017 <sup>28</sup> No relevant outcomesFeguri 2017 <sup>32</sup> Incorrect populationFeguri 2017 <sup>33</sup> No relevant outcomesFeguri 2017 <sup>34</sup> No relevant outcomesFeguri 2017 <sup>35</sup> Incorrect populationFeguri 2017 <sup>34</sup> No relevant outcomesFeguri 2017 <sup>35</sup> Incorrect populationFeng 1995 <sup>33</sup> Not in EnglishGava 2016 <sup>34</sup> No relevant outcomesGava 2016 <sup>34</sup> No relevant outcomes <tr <td=""></tr>		Not available			
Awad 2013 <sup>8</sup> Systematic Review : references screenedAzagury 2015 <sup>9</sup> Not availableBhaskaran 2018 <sup>10</sup> Incorrect comparisonBilku 2014 <sup>11</sup> Systematic Review : references screenedBisgaard 2004 <sup>12</sup> Incorrect comparisonBopp 2011 <sup>13</sup> No relevant outcomesBorges Dock-NascimentoNo relevant outcomes2011 <sup>14</sup> Systematic Review : references screenedBreuer 2006 <sup>16</sup> Incorrect populationCampos 2018 <sup>18</sup> Incorrect study designChen 2015 <sup>22</sup> Not in EnglishChen 2015 <sup>23</sup> Citation onlyde Aguilar-Nascimento 2014 <sup>24</sup> No relevant outcomesDilmen 2017 <sup>27</sup> No relevant outcomesDilmen 2017 <sup>272</sup> No relevant outcomesDock-Nascimento 2012 <sup>28</sup> No relevant outcomesFeguri 2017 <sup>32</sup> No relevant outcomesFeguri 2017 <sup>34</sup> No relevant outcomesFeguri 2016 <sup>34</sup> No relevant outcomes<	Anonymous 2017 <sup>29</sup>	Incorrect comparison			
Azagury 20159Not availableBhaskaran 201810Incorrect comparisonBilku 201411Systematic Review : references screenedBisgaard 200412Incorrect comparisonBopp 201113No relevant outcomesBorges Dock-Nascimento 201114No relevant outcomesBrady 200315Systematic Review : references screenedBreuer 200616Incorrect populationCampos 201818Incorrect study designChen 201421Not in EnglishChen 201522Not in EnglishChictr 201823Citation onlyde Aguilar-Nascimento 201025No relevant outcomesDilmen 201727No relevant outcomesDock-Nascimento 201228No relevant outcomesDock-Nascimento 201424No relevant outcomesDilmen 201727No relevant outcomesDock-Nascimento 201428No relevant outcomesFeguri 201732Incorrect populationFeguri 201733Not in EnglishCharcet populationNo relevant outcomesCock-Nascimento 201228No relevant outcomesFeguri 201732Incorrect populationFeguri 201733Not in EnglishGava 201634No relevant outcomesGava 201634No relevant outcomesGava 201634No relevant outcomesGava 201634No relevant outcomesGava 201634Incorrect population	Aronsson 2009 <sup>6</sup>	Incorrect comparison			
Bhaskaran 201810Incorrect comparisonBilku 201411Systematic Review : references screenedBisgaard 200412Incorrect comparisonBopp 201113No relevant outcomesBorges Dock-Nascimento 201114No relevant outcomesBrady 200315Systematic Review : references screenedBreuer 200616Incorrect populationChen 201421Not in EnglishChen 201522Not in EnglishChictr 201823Citation onlyde Aguilar-Nascimento 201025No relevant outcomesDilmen 201727No relevant outcomesDock-Nascimento 201634No relevant outcomesDock-Nascimento 201635Incorrect study designChen 201522Not in EnglishChen 201523Citation onlyde Aguilar-Nascimento 201025Incorrect study designDilmen 201727No relevant outcomesDock-Nascimento 201228No relevant outcomesFeguri 201732Incorrect populationFeng 199533Not in EnglishGava 201634No relevant outcomesGava 201634No relevant outcomesGhorashi 201435Incorrect population	Awad 2013 <sup>8</sup>	Systematic Review : references screened			
Bilku 2014 <sup>11</sup> Systematic Review : references screenedBisgaard 2004 <sup>12</sup> Incorrect comparisonBopp 2011 <sup>13</sup> No relevant outcomesBorges Dock-Nascimento 2011 <sup>14</sup> No relevant outcomesBrady 2003 <sup>15</sup> Systematic Review : references screenedBreuer 2006 <sup>16</sup> Incorrect populationCampos 2018 <sup>18</sup> Incorrect study designChen 2014 <sup>21</sup> Not in EnglishChen 2015 <sup>22</sup> Not in EnglishChildr 2018 <sup>23</sup> Citation onlyde Aguilar-Nascimento 2014 <sup>24</sup> No relevant outcomesDilmen 2017 <sup>27</sup> No relevant outcomesDock-Nascimento 2012 <sup>28</sup> No relevant outcomesDock-Nascimento 2012 <sup>28</sup> No relevant outcomesFeguri 2017 <sup>32</sup> Incorrect populationFeguri 2017 <sup>33</sup> Not in EnglishGava 2016 <sup>34</sup> No relevant outcomesGhorashi 2014 <sup>35</sup> Incorrect population	Azagury 2015 <sup>9</sup>	Not available			
Bisgaard 200412Incorrect comparisonBopp 201113No relevant outcomesBorges Dock-Nascimento 201114No relevant outcomesBrady 200315Systematic Review : references screenedBreuer 200616Incorrect populationCampos 201818Incorrect study designChen 201421Not in EnglishChen 201522Not in EnglishChiCtr 201823Citation onlyde Aguilar-Nascimento 201424Incorrect study designDilmen 201727No relevant outcomesDock-Nascimento 201228No relevant outcomesDock-Nascimento 201228No relevant outcomesFeguri 201732Incorrect populationFeguri 201732No relevant outcomesGava 201634No relevant outcomesGhorashi 201435Incorrect population	Bhaskaran 2018 <sup>10</sup>	Incorrect comparison			
Bopp 201113No relevant outcomesBorges Dock-Nascimento 201114No relevant outcomesBrady 200315Systematic Review : references screenedBreuer 200616Incorrect populationCampos 201818Incorrect study designChen 201421Not in EnglishChen 201522Not in EnglishChictr 201823Citation onlyde Aguilar-Nascimento 201025Incorrect study designDilmen 201727No relevant outcomesDock-Nascimento 201228No relevant outcomesDock-Nascimento 201228No relevant outcomesFeguri 201732Incorrect populationFeguri 201732No relevant outcomesFeguri 201634No relevant outcomesGava 201634No relevant outcomesGhorashi 201435Incorrect population	Bilku 2014 <sup>11</sup>	Systematic Review : references screened			
NoNorelevant outcomes201114Norelevant outcomesBrady 200315Systematic Review : references screenedBreuer 200616Incorrect populationCampos 201818Incorrect study designChen 201421Not in EnglishChen 201522Not in EnglishChiCtr 201823Citation onlyde Aguilar-Nascimento 201025Incorrect study designde Aguilar-Nascimento 201424No relevant outcomesDilmen 201727No relevant outcomesDock-Nascimento 201228No relevant outcomesFeguri 201732Incorrect populationFeguri 201733Not in EnglishGava 201634No relevant outcomesGhorashi 201435Incorrect population	Bisgaard 2004 <sup>12</sup>	Incorrect comparison			
201114Brady 200315Systematic Review : references screenedBreuer 200616Incorrect populationCampos 201818Incorrect study designChen 201421Not in EnglishChen 201522Not in EnglishChiCtr 201823Citation onlyde Aguilar-Nascimento 201424Incorrect study designDilmen 201727No relevant outcomesDock-Nascimento 201228No relevant outcomesFeguri 201732Incorrect populationFeguri 201732Incorrect populationFeguri 201634No relevant outcomesGava 201634No relevant outcomesGhorashi 201435Incorrect population	Bopp 2011 <sup>13</sup>	No relevant outcomes			
Breuer 2006 <sup>16</sup> Incorrect populationCampos 2018 <sup>18</sup> Incorrect study designChen 2014 <sup>21</sup> Not in EnglishChen 2015 <sup>22</sup> Not in EnglishChiCtr 2018 <sup>23</sup> Citation onlyde Aguilar-Nascimento 2010 <sup>25</sup> Incorrect study designde Aguilar-Nascimento 2014 <sup>24</sup> No relevant outcomesDilmen 2017 <sup>27</sup> No relevant outcomesDock-Nascimento 2012 <sup>28</sup> No relevant outcomesFeguri 2017 <sup>32</sup> Incorrect populationFeng 1995 <sup>33</sup> Not in EnglishGava 2016 <sup>34</sup> No relevant outcomesGhrashi 2014 <sup>35</sup> Incorrect population	Borges Dock-Nascimento 2011 <sup>14</sup>	No relevant outcomes			
Campos 2018 <sup>18</sup> Incorrect study designChen 2014 <sup>21</sup> Not in EnglishChen 2015 <sup>22</sup> Not in EnglishChictr 2018 <sup>23</sup> Citation onlyde Aguilar-Nascimento 2010 <sup>25</sup> Incorrect study designde Aguilar-Nascimento 2014 <sup>24</sup> No relevant outcomesDilmen 2017 <sup>27</sup> No relevant outcomesDock-Nascimento 2012 <sup>28</sup> No relevant outcomesFeguri 2017 <sup>32</sup> Incorrect populationFeng 1995 <sup>33</sup> Not in EnglishGava 2016 <sup>34</sup> No relevant outcomesGhrashi 2014 <sup>35</sup> Incorrect population	Brady 2003 <sup>15</sup>	Systematic Review : references screened			
Chen 201421Not in EnglishChen 201522Not in EnglishChiCtr 201823Citation onlyde Aguilar-Nascimento 201025Incorrect study designde Aguilar-Nascimento 201424No relevant outcomesDilmen 201727No relevant outcomesDock-Nascimento 201228No relevant outcomesFeguri 201732Incorrect populationFeng 199533Not in EnglishGava 201634No relevant outcomesIncorrect populationIncorrect population	Breuer 2006 <sup>16</sup>	Incorrect population			
Chen 201522Not in EnglishChiCtr 201823Citation onlyde Aguilar-Nascimento 201025Incorrect study designde Aguilar-Nascimento 201424No relevant outcomesDilmen 201727No relevant outcomesDock-Nascimento 201228No relevant outcomesFeguri 201732Incorrect populationFeng 199533Not in EnglishGava 201634No relevant outcomesIncorrect populationIncorrect population	Campos 2018 <sup>18</sup>	Incorrect study design			
ChiCtr 201823Citation onlyde Aguilar-Nascimento 201025Incorrect study designde Aguilar-Nascimento 201424No relevant outcomesDilmen 201727No relevant outcomesDock-Nascimento 201228No relevant outcomesFeguri 201732Incorrect populationFeng 199533Not in EnglishGava 201634No relevant outcomesIncorrect populationIncorrect population	Chen 2014 <sup>21</sup>	Not in English			
de Aguilar-Nascimento 201025Incorrect study designde Aguilar-Nascimento 201424No relevant outcomesDilmen 201727No relevant outcomesDock-Nascimento 201228No relevant outcomesDock-Nascimento 201228No relevant outcomesFeguri 201732Incorrect populationFeng 199533Not in EnglishGava 201634No relevant outcomesIncorrect populationNo relevant outcomes	Chen 2015 <sup>22</sup>	Not in English			
201025de Aguilar-Nascimento 201424No relevant outcomesDilmen 201727No relevant outcomesDock-Nascimento 201228No relevant outcomesFeguri 201732Incorrect populationFeng 199533Not in EnglishGava 201634No relevant outcomesGhorashi 201435Incorrect population	ChiCtr 2018 <sup>23</sup>	Citation only			
201424Dilmen 201727No relevant outcomesDock-Nascimento 201228No relevant outcomesFeguri 201732Incorrect populationFeng 199533Not in EnglishGava 201634No relevant outcomesGhorashi 201435Incorrect population	de Aguilar-Nascimento 2010 <sup>25</sup>	Incorrect study design			
Dock-Nascimento 201228No relevant outcomesFeguri 201732Incorrect populationFeng 199533Not in EnglishGava 201634No relevant outcomesGhorashi 201435Incorrect population	de Aguilar-Nascimento 2014 <sup>24</sup>	No relevant outcomes			
Feguri 2017 <sup>32</sup> Incorrect populationFeng 1995 <sup>33</sup> Not in EnglishGava 2016 <sup>34</sup> No relevant outcomesGhorashi 2014 <sup>35</sup> Incorrect population	Dilmen 2017 <sup>27</sup>	No relevant outcomes			
Feng 199533Not in EnglishGava 201634No relevant outcomesGhorashi 201435Incorrect population	Dock-Nascimento 2012 <sup>28</sup>	No relevant outcomes			
Gava 201634No relevant outcomesGhorashi 201435Incorrect population	Feguri 2017 <sup>32</sup>	Incorrect population			
Ghorashi 2014 <sup>35</sup> Incorrect population	Feng 1995 <sup>33</sup>	Not in English			
	Gava 2016 <sup>34</sup>	No relevant outcomes			
Gianotti 2018 <sup>36</sup> Incorrect comparison	Ghorashi 2014 <sup>35</sup>	Incorrect population			
	Gianotti 2018 <sup>36</sup>	Incorrect comparison			
Gonik 2016 <sup>38</sup> Incorrect population	Gonik 2016 <sup>38</sup>	Incorrect population			
Goodwin 1991 <sup>39</sup> Incorrect population	Goodwin 1991 <sup>39</sup>	Incorrect population			
Harsten 2012 <sup>40</sup> Data included within Systematic review included	Harsten 2012 <sup>40</sup>	Data included within Systematic review included			
Hausel 2005 <sup>42</sup> Data included within Systematic review included					
Henriksen 2003 <sup>45</sup> Data included within Systematic review included	Henriksen 2003 <sup>45</sup>	Data included within Systematic review included			

© NICE 2019. All rights reserved. Subject to Notice of rights.

Reference	Reason for exclusion
Hosny 2018 <sup>46</sup>	Incorrect population
Hutchinson 1988 <sup>47</sup>	Incorrect comparison
Itou 2012 <sup>48</sup>	Incorrect comparison
Jones 2011 <sup>49</sup>	Incorrect study design
Karlsson 2016 <sup>50</sup>	No relevant outcomes
Kaska 2006 <sup>51</sup>	
Kaska 2006 Kaska 2010 <sup>52</sup>	Not in English
Kwon 1994 <sup>53</sup>	Data included within Systematic review included
	Not in English
Lagerkranser 1997 <sup>54</sup>	Abstract only
Lam 1993 <sup>55</sup>	Incorrect study design – non randomized
Lambert 2016 <sup>56</sup>	Systematic Review : references screened
Lauwick 2009 <sup>57</sup>	Incorrect comparison
Li 2012 <sup>59</sup>	Systematic Review : references screened
Li 2015 <sup>60</sup>	Not in English
Lidder 2013 <sup>61</sup>	Data included within Systematic review included
Liu 2018 <sup>62</sup>	Incorrect population
Ljunggren 2014 <sup>63</sup>	No relevant outcomes
Ljungqvist 1998 <sup>64</sup>	Abstract only
Ljungqvist 2001 <sup>65</sup>	Incorrect study design
Ludwig 2013 <sup>66</sup>	Incorrect study design
Maltby 1986 <sup>68</sup>	Incorrect population
Maltby 2006 <sup>67</sup>	Incorrect study design
Manchikanti 2011 <sup>69</sup>	Incorrect study design
Mathur 2010 <sup>70</sup>	Data included within Systematic review included
McKenna 2008 <sup>71</sup>	Incorrect study design
Meisner 2008 <sup>72</sup>	Not in English
Miller 1983 <sup>74</sup>	No relevant outcomes
Morimoto 2019 <sup>75</sup>	No relevant outcomes
Noba 2019 <sup>78</sup>	Incorrect comparisons
Noblett 2006 <sup>79</sup>	Incorrect comparison
Nygren 1996 <sup>81</sup>	Abstract only
Nygren 1999 <sup>80</sup>	No relevant outcomes
Nygren 2007 <sup>82</sup>	Incorrect study design
Nygren 2015 <sup>83</sup>	Incorrect study design
Orbey 2009 <sup>85</sup>	Incorrect comparison
Ozdemir 2011 <sup>86</sup>	Not in English
Ozkan 2000 <sup>87</sup>	Not in English
Perrone 2011 <sup>88</sup>	Incorrect comparison
Pexe-Machado 2013 <sup>89</sup>	Data included within Systematic review included
Pimenta 2014 <sup>90</sup>	
Pimenta 2014 Popovic 2019 <sup>91</sup>	Incorrect study design
Popovic 2019 Pousman 2009 <sup>92</sup>	Systematic Review : references screened
	Incorrect study design & population
Power 2012 <sup>93</sup>	Incorrect study design
Pu 2005 <sup>95</sup>	Not in English
Savluk 2017 <sup>99</sup>	Incorrect population

 $\ensuremath{\textcircled{\sc online \sc on$ 

Reference	Reason for exclusion
Singh 2015 <sup>100</sup>	No relevant outcomes
Smith 2012 <sup>101</sup>	Systematic review: incorrect population
Soop 1998 <sup>103</sup>	Not in English
Soreide 1996 <sup>104</sup>	Incorrect study design
Tran 2013 <sup>105</sup>	Incorrect population
van Ginhoven 2011 <sup>106</sup>	Incorrect intervention
Xu 2017 <sup>108</sup>	Systematic Review : references screened
Yagci 2008 <sup>109</sup>	No relevant outcomes
Yildiz 2013 <sup>111</sup>	Systematic Review : references screened
Yilmaz 2013 <sup>112</sup>	No relevant outcomes
Zhan 2018 <sup>114</sup>	Incorrect population

## 2 I.2 Excluded health economic studies

Published health economic studies that met the inclusion criteria (relevant population, comparators, economic study design, published 2003 or later and not from non-OECD country or USA) but that were excluded following appraisal of applicability and methodological quality are listed below. See the health economic protocol for more details

#### Table 18: Studies excluded from the health economic review

	Reference	Reason for exclusion		
	None.			

# **Appendix J: Research recommendation**

#### **Research question**

4 What is the optimal timing of administration of carbohydrate drinks as part of a preoperative 5 fasting strategy?

#### 6 Why this is important

Patients are expect to be 'nil by mouth', or have a period of starvation, prior to undergoing a surgical procedure that requires a general anaesthetic. While some may not fully understand the mechanism of risk (aspiration of stomach contents), all are aware that eating and drinking prior to your operation can be very bad for you.

- While we have consensus guidance from the royal colleges of Anaesthetists and Nursing
   promoting the liberal, or relaxed, fasting guidance we still see variance in our local practice.
   Unsurprisingly this causes confusion, not only for the patient, but also the clinical staff, who
   often opt for a 'better safe than sorry' strategy. This in turn leads to prolonged periods of
   starvation and the negative consequences being without fluid and sustenance.
- 16 Over the past 10 years we have seen perioperative care evolve. One such advancement is 17 the use of high energy, carbohydrate rich, drinks to aid recovery. These are given before and 18 after surgery with the assumption that they provide the patient with a metabolic boost to 19 overcome the negative effects, and reduce the complications, of surgery. Again, as with 20 fasting, the timing and impact of these drinks appears varied, with no clear guide on 21 appropriate timing or dosing of these drinks.
  - This research question will explore the optimal timing of carbohydrate drunks to hopefully clarify these issues and provide clinicians the detail needed to develop standardised and safe fasting protocols.

0	E
/	ົ
_	~

22

23 24

1

2

3

7

8 9

10

26